

(12) **United States Patent**  
**Kawaoka et al.**

(10) **Patent No.:** **US 11,389,523 B2**  
(45) **Date of Patent:** **Jul. 19, 2022**

(54) **VECTORS FOR ELICITING IMMUNE RESPONSES TO NON-DOMINANT EPITOPES IN THE HEMAGGLUTININ (HA) PROTEIN**

(71) Applicant: **Wisconsin Alumni Research Foundation (WARF)**, Madison, WI (US)

(72) Inventors: **Yoshihiro Kawaoka**, Middleton, WI (US); **Gabriele Neumann**, Madison, WI (US); **Huihui Kong**, Madison, WI (US)

(73) Assignee: **Wisconsin Alumni Research Foundation (WARF)**, Madison, WI (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 29 days.

(21) Appl. No.: **16/545,761**

(22) Filed: **Aug. 20, 2019**

(65) **Prior Publication Data**  
US 2020/0188506 A1 Jun. 18, 2020

**Related U.S. Application Data**

(60) Provisional application No. 62/719,952, filed on Aug. 20, 2018.

(51) **Int. Cl.**  
**A61K 39/145** (2006.01)  
**C12N 15/86** (2006.01)  
**C07K 16/34** (2006.01)  
**C07K 16/10** (2006.01)  
**A61K 39/00** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 39/145** (2013.01); **C07K 16/1018** (2013.01); **C07K 16/34** (2013.01); **C12N 15/86** (2013.01); **A61K 2039/521** (2013.01); **A61K 2039/5258** (2013.01)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2011/0020374 A1\* 1/2011 Frazer ..... A61K 48/0066 424/184.1  
2012/0058124 A1 3/2012 Kurosawa et al.  
2020/0188506 A1\* 6/2020 Kawaoka ..... C07K 16/1018

**FOREIGN PATENT DOCUMENTS**

WO WO-2017/136575 A1 8/2017  
WO WO-202/0041311 A1 2/2020

**OTHER PUBLICATIONS**

Li et al. (Nature Microbiology. 2016; 1 (6): 1-10).\*  
Nara et al. (PLoS Biology. 2010; 8 (12): e1000571).\*  
(Continued)

*Primary Examiner* — Shanon A. Foley


(74) *Attorney, Agent, or Firm* — Schwegman Lundberg & Woessner, P.A.

(57) **ABSTRACT**

Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., influenza virus VLPs or non-influenza viruses or VLPs thereof expressing or having influenza HAs with altered immunogenicity as a result of altered immunodominant epitopes therein are provided.

**19 Claims, 45 Drawing Sheets**

**Specification includes a Sequence Listing.**



(56)

**References Cited**

OTHER PUBLICATIONS

Broecker, Felix, et al., "A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains", *npj Vaccines* (2019) 31, [www.nature.com/npjvaccines](http://www.nature.com/npjvaccines) Published in partnership with the Sealy Center for Vaccine Development, (Jul. 19, 2019), 9 pages.

Broecker, Felix, et al., "Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice", *Journal of Virology*, 92(20): e01100-18, (Oct. 2018), 1-13.

Sun, Weina, et al., "Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach", *Ameri-*

*can Society For Microbiology, Journal of Virology, Vaccines and Antiviral Agents*, vol. 93, Issue 12, (Jun. 2019), 1-17.

"International Application Serial No. PCT/US2019/047263, International Search Report dated Dec. 20, 2019", 5 pgs.

"International Application Serial No. PCT/US2019/047263, Written Opinion dated Dec. 20, 2019", 6 pgs.

Cho, Alice, et al., "Implications of Broadly Neutralizing Antibodies in the Development of a Universal Influenza Vaccine", *Current Opinion in Virology*, vol. 17, (Apr. 1, 2016), 110-115.

Giles, Brendan Michael, "Development of Broadly Reactive Vaccine for Highly Pathogenic H5N1 Influenza", Retrieved from the Internet: <URL<<http://search.proquest.com/docview/928138363>>, (Jan. 1, 2011), 283 pgs.

Popova, Lyubov, et al., "Immunodominance of Antigenic Site B over Site of Hemagglutinin of Recent H3N2 Influenza Viruses", *PLoS ONE*, vol. 7 No. 7, (Jul. 25, 2012), e41895, 1-11.

\* cited by examiner




FIG. 1




FIG. 2




FIG. 3A, 3B, 3C, 3D




FIG. 4A, 4B




FIG. 5

DEFINITION hemagglutinin, partial [Influenza A virus  
(A/California/7/2004(H3N2))].

ACCESSION ABH01021

1 qklpgndnst atlclghhav pngtivkttit ndqievtnat elvqssstgg icdsphqild  
61 genctlidal lgdpqcdgfg nkkwdlfver skaysncypy dvpdyaslrs lvassgtlef  
121 nnesfnwtgv tqngtsssck rrsnnsffsr lnwlthlkfk ypalnvtmpn nekfdklyiw  
181 gvhhpgtndnd qislytqasg ritvstkrsq qtvipnigr prvrtdipsri siywtivkpg  
241 dillinstgn liaprgyfki rsgkssimrs dapigkcense citpngsipn dkpfnqvnri

**301 tygacpryvk qntlklatgm rnvpekqtr**

DEFINITION hemagglutinin, partial [Influenza A virus(A/California/7/2004  
(cell-passaged) (H3))].

ACCESSION ABO37489

1 qklpgndnst atlclghhav pngtivkttit ndqievtnat elvqssstgg icdsphqild  
61 genctlidal lgdpqcdgfg nkkwdlfver skaysncypy dvpdyaslrs lvassgtlef  
121 nnesfnwtgv tqngtssack rrsnnsffsr lnwlthlkfk ypalnvtmpn nekfdklyiw  
181 gvhhpgtndnd qislyaqasg ritvstkrsq qtvipnigr prvrtdipsri siywtivkpg  
241 dillinstgn liaprgyfki rsgkssimrs dapigkcense citpngsipn dkpfnqvnri  
301 tygacpryvk qntlklatgm rnvpekqtrg ifgaiagfie ngwegmvdgw ygfrhqanseg  
361 igqaadlkst qaainqingk lnrligktne kfhqiekefs evegriqdle kyvedtkidl  
421 wsynaellva lenghtidlt dsemnklfer tkkqlrenae dmgnqcfkiy hkcdnacigs

**481 irngtydhdv yrdealnnrf qikgvelksg yk**

DEFINITION hemagglutinin, partial [Influenza A virus(A/California/7/2004  
(egg-passaged) (H3))].

ACCESSION ABO37490

1 qklpgndnst atlclghhav pngtivkttit ndqievtnat elvqssstgg icdsphqild  
61 genctlidal lgdpqcdgfg nkkwdlfver skaysncypy dvpdyaslrs lvassgtlef  
121 nnesfnwtgv tqngtsssck rrsnnsffsr lnwlthlkfk ypalnvtmpn nekfdklyiw  
181 gvhhpgtndnd qislytqasg ritvstkrsq qtvipnigr prvrtdipsri siywtivkpg  
241 dillinstgn liaprgyfki rsgkssimrs dapigkcense citpngsipn dkpfnqvnri  
301 tygacpryvk qntlklatgm rnvpekqtrg ifgaiagfie ngwegmvdgw ygfrhqanseg  
361 igqaadlkst qaainqingk lnrligktne kfhqiekefs evegriqdle kyvedtkidl

**FIG. 6A**

421 wsynaellva lenqhtidlt dsemnklfer tkkqlrenae dmngncfkiy hkcdnacigs  
 481 irngtydhdv yrdealnrf qikgvelksq yk

**Accession No. ATD11305**

1 mktiialsci lclvftqkip gndnstatic lghhavpngt ivkttitndri evtnatelvq  
 61 nssigeicds phqildgenc tlidallgdp qcdgfgnkqw dlfvernkay sncypydvdp  
 121 yaslrslvas sgtlefnnes fnwagvtqng tssscirgsk ssffsrlnwl thlnskypal  
 181 nvtmpneqf dklyiwgvhh pgtddkqisl yaqssgrity stkrsgqavi pnigsrprir  
 241 dipsrisiyw tivkpgdill instgnliap rgyfkiirsgk ssimrsdapi gkcksecitp  
 301 ngsipndkpf qnvnrityga cpryvkqstl klatgmrnvp erqtrgifga iagfiengwe  
 361 gmvdgwygfr hqnsegrrgqa adlkstqaai dqingklrnl igktnekfhq iekefseveg  
 421 rigdlekyve dtkidlwsyn aellvalenq htidldtsem nklfektkkq lrenaedmgn  
 481 gcfkiyhkcd nacigsirng tydhnyvrde alnrfqikg velksygdw ilwisfaisc  
 541 fllecvallgf imwacqkgni renici

**Sequence : gb:KP307984|gi:748112957|UniProtKB:A0A0C4X0C0|Organism:  
 Influenza A virus (A/gyrfalcon/Washington/41088-6/2014 (H5N8))|St rain  
 Name:A/gyrfalcon/Washington/41088-6/2014|Protein Name:HAHemagglutinin|  
 Gene Symbol:HA|Segment:4|Subtype:H5N8|Host:Falcon**

MEKIVLLAV	ISLVKSDQIC	IGYHANNSTK	QVDTIMEKNV	TVTHAQDILE	050
KTHNGKLCDL	NGVKPLILKD	CSVAGWLLGN	PMCDEFIRVP	EWSYIVERAN	100
PANDLCYPGT	LNDYEELKHL	LSRINHFEKT	LIIPRSSWPN	HETSLGVSAA	150
CPYQGASSFF	RNVVWLIKKN	DAYPTIKISY	NNTNREDLLI	LWGIHHSNNA	200
AEQTNLYKNP	DTYVSVGTST	LNQRLVPKIA	TRSQVNGQSG	RMDFFWTILK	250
PNDAIHFESN	GNFIAPEYAY	KIVKKGSTI	MKSEMEYGHC	NTKCQTPIGA	300
INSSMPFHNI	HPLTIGCEPK	YVKSNNLVLA	TGLRNSPLRE	RRRKRGLFGA	350
IAGFIEGGWQ	GMVDGWYGYH	HSNEQSGGYA	ADKESTQKAI	DGVTNKVNSI	400
IDKMNTQFEA	VGREFNNLER	RIENLNKKME	DGFLDVWTYN	AELLVLMENE	450
RTLDFHDSNV	KNLYDKVRLQ	LRDNAKELGN	GCFEFYHKCD	NECMESVRNG	500
TYDYPKYSEE	AILKREEISG	VKLESIGTYQ	ILSIYSTVAS	SLALAIIVAG	550
LSLWMCSSNGS	LQCRICI				567

**FIG. 6B**

Sequence : gb:KP307984|gi:748112957|UniProtKB:A0A0C4X0C0|Organism:  
 Influenza A virus (A/gyrfalcon/Washington/41088-6/2014(H5N8))|Strain  
 Name:A/gyrfalcon/Washington/41088-6/2014|Protein Name:HA Hemagglutinin  
 |Gene Symbol:HA|Segment:4|Subtype:H5N8|Host:Falcon

MEKIVLLLVAV	ISLVKSDQIC	IGYHANNSTK	QVDTIMEKNV	TVTHAQDILE	050
KTHNGKLCDL	NGVKPLILKD	CSVAGWLLGN	PMCDEFIRVP	EWSYIVERAN	100
PANDLCYPGT	LNDYEELKHL	LSRINHFEKT	LIIPRSSWPN	HETSLGVSAA	150
CPYQGASSFF	RNVVWLIKKN	DAYPTIKISY	NNTNREDLLI	LWGIHHSNNA	200
AEQTNLYKNP	DTYVSVGTST	LNQRLVPKIA	TRSQVNGQSG	RMDFFWTILK	250
PNDAIHFESN	GNFIAPEYAY	KIVKKG DSTI	MKSEMEYGHC	NTKCQTPIGA	300
INSSMPFHNI	HPLTIGECPK	YVKS NKLVLA	TGLRNSPLRE	RRRKRGLFGA	350
IAGFIEGGWQ	GMVDGWYGYH	HSNEQGS GYA	ADKESTQKAI	DGVTNKVNSI	400
IDKMNTQFEA	VGREFNNLER	RIENLNKKME	DGFLDVWTYN	AELLVLMENE	450
RTLDFHDSNV	KNLYDKVRLQ	LRDNAKELGN	GCFEFYHKCD	NECMESVRNG	500
TYDYPKYSEE	AILKREEISG	VKLESIGTYQ	ILSIYSTVAS	SLALAIIVAG	550
LSLWMCSNGS	LQCRICI				567

FIG. 7

**M**KANLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLLED SHNGKLCRLKGIAPLQLKG  
KCNIAGWLLGNPECDPLLPVRSWSYIVETPNESENGICYPGDFIDYEELREQLSSVSSFERFEIFPKE  
SSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLNSYVNKKGKEVLVLWGIHHPPNSKEQQN  
LYQENAYVSVVTSNYNRRFTPEIAERP KVRDQAGR**M**NYYWTL LKPGDTIIFEANGNLIAP**M**YAFALS  
RGFGSGIITSNAS**M**HECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRS AKLR**M**VTGLRNIPSIQS  
RGLFGAIAGFIEGGWT**G**MIDGWYGYHHQNEQSGY**AADQ**KSTQNAINGITNKVNTV**IEM**NIQFTAVGK  
EFNKLEKR**M**ENLNKKVDDGFLDIWTYNAELLVLLV LLENERTLDFHDSNVKNLYEKVKSQ LKNNAKE  
IGNGCFEFYHKCDNEC**M**ESVRNGTYDYPKYSEESKLNREKVDG VKLES**M**GIIYQILAIYSTVSSLVLLV  
SLGAISFW**M**C SNGSLQCRIC

**FIG. 8**

1 Maiiyllillf tavrgdqici gyhannstek vtilernvt vthakdilek thngklckln  
61 gipplelgdc siagwllgnp ecdrlsvpe wsyimekenp rdglcypgsf ndyeelkhll  
121 ssvkhfekvk ilpkdrwtqh tttggsraca vasgnpsffrn mwvltekgsn ypvakgsynr  
181 tsgeqmliiw gvhhpndate qrtlyqnvgt yvsvgtstln krstpeiater pkvnggggrm  
241 efswtlldmw dtinfestgn liapeygfki skrgssgimk tegtlenct kcqtplgain  
301 ttlpfhnvhp ltigecpkyv kseklvlatg lrnvpqiesr glfgaiagfi eggwqgmvdg  
361 wyghhsadq gsgyaadkes tqkafdgitn kvnsviekmn tqfeavgkef snlerrlenl  
421 nkkmedgfld vwtynaellv lmenertldf hdsnvknlyd kvrmqlrdnv kelgngcfef  
481 yhkcddecmn svkngtydyp kyeesklnr neikgvklss mgvyqilaiy atvagslsla  
541 immagisfwm csngslqcri ci

FIG. 9

1 Maiiylillf tavrgdqici gyhannstek vtilernvt vthakdilek thngklckln  
61 gipplelgdc siagwllgnp ecdrlsvpe wsyimekenp rdglcypgsf ndyeelkhll  
121 ssvkhfekvk ilpkdrwtqh tttggsraca vasgnpsffrn mvwltekgsn ypvakgsynn  
181 tsgeqmliiw gvhhpndate qrtlyqnvgt yvsvgtstln krstpeiater pkvngqggm  
241 efswtlldmw dtinfestgn liapeygfki skrgssgimk tegtlenct kcqtplgain  
301 ttlpfhnvhp ltigecpkyv kseklvlatg lrvnpqiesr glfgaiagfi eggwqgmvdg  
361 wyghhsadq gsgyaadkes tqkafdgitn kvnsviekmn tqfeavgkef snlerrlenl  
421 nkkmedgfld vwtynaellv lmenertldf hdsnvknlyd kvrmqlrdnv kelgngcfef  
481 yhkcddecmn svkngtydyp kyeesklnr neikgvklss mgvyqilaiy atvagslsla  
541 immagisfwm csngslqcri ci

FIG. 10




FIG. 11A

POSITION	MUTANTS																													
	WT	1	2	4	5	6	9	10	11	12	14	15	16	17	22	23	24	25	26	28	29	30								
1	N	Y	M	K	Q	V	V	R	T	I	V	A	V	V	S	V	L	R	V	F	S	F								
2	T	V	V	R	R	R	K	V	G	T	M	K	C	C	S	Q	R	R	R	D	R	V								
3	T	V	G	G	T	R	V	K	L	N	3	S	N	L	T	V	N	I	Y	S	K	W								
4	A	K	D	A	K	F	T	W	R	K	4	R	I	L	K	R	T	V	K	K	T	S								
5	I	W	F	P	L	M	H	M	C	T	T	N	K	R	S	R	K	N	T	G	N	M								
6	R	S	T	D	N	N	E	G	S	Y	G	D	R	F	Q	E	T	G	A	N	R	H								
7	S	G	D	A	T	T	R	V	G	D	A	G	P	K	G	H	N	T	E	V	A	Q								
8	S	P	R	G	P	W	R	P	R	S	W	V	D	T	S	S	S	R	Q	K	P	P								
9	T	V	C	M	9	V	A	I	Y	R	Q	R	A	I	R	V	Q	W	T	P	Q	Q	- - -							
10	H	G	A	T	P	A	S	G	P	S	S	S	A	P	P	T	K	P	L	T	H	G								
11	L	V	N	S	D	L	P	P	L	S	R	R	G	S	I	L	R	S	W	R	M	R								
12	N	R	G	P	R	H	V	V	Q	S	L	F	A	P	K	R	F	P	G	R	K	C								
13	N	D	R	K	T	T	R	F	T	F	Q	T	L	Q	E	H	S	R	R	L	F	T								
14	K	N	E	D	A	I	R	T	F	A	L	E	A	N	P	L	F	S	Y	S	T	S								
15	F	A	G	G	Q	S	T	R	A	Q	R	A	P	S	N	T	T	S	Q	00	N	E								
16	A	Q	N	L	V	R	I	R	R	Q	R	Y	S	T	V	M	V	V	M	P	F	A								
17	D	K	K	E	L	P	S	P	T	C	E	G	S	S	Q	G	S	R	N	S	C	Y								

FIG. 11B




FIG. 12A

HK68 → HK14

Ab 1 ↓

HK 68	EN72	VVS	TX77	BK79	SI87	BE89	BE92	WH95	SY97	FU02	CA04	WI05	PE09
>50	>50	>50	>50	>50	>50	>50	>50	>50	6.25	3.13	0.20	0.20	0.20
>50	>50	>50	>50	6.25	>50	6.25	>50	>50	0.20	1.56	0.39	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	3.13	0.20	0.20	0.78
>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	3.13	0.20	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	3.13	0.20	0.20	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.20	3.13	0.39	0.20	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.20	1.56	0.20	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	3.13	0.39	0.20	0.20
>50	>50	>50	>50	>50	6.25	>50	3.13	3.13	1.56	6.25	0.20	0.20	12.50
>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	12.50	12.50	0.78	0.39
>50	>50	>50	6.25	0.78	0.39	1.56	1.56	3.13	3.13	12.50	12.50	12.50	3.13
>50	25.00	>50	>50	25.00	>50	>50	25.00	>50	>50	>50	>50	12.50	6.25
>50	0.20	>50	>50	0.20	0.20	6.25	1.56	1.56	0.20	>50	6.25	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	0.20	0.20	0.20	1.56	1.56	1.56	>50	>50	12.50	0.39
>50	>50	0.20	3.13	0.20	0.20	>50	1.56	0.78	0.20	1.56	0.20	0.20	0.20
>50	>50	>50	>50	>50	25.00	0.30	3.13	3.13	0.20	3.13	0.30	0.30	>50
25.00	>50	0.78	1.56	0.78	1.56	>50	3.13	3.13	12.50	3.13	6.25	12.50	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	3.13	3.13	0.78	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	6.25	12.50	0.20	1.56	0.20	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	1.56	0.20	0.20
25.00	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
1.56	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50

FIG. 12B

		WT ←	HK14										→ 17 AA mutants
TX12	HK14	WT	mul-1	mul-2	mul-4	mul-6	mul-8	mul-7	mul-9	mul-10	mul-11	mul-12	mul-14
0.78	>50	1.98	0.04	0.06	0.04	0.05	0.04	0.00	0.08	0.06	0.04	0.04	0.00
1.56	>50	1.99	0.04	0.06	0.05	0.04	0.08	0.11	0.08	0.06	0.04	0.05	0.10
1.56	>50												
1.56	>50	1.66	1.39	0.00	0.10	0.00	0.10	0.07	0.10	0.07	0.07	0.06	0.12
6.25	>50	2.06	0.04	0.06	0.11	0.04	0.04	0.11	0.00	0.07	0.04	0.05	0.11
25.00	>50	1.91	0.04	0.07	0.05	0.04	0.05	0.11	0.10	0.06	0.04	0.05	0.14
1.56	>50	1.94	0.04	0.06	0.05	0.05	0.07	0.00	0.08	0.07	0.04	0.05	0.10
1.56	>50												
3.13	>50												
3.13	>50	1.96	0.05	0.08	0.06	0.06	0.06	0.12	0.10	0.08	0.06	0.06	0.21
6.25	12.50	1.88	0.53	0.06	0.06	0.55	0.24	0.58	0.61	0.17	0.40	0.06	1.63
25.00	>50	1.64	0.27	0.21	0.26	0.42	0.26	0.55	0.62	0.10	0.24	0.36	1.29
1.56	6.25	1.85	0.04	0.05	0.05	0.04	0.05	0.00	0.00	0.06	0.20	0.05	0.27
>50	>50												
6.25	>50	1.83	0.04	0.05	0.05	0.04	0.05	0.00	0.00	0.06	0.14	0.06	0.11
1.56	1.56	1.88	0.04	0.04	0.05	0.04	0.04	0.08	0.00	0.06	0.04	0.05	0.08
3.13	>50	1.98	0.05	0.06	0.04	0.04	0.04	0.10	0.08	0.05	0.04	0.05	0.11
6.25	25.00	1.65	0.51	0.41	0.30	0.51	0.30	0.71	0.63	0.18	0.40	0.00	1.79
1.56	>50	1.91	0.04	0.08	0.04	0.05	0.06	0.10	0.00	0.07	0.04	0.05	0.66
1.56	>50	1.83	0.04	0.07	0.05	0.05	0.25	0.10	0.00	0.06	0.04	0.05	0.15
0.78	>50	1.94	0.97	0.00	0.00	0.10	0.17	0.10	0.08	0.07	0.08	0.06	0.12
>50	>50												
>50	>50												

FIG. 12C

mul-15	mul-16	mul-17	mul-21	mul-22	mul-23	mul-24	mul-25	mul-60	mul-67	mul-68	mul-70	mul-71
0.07	0.11	0.12	0.08	0.08	0.10	0.08	0.13	0.07	0.08	0.00	0.07	0.08
0.26	0.13	0.11	0.08	0.08	0.15	0.08	0.14	0.07	0.08	0.08	0.07	0.08
0.08	0.12	0.11	0.07	0.08	0.10	0.08	0.17	0.07	0.07	0.00	0.06	0.00
0.13	0.12	0.15	0.00	0.10	0.40	0.10	0.16	0.07	0.00	0.07	0.08	0.08
0.14	0.15	0.20	0.00	0.11	0.94	0.11	0.24	0.08	0.00	0.08	0.00	0.07
0.59	0.13	0.15	0.08	0.00	0.11	0.10	0.18	0.07	0.00	0.00	0.07	0.06
0.16	0.20	0.21	0.11	0.13	0.17	0.13	0.24	0.00	0.10	0.10	0.08	0.00
0.15	0.11	0.39	0.00	0.26	1.50	0.28	0.36	0.13	0.40	0.60	0.50	0.62
1.47	1.55	1.87	0.62	1.42	1.45	1.39	1.84	0.58	0.56	0.62	0.58	0.64
0.00	0.11	0.13	0.00	0.11	1.02	0.10	0.15	0.08	0.08	0.08	0.07	0.07
0.00	0.12	0.15	0.08	0.00	0.86	0.10	0.15	0.08	0.07	0.08	0.07	0.07
0.08	0.00	0.10	0.00	0.07	0.38	0.07	0.11	0.07	0.08	0.07	0.07	0.07
0.40	0.16	0.13	0.00	0.08	1.25	0.00	0.13	0.07	0.08	0.08	0.07	0.08
1.27	0.43	0.74	0.08	1.30	1.78	0.89	1.18	0.34	0.52	0.61	0.64	0.59
0.58	0.23	0.17	0.08	0.11	0.17	0.10	0.20	0.08	0.00	0.10	0.07	0.08
1.66	0.16	0.17	0.08	0.11	0.38	0.11	0.17	0.08	0.08	0.10	0.08	0.07
0.12	0.14	0.15	0.08	0.12	0.13	0.10	0.14	0.08	0.08	0.00	0.07	0.08

FIG. 12D

>50	>50	25.00	>50	25.00	12.50	12.50	25.00	25.00	25.00	>50	>50	6.25	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	3.13	0.20	0.39
>50	>50	25.00	>50	>50	12.50	25.00	>50	25.00	25.00	>50	>50	>50	>50
>50	>50	>50	>50	12.50	12.50	25.00	>50	>50	25.00	25.00	25.00	12.50	12.50
>50	>50	6.25	3.13	3.13	>50	25.00	>50	>50	>50	>50	1.56	25.00	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	1.56	0.30	0.78
>50	>50	>50	>50	25.00	>50	25.00	>50	>50	>50	>50	>50	>50	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	1.56	>50	12.50	6.25	0.39
>50	>50	>50	>50	>50	>50	25.00	>50	>50	>50	0.78	3.13	0.20	0.39
>50	>50	25.00	25.00	1.56	12.50	0.78	3.13	3.13	6.25	0.78	6.25	0.39	6.25
>50	>50	>50	>50	>50	12.50	12.50	0.20	0.20	0.20	0.78	3.13	0.20	12.50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	25.00	>50	25.00	>50	>50	25.00	>50
25.00	25.00	12.50	25.00	12.50	25.00	12.50	12.50	12.50	12.50	25.00	>50	6.25	12.50
6.25	6.25	3.13	6.25	>50	>50	>50	>50	>50	>50	6.25	12.50	3.13	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00	0.20	0.20	0.20	3.13
>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	0.20	0.20	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	12.50	12.50	>50	25.00	12.50	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00
>50	>50	>50	>50	12.50	>50	12.50	12.50	25.00	25.00	25.00	>50	12.50	25.00
>50	25.00	>50	>50	>50	25.00	6.25	12.50	12.50	>50	25.00	25.00	6.25	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00
>50	>50	>50	>50	25.00	>50	>50	25.00	>50	>50	>50	>50	>50	25.00



FIG. 12E

25.00	25.00	1.70	0.41	0.40	0.27	0.54	0.37	0.62	0.68	0.30	0.50	0.42	1.64
0.78	>50	1.82	0.04	0.07	0.04	0.05	0.04	0.10	0.00	0.06	0.04	0.05	0.13
>50	>50	1.02	1.91	0.64	0.26	1.00	1.42	0.11	0.11	0.20	0.14	0.18	0.30
>50	>50												
>50	>50	0.91	0.10	0.83	0.14	0.84	0.08	0.12	0.31	0.17	0.11	0.20	0.25
0.78	>50												
>50	>50	1.44	0.11	1.79	0.95	2.08	0.11	0.61	0.65	1.08	1.21	0.97	1.40
>50	>50	1.80	0.69	0.10	0.08	0.00	0.08	0.00	0.08	0.08	0.00	0.08	0.11
1.56	>50												
>50	12.50	1.77	0.04	0.04	0.05	0.04	0.04	0.60	0.08	0.05	0.04	0.05	0.00
6.25	>50												
>50	>50												
>50	>50												
>50	>50												
12.50	>50	1.69	0.11	0.10	0.08	0.42	0.00	0.61	0.08	0.08	0.00	0.08	0.12
0.78	12.50	1.98	0.04	0.06	0.04	0.04	0.04	0.10	0.08	0.06	0.04	0.05	0.16
0.30	3.13	1.81	1.90	0.10	0.07	0.00	1.49	0.00	0.08	0.08	0.12	0.08	0.30
0.30	>50	2.00	1.96	0.10	0.07	0.10	1.65	0.00	0.07	0.00	0.08	0.00	0.34
>50	>50	1.64	1.82	1.57	0.88	2.09	1.45	0.70	0.74	0.71	1.23	1.02	1.33
>50	>50												
>50	>50	1.63	1.99	1.76	0.91	1.94	1.53	0.64	0.71	0.82	1.31	1.24	1.72
>50	>50	1.96	0.84	1.50	1.12	1.69	0.17	0.68	0.77	0.96	1.27	1.07	1.74
>50	>50	1.39	0.58	1.84	1.23	2.13	0.07	0.67	0.70	0.86	1.43	1.17	1.56
>50	>50												

FIG. 12F

1.51	1.64	2.04	0.66	1.52	1.56	1.64	1.92	0.63	0.64	0.66	0.64	0.64
0.13	0.15	0.16	0.08	0.13	0.33	0.10	0.15	0.07	0.08	0.00	0.06	0.07
0.24	0.30	0.36	0.13	0.37	0.22	0.22	0.36	0.07	0.00	0.12	0.08	0.08
0.17	0.50	0.51	0.44	0.35	0.20	0.21	0.26	0.11	0.08	0.30	0.12	0.16
1.22	1.42	1.86	0.61	1.11	0.99	1.32	1.86	0.51	0.43	0.63	0.58	0.55
0.00	0.10	1.11	0.08	0.10	0.10	0.11	0.13	0.07	0.07	0.07	0.15	0.24
0.08	0.10	0.10	0.08	0.08	0.12	0.83	0.13	0.07	0.07	0.61	0.08	0.07
0.11	0.12	0.14	0.08	0.11	0.12	0.63	0.16	0.07	0.08	0.59	0.07	0.07
0.11	0.16	0.18	0.08	0.12	0.12	0.10	0.18	0.08	0.08	0.00	0.07	0.07
0.11	0.17	0.18	0.08	0.15	0.13	0.00	0.17	0.07	0.08	0.00	0.07	0.07
0.13	0.10	0.10	0.07	0.10	0.15	0.00	0.16	0.08	0.08	0.08	0.06	0.06
1.47	1.54	1.88	0.69	1.60	1.37	1.43	1.91	0.68	0.71	0.74	0.64	0.57
1.43	1.44	1.95	0.67	1.50	1.35	1.58	1.97	0.63	0.67	0.68	0.65	0.65
1.44	1.65	2.06	0.68	1.71	1.61	1.41	1.95	0.68	0.70	0.70	0.70	0.65
1.38	1.34	1.26	0.66	1.30	1.26	1.41	1.87	0.57	0.47	0.62	0.60	0.57

FIG. 12G

>50	25.00	6.25	6.25	3.13	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.39	0.78	0.39	0.20	0.39
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.39	0.20	0.39	0.20	25.00
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00	25.00	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.20	0.20	0.39	0.78	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	12.50	0.78	0.20	1.56
>50	>50	>50	>50	>50	>50	>50	>50	>50	0.39	0.20	1.56	>50	25.00
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
25.00	25.00	>50	>50	12.50	>50	25.00	25.00	12.50	12.50	25.00	25.00	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00	>50	>50	25.00
12.50	12.50	12.50	12.50	>50	>50	>50	>50	>50	25.00	6.25	12.50	12.50	>50
>50	25.00	>50	>50	12.50	>50	25.00	12.50	12.50	25.00	6.25	12.50	>50	6.25
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
6.25	6.25	6.25	6.25	>50	>50	>50	>50	>50	6.25	25.00	12.50	6.25	25.00
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
3.13	1.56	6.25	3.13	25.00	>50	>50	>50	>50	3.13	3.13	6.25	6.25	3.13
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
12.50	6.25	12.50	12.50	>50	>50	12.50	>50	0.78	12.50	25.00	>50	12.50	25.00
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	0.20	0.30	>50	0.20	0.20	1.56	>50	>50
6.25	3.13	25.00	6.25	>50	>50	3.13	>50	>50	6.25	25.00	25.00	25.00	>50
6.25	3.13	>50	6.25	>50	>50	3.13	>50	>50	12.50	>50	>50	>50	>50



FIG. 12H

12.50	>50	0.81	0.13	0.80	0.16	0.85	0.08	0.16	0.32	0.16	0.13	0.18	0.31
25.00	>50	1.94	1.69	0.10	0.07	0.19	1.02	0.08	0.08	0.07	0.44	0.08	0.22
>50	>50												
12.50	>50												
6.25	>50												
>50	>50	1.99	0.04	0.05	0.04	0.05	0.05	0.00	0.00	0.06	0.04	0.05	0.24
25.00	>50												
25.00	>50												
>50	>50												
>50	>50												
>50	>50												
1.56	>50	1.53	0.21	0.18	0.19	0.37	0.18	0.56	0.60	0.14	0.20	0.26	1.54
>50	>50												
0.30	>50	1.43	0.04	0.07	0.04	0.05	0.04	0.22	0.08	0.07	0.05	0.04	0.12
>50	>50												
>50	12.50	1.30	0.04	0.10	0.04	0.05	0.05	0.25	0.09	0.07	0.04	0.04	0.17
>50	>50												
>50	>50												
>50	>50												
>50	>50												
25.00	>50	1.64	0.05	0.00	0.05	0.05	0.05	0.11	0.00	0.07	0.04	0.05	0.18
>50	>50	1.70	0.05	0.00	0.05	0.05	0.05	0.66	0.00	0.08	0.04	0.05	0.36

FIG. 12I

0.10	0.42	0.55	0.30	0.32	0.23	0.24	0.27	0.11	0.10	0.28	0.14	0.14
0.11	0.12	0.18	0.08	0.13	0.80	0.17	0.17	0.15	0.07	0.07	0.07	0.07
0.15	0.17	0.23	0.08	0.15	0.16	0.15	0.22	0.08	0.07	0.08	0.07	0.07
0.99	1.61	2.00	0.57	1.30	1.24	1.99	1.83	0.55	0.56	0.58	0.55	0.55
0.15	0.19	0.18	0.08	0.12	0.00	0.00	0.13	0.07	0.08	0.58	0.07	0.07
0.16	0.18	0.21	0.08	0.16	0.14	0.10	0.21	0.08	0.08	0.62	0.06	0.06
0.22	0.16	0.21	0.07	0.14	0.43	0.10	0.10	0.08	0.08	0.10	0.06	0.08
0.16	0.19	0.40	0.07	0.17	0.14	0.17	0.18	0.07	0.08	0.71	0.06	0.08

FIG. 12J

6.25	3.13	25.00	12.50	>50	>50	3.13	>50	>50	6.25	>50	>50	25.00	>50
12.50	6.25	>50	6.25	>50	>50	6.25	>50	>50	6.25	12.50	>50	>50	25.00
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	0.78	3.13	12.50	0.20	0.39	>50	>50	>50	>50	>50	6.25	3.13	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	25.00	12.50	>50	0.20
12.50	6.25	12.50	12.50	6.25	25.00	25.00	6.25	12.50	3.13	>50	>50	12.50	>50
>50	>50	>50	12.50	>50	0.20	1.56	0.39	0.39	0.20	0.39	0.20	>50	0.78
>50	>50	>50	>50	>50	>50	>50	>50	>50	3.13	0.20	0.39	>50	>50
>50	25.00	>50	>50	>50	>50	25.00	>50	>50	25.00	>50	>50	>50	12.50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	25.00	>50	0.20	>50	0.20	0.39	0.20	0.78	0.20	1.56	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	0.20	0.39	0.20
>50	>50	>50	>50	>50	>50	0.78	0.78	1.56	0.78	12.50	>50	>50	>50
>50	12.50	>50	>50	12.50	>50	25.00	25.00	>50	25.00	>50	25.00	25.00	12.50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	0.78	0.39	0.20	>50	12.50	3.13	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	0.20	0.20
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	1.56
>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50	>50



Ab 98

FIG. 12K

25.00	>50	1.65	0.04	0.07	0.04	0.04	0.04	0.38	0.08	0.07	0.05	0.04	0.18
12.50	>50												
>50	>50												
>50	>50												
>50	>50												
>50	>50												
0.30	>50	1.40	1.74	0.00	0.07	0.00	0.85	0.08	0.00	0.06	0.07	0.07	0.20
>50	>50												
0.30	6.25	1.87	0.10	0.00	0.06	0.10	0.07	0.00	0.08	0.07	0.24	0.08	0.18
12.50	>50												
>50	>50	1.61	1.81	1.51	0.58	2.08	1.65	0.34	0.43	0.45	0.56	0.77	0.96
>50	>50												
>50	>50												
6.25	>50	0.80	0.08	0.00	0.07	0.08	0.07	0.08	0.08	0.08	0.00	0.07	0.12
0.78	>50												
>50	>50												
>50	25.00	1.43	0.36	0.30	0.22	0.52	0.24	0.66	0.69	0.21	0.33	0.32	1.40
>50	>50												
>50	>50												
0.20	0.30	1.67	0.04	0.05	0.04	0.04	0.04	0.07	0.08	0.05	0.05	0.04	0.00
>50	>50												
>50	>50												
6.25	6.25	1.80	0.52	0.48	0.43	0.51	0.53	0.65	0.69	0.47	0.52	0.51	2.22
>50	>50												

FIG. 12L

0.14	0.18	0.21	0.07	0.15	0.15	0.11	0.16	0.07	0.08	0.73	0.06	0.07
0.13	0.15	0.21	0.08	0.13	0.12	0.11	0.16	0.06	0.08	0.08	0.08	0.07
0.15	0.17	0.25	0.07	0.16	1.17	0.12	0.17	0.07	0.08	0.07	0.06	0.07
0.76	0.00	1.48	0.38	1.13	0.83	0.74	1.20	0.15	0.11	0.58	0.26	0.33
0.15	0.14	0.24	0.08	0.14	1.17	0.12	0.18	0.07	0.07	0.08	0.07	0.07
1.15	1.20	1.00	0.63	1.56	1.27	1.26	1.83	0.65	0.60	0.63	0.56	0.55
0.08	0.10	0.11	0.00	0.08	0.08	0.00	0.12	0.07	0.07	0.07	0.06	0.07
1.83	1.96	2.18	0.62	2.05	1.86	1.72	1.88	0.58	0.63	0.61	0.65	0.63

FIG. 12M





FIG. 13A

WT ←————— 17 AAmutants —————→

Antibodies	1	1.98	0.04	0.06	0.01	0.05	0.04	0.09	0.08	0.06	0.04	0.04	0.09	0.07	0.11	0.12	0.08	0.08	0.10	0.08	0.13	0.07	0.08	0.09	0.07	0.08	-
	2	1.96	0.04	0.06	0.05	0.04	0.08	0.11	0.08	0.06	0.04	0.05	0.10	0.26	0.13	0.11	0.08	0.08	0.15	0.08	0.14	0.07	0.08	0.08	0.07	0.08	H
	5	2.06	0.04	0.06	0.11	0.04	0.04	0.11	0.09	0.07	0.04	0.05	0.11	0.13	0.12	0.15	0.09	0.10	0.10	0.10	0.16	0.07	0.09	0.07	0.08	0.08	-
	10	1.96	0.05	0.08	0.06	0.06	0.06	0.12	0.10	0.08	0.06	0.06	0.21	0.16	0.20	0.21	0.11	0.13	0.17	0.13	0.24	0.09	0.10	0.10	0.08	0.09	-
	16	1.88	0.04	0.04	0.05	0.06	0.04	0.08	0.09	0.06	0.04	0.05	0.08	0.08	0.09	0.10	0.09	0.07	0.13	0.07	0.11	0.07	0.08	0.07	0.07	0.07	-
	25	1.32	0.24	0.07	0.01	0.25	0.04	0.10	0.09	0.06	0.04	0.05	0.13	0.13	0.15	0.16	0.08	0.10	0.13	0.10	0.15	0.07	0.08	0.09	0.06	0.07	-
	40	1.93	0.34	0.06	0.01	0.01	0.04	0.10	0.08	0.06	0.04	0.05	0.16	0.11	0.15	0.18	0.08	0.12	0.12	0.00	0.18	0.08	0.08	0.09	0.07	0.08	-
	54	1.95	0.24	0.05	0.01	0.25	0.05	0.09	0.09	0.06	0.04	0.05	0.24	0.15	0.17	0.23	0.08	0.15	0.15	0.15	0.22	0.08	0.07	0.08	0.07	0.07	-
	71	1.61	0.35	0.09	0.05	0.25	0.05	0.11	0.09	0.07	0.04	0.05	0.18	0.22	0.15	0.21	0.07	0.14	0.18	0.00	0.19	0.08	0.08	0.08	0.06	0.08	H
	95	1.67	0.34	0.05	0.01	0.01	0.04	0.07	0.08	0.05	0.05	0.04	0.09	0.08	0.10	0.11	0.09	0.08	0.18	0.09	0.12	0.07	0.07	0.07	0.06	0.07	-
	4	1.66	1.39	0.09	1.10	0.05	0.09	0.07	0.10	0.07	0.07	0.06	0.12	0.08	0.12	0.11	0.07	0.08	0.10	0.08	0.17	0.07	0.07	0.09	0.06	0.09	-
	6	1.91	0.04	0.07	0.05	0.04	0.05	0.11	0.10	0.06	0.04	0.05	0.14	0.14	0.15	0.20	0.09	0.11	0.90	0.11	0.24	0.08	0.09	0.08	0.09	0.07	-
	7	1.94	0.04	0.06	0.05	0.06	0.07	0.09	0.08	0.07	0.04	0.05	0.10	0.09	0.13	0.15	0.08	1.09	0.10	0.00	0.18	0.07	0.09	0.09	0.07	0.06	-
	13	1.85	0.04	0.05	0.05	0.00	0.06	0.09	0.09	0.06	0.20	0.06	0.27	0.09	0.11	0.13	0.09	0.11	1.02	0.00	0.15	0.08	0.08	0.08	0.07	0.07	H
	15	1.83	0.04	0.05	0.05	0.00	0.05	0.09	0.09	0.06	0.14	0.06	0.11	0.09	0.12	0.15	0.08	0.09	1.30	0.00	0.15	0.08	0.07	0.08	0.07	0.07	H

FIG. 13B

17	1.98	0.06	0.06	0.04	0.04	0.10	0.08	0.06	0.04	0.05	0.05	0.11	0.19	0.15	0.13	0.09	0.08	1.25	0.09	0.13	0.07	0.08	0.00	0.07	0.08	-
19	1.81	0.04	0.08	0.01	0.05	0.06	0.10	0.09	0.07	0.04	0.05	0.15	0.53	0.29	0.17	0.08	0.11	0.17	0.00	0.20	0.08	0.09	0.00	0.08	0.08	-
20	1.80	0.04	0.07	0.05	0.05	0.25	0.10	0.09	0.06	0.04	0.06	0.15	1.65	0.15	0.17	0.08	0.11	0.18	0.11	0.17	0.08	0.08	0.10	0.08	0.07	
21	1.94	0.97	0.09	0.09	0.10	0.17	0.10	0.08	0.07	0.08	0.06	0.12	0.12	0.14	0.15	0.08	0.12	0.13	0.10	0.14	0.08	0.08	0.09	0.07	0.08	-
26	1.02	1.91	0.54	0.25	1.00	1.42	0.11	0.11	0.20	0.14	0.18	0.30	0.21	0.39	0.36	0.13	0.37	0.22	0.22	0.36	0.07	0.09	0.12	0.08	0.08	H
28	0.91	0.10	0.83	0.30	0.80	0.08	0.12	0.31	0.17	0.11	0.20	0.25	0.17	0.50	0.51	0.44	0.35	0.20	0.21	0.26	0.11	0.08	0.30	0.12	0.16	-
31	1.80	0.69	0.10	0.08	0.08	0.08	0.09	0.08	0.08	0.09	0.08	0.11	0.09	0.10	0.11	0.08	0.10	0.10	0.11	0.13	0.07	0.07	0.07	0.15	0.24	-
33	1.77	0.04	0.04	0.05	0.00	0.00	0.60	0.08	0.05	0.14	0.05	0.09	0.08	0.10	0.10	0.08	0.08	0.12	0.83	0.13	0.07	0.07	0.61	0.08	0.07	H
39	1.09	0.11	0.10	0.08	0.42	0.09	0.61	0.08	0.08	0.09	0.08	0.12	0.11	0.12	0.14	0.08	0.11	0.12	0.63	0.16	0.07	0.08	0.59	0.07	0.07	H
41	1.81	1.90	0.10	0.07	0.09	1.43	0.09	0.08	0.08	0.12	0.08	0.30	0.11	0.17	0.18	0.08	0.15	0.13	0.09	0.17	0.07	0.08	0.09	0.07	0.07	-
42	2.00	1.96	0.10	0.07	0.10	1.65	0.09	0.07	0.09	0.08	0.09	0.34	0.13	0.19	0.19	0.07	0.10	0.15	0.09	0.16	0.08	0.08	0.08	0.06	0.07	-
49	0.81	0.13	0.30	0.15	0.85	0.08	0.16	0.32	0.15	0.13	0.18	0.31	0.19	0.42	0.55	0.30	0.32	0.29	0.24	0.27	0.11	0.10	0.28	0.14	0.17	-
50	1.94	1.89	0.10	0.07	0.15	1.02	0.08	0.08	0.07	0.44	0.08	0.22	0.11	0.12	0.18	0.08	0.13	0.80	0.12	0.17	0.15	0.07	0.07	0.07	0.07	-
64	1.48	0.04	0.07	0.01	0.05	0.04	0.22	0.08	0.07	0.05	0.04	0.12	0.15	0.19	0.18	0.08	0.12	0.09	0.09	0.13	0.07	0.08	0.58	0.07	0.07	H
66	1.30	0.04	0.10	0.01	0.05	0.05	0.25	0.09	0.07	0.04	0.04	0.17	0.16	0.18	0.21	0.08	0.16	0.14	0.08	0.21	0.08	0.08	0.62	0.06	0.08	H
72	1.70	0.05	0.09	0.05	0.05	0.05	0.65	0.09	0.08	0.05	0.05	0.36	0.16	0.19	0.08	0.07	0.17	0.34	0.17	0.18	0.07	0.08	0.71	0.06	0.08	H
73	1.71	0.05	0.08	0.01	0.91	0.05	0.63	0.08	0.07	0.04	0.05	0.23	0.13	0.17	0.28	0.08	0.15	0.34	0.12	0.16	0.08	0.08	0.74	0.06	0.08	H
75	1.65	0.04	0.07	0.01	0.65	0.04	0.38	0.08	0.07	0.05	0.04	0.18	0.14	0.18	0.21	0.07	0.15	0.15	0.11	0.16	0.07	0.08	0.79	0.06	0.07	H


FIG. 13C

81	1.49	1.74	0.09	0.07	0.01	0.85	0.08	0.09	0.06	0.07	0.07	0.20	0.13	0.15	0.21	0.08	0.13	0.12	0.11	0.16	0.06	0.08	0.08	0.08	0.07	-
88	1.87	0.00	0.09	0.06	0.10	0.07	0.09	0.08	0.07	0.24	0.08	0.18	0.15	0.17	0.25	0.07	0.15	0.12	0.12	0.17	0.07	0.08	0.07	0.06	0.07	-
89	0.80	0.08	0.09	0.07	0.08	0.08	0.08	0.09	0.07	0.12	0.15	0.14	0.24	0.08	0.14	1.17	0.12	0.18	0.12	0.18	0.07	0.07	0.08	0.07	0.07	-

11	1.88	0.53	0.06	0.06	0.55	0.24	0.58	0.61	0.17	0.40	0.06	1.63	0.15	0.11	0.39	0.09	0.26	1.50	0.28	0.96	0.13	0.40	0.60	0.59	0.63	Head
18	1.65	0.51	0.41	0.50	0.50	0.30	0.71	0.63	0.18	0.40	0.09	1.79	1.27	0.43	0.74	0.08	1.30	1.78	0.89	1.18	0.34	0.52	0.61	0.54	0.59	
30	1.44	0.11	1.79	0.96	2.08	0.11	0.61	0.65	1.08	1.21	0.97	1.40	1.22	0.42	1.86	0.51	1.11	0.96	1.32	1.86	0.51	0.43	0.63	0.58	0.55	
43	1.61	1.82	1.57	0.88	2.49	1.45	0.70	0.74	0.71	1.29	1.02	1.33	1.47	1.51	1.88	0.59	1.60	1.37	1.43	1.91	0.68	0.71	0.74	0.54	0.59	
46	1.96	0.84	1.50	1.12	1.69	0.17	0.68	0.77	0.96	1.27	1.07	1.74	1.44	1.65	2.06	0.58	1.71	1.61	1.41	1.95	0.68	0.70	0.70	0.70	0.63	
86	1.60	1.81	1.51	0.58	2.08	1.65	0.34	0.43	0.45	0.56	0.77	0.96	0.76	0.90	1.48	0.38	1.13	0.60	0.74	1.29	0.15	0.11	0.58	0.26	0.33	
98	1.80	0.52	0.18	0.48	0.50	0.53	0.65	0.69	0.47	0.52	0.51	2.22	1.83	1.96	2.13	0.52	2.05	1.86	1.72	1.88	0.58	0.63	0.61	0.55	0.63	

12	1.64	0.27	0.21	0.25	0.42	0.26	0.55	0.62	0.19	0.20	0.36	1.29	1.47	1.55	1.87	0.52	1.42	1.45	1.39	1.84	0.58	0.56	0.62	0.58	0.54	Stem
24	1.70	0.41	0.40	0.25	0.50	0.37	0.62	0.68	0.30	0.50	0.42	1.64	1.51	1.64	2.04	0.56	1.52	1.56	1.64	1.92	0.63	0.64	0.66	0.54	0.54	
45	1.63	1.99	1.76	0.50	1.50	1.53	0.64	0.71	0.82	1.31	1.24	1.72	1.43	1.41	1.95	0.57	1.50	1.35	1.58	1.97	0.63	0.67	0.68	0.65	0.53	
47	1.39	0.58	1.84	1.29	2.13	0.07	0.67	0.70	0.86	1.43	1.17	1.56	1.38	1.31	1.96	0.56	1.30	1.35	1.41	1.87	0.57	0.47	0.62	0.60	0.53	
61	1.53	0.21	0.18	0.19	0.30	0.13	0.56	0.60	0.14	0.20	0.26	1.54	0.99	1.60	2.00	0.57	1.30	1.21	1.33	1.83	0.55	0.56	0.58	0.55	0.53	
92	1.43	0.36	0.30	0.29	0.52	0.24	0.66	0.69	0.21	0.33	0.32	1.40	1.15	1.29	1.99	0.63	1.56	1.25	1.26	1.83	0.65	0.60	0.63	0.56	0.55	

FIG. 13D



POSITION	MUTANTS																													
	WT	1	2	4	5	6	9	10	11	12	14	15	16	17	22	23	24	25	26	28	29	30								
1	N	Y	M	K	Q	V	V	R	T	I	V	A	V	V	S	V	L	R	V	F	S	F								
2	T	V	V	R	R	R	K	V	G	T	M	K	C	C	S	Q	R	R	R	D	R	V								
3	T	V	G	G	T	R	V	K	L	N	3	S	N	L	T	V	N	I	Y	S	K	W								
4	A	K	D	A	K	F	T	W	R	K	4	R	I	L	K	R	T	V	K	K	T	S								
5	I	W	F	P	L	M	H	M	C	T	T	N	K	R	S	R	K	N	T	G	N	M								
6	R	S	T	D	N	N	E	G	S	Y	G	D	R	F	Q	E	T	G	A	N	R	H								
7	S	G	D	A	T	T	R	V	G	D	A	G	P	K	G	H	N	T	E	V	A	Q								
8	S	P	R	G	P	W	R	P	R	S	W	V	D	T	S	S	S	R	Q	K	P	P								
9	T	V	C	M	9	V	A	I	Y	R	Q	R	A	I	R	V	Q	W	T	P	Q	Q								
10	H	G	A	T	P	A	S	G	P	S	S	S	A	P	P	T	K	P	L	T	H	G								
11	L	V	N	S	D	L	P	P	L	S	R	R	G	S	I	L	R	S	W	R	M	R								
12	N	R	G	P	R	H	V	V	Q	S	L	F	A	P	K	R	F	P	G	R	K	C								
13	N	D	R	K	T	T	R	F	T	F	Q	T	L	Q	E	H	S	R	R	L	F	T								
14	K	N	E	D	A	I	R	T	F	A	L	E	A	N	P	L	F	S	Y	S	T	S								
15	F	A	G	G	Q	S	T	R	A	Q	R	A	P	S	N	T	T	S	Q	00	N	E								
16	A	Q	N	L	V	R	I	R	R	Q	R	Y	S	T	V	M	V	V	M	P	F	A								
17	D	K	K	E	L	P	S	P	T	C	E	G	S	S	Q	G	S	R	N	S	C	Y								

FIG. 14A

WT ←————— 17 AAmutants —————→

Antibodies	1	1.98	0.04	0.06	0.01	0.05	0.04	0.09	0.08	0.06	0.04	0.04	0.09	0.07	0.11	0.12	0.08	0.08	0.10	0.08	0.13	0.07	0.08	0.09	0.07	0.08	-
	2	1.96	0.04	0.06	0.05	0.04	0.08	0.11	0.08	0.06	0.04	0.05	0.10	0.26	0.13	0.11	0.08	0.08	0.15	0.08	0.14	0.07	0.08	0.08	0.07	0.08	H
	5	2.06	0.04	0.06	0.11	0.04	0.04	0.11	0.09	0.07	0.04	0.05	0.11	0.13	0.12	0.15	0.09	0.10	0.10	0.10	0.16	0.07	0.09	0.07	0.08	0.08	-
	10	1.96	0.05	0.08	0.06	0.06	0.06	0.12	0.10	0.08	0.06	0.06	0.21	0.16	0.20	0.21	0.11	0.13	0.17	0.13	0.24	0.09	0.10	0.10	0.08	0.09	-
	16	1.88	0.04	0.04	0.05	0.06	0.04	0.08	0.09	0.06	0.04	0.05	0.08	0.08	0.09	0.10	0.09	0.07	0.13	0.07	0.11	0.07	0.08	0.07	0.07	0.07	-
	25	1.32	0.24	0.07	0.01	0.25	0.04	0.10	0.09	0.06	0.04	0.05	0.13	0.13	0.15	0.16	0.08	0.10	0.13	0.10	0.15	0.07	0.08	0.09	0.06	0.07	-
	40	1.93	0.34	0.06	0.01	0.01	0.04	0.10	0.08	0.06	0.04	0.05	0.16	0.11	0.15	0.18	0.08	0.12	0.12	0.00	0.18	0.08	0.08	0.09	0.07	0.08	-
	54	1.95	0.24	0.05	0.01	0.25	0.05	0.09	0.09	0.06	0.04	0.05	0.24	0.15	0.17	0.23	0.08	0.15	0.15	0.15	0.22	0.08	0.07	0.08	0.07	0.07	-
	71	1.61	0.35	0.09	0.05	0.25	0.05	0.11	0.09	0.07	0.04	0.05	0.18	0.22	0.15	0.21	0.07	0.14	0.18	0.00	0.19	0.08	0.08	0.08	0.06	0.08	H
	95	1.67	0.34	0.05	0.01	0.01	0.04	0.07	0.08	0.05	0.05	0.04	0.09	0.08	0.10	0.11	0.09	0.08	0.18	0.09	0.12	0.07	0.07	0.07	0.06	0.07	-
	4	1.66	1.39	0.09	1.10	0.05	0.09	0.07	0.10	0.07	0.07	0.06	0.12	0.08	0.12	0.11	0.07	0.08	0.10	0.08	0.17	0.07	0.07	0.09	0.06	0.09	-
	6	1.91	0.04	0.07	0.05	0.04	0.05	0.11	0.10	0.06	0.04	0.05	0.14	0.14	0.15	0.20	0.09	0.11	0.90	0.11	0.24	0.08	0.09	0.08	0.09	0.07	-
	7	1.94	0.04	0.06	0.05	0.06	0.07	0.09	0.08	0.07	0.04	0.05	0.10	0.09	0.13	0.15	0.08	1.09	0.10	0.00	0.18	0.07	0.09	0.09	0.07	0.06	-
	13	1.85	0.04	0.05	0.05	0.00	0.06	0.09	0.09	0.06	0.20	0.06	0.27	0.09	0.11	0.13	0.09	0.11	1.02	0.00	0.15	0.08	0.08	0.08	0.07	0.07	H
	15	1.83	0.04	0.05	0.05	0.00	0.05	0.09	0.09	0.06	0.14	0.06	0.11	0.09	0.12	0.15	0.08	0.09	1.30	0.00	0.15	0.08	0.07	0.08	0.07	0.07	H

FIG. 14B

17	1.98	0.06	0.06	0.04	0.04	0.10	0.08	0.06	0.04	0.05	0.05	0.11	0.19	0.15	0.13	0.09	0.08	1.25	0.09	0.13	0.07	0.08	0.00	0.07	0.08	-
19	1.81	0.04	0.08	0.01	0.05	0.06	0.10	0.09	0.07	0.04	0.05	0.15	0.53	0.29	0.17	0.08	0.11	0.17	0.00	0.20	0.08	0.09	0.00	0.08	0.08	-
20	1.80	0.04	0.07	0.05	0.05	0.25	0.10	0.09	0.06	0.04	0.06	0.15	1.65	0.15	0.17	0.08	0.11	0.18	0.11	0.17	0.08	0.08	0.10	0.08	0.07	
21	1.94	0.97	0.09	0.09	0.10	0.17	0.10	0.08	0.07	0.08	0.06	0.12	0.12	0.14	0.15	0.08	0.12	0.13	0.10	0.14	0.08	0.08	0.09	0.07	0.08	-
26	1.02	1.91	0.54	0.25	1.00	1.42	0.11	0.11	0.20	0.14	0.18	0.30	0.21	0.39	0.36	0.13	0.37	0.22	0.22	0.36	0.07	0.09	0.12	0.08	0.08	H
28	0.91	0.10	0.83	0.30	0.80	0.08	0.12	0.31	0.17	0.11	0.20	0.25	0.17	0.50	0.51	0.44	0.35	0.20	0.21	0.26	0.11	0.08	0.30	0.12	0.16	-
31	1.80	0.69	0.10	0.08	0.08	0.08	0.09	0.08	0.08	0.09	0.08	0.11	0.09	0.10	0.11	0.08	0.10	0.10	0.11	0.13	0.07	0.07	0.07	0.15	0.24	-
33	1.77	0.04	0.04	0.05	0.00	0.00	0.60	0.08	0.05	0.14	0.05	0.09	0.08	0.10	0.10	0.08	0.08	0.12	0.83	0.13	0.07	0.07	0.61	0.08	0.07	H
39	1.09	0.11	0.10	0.08	0.42	0.09	0.61	0.08	0.08	0.09	0.08	0.12	0.11	0.12	0.14	0.08	0.11	0.12	0.63	0.16	0.07	0.08	0.59	0.07	0.07	H
41	1.81	1.90	0.10	0.07	0.09	1.43	0.09	0.08	0.08	0.12	0.08	0.30	0.11	0.17	0.18	0.08	0.15	0.13	0.09	0.17	0.07	0.08	0.09	0.07	0.07	-
42	2.00	1.96	0.10	0.07	0.10	1.65	0.09	0.07	0.09	0.08	0.09	0.34	0.13	0.19	0.19	0.07	0.10	0.15	0.09	0.16	0.08	0.08	0.08	0.06	0.07	-
49	0.81	0.13	0.30	0.15	0.85	0.08	0.16	0.32	0.15	0.13	0.18	0.31	0.19	0.42	0.55	0.30	0.32	0.29	0.24	0.27	0.11	0.10	0.28	0.14	0.17	-
50	1.94	1.89	0.10	0.07	0.15	1.02	0.08	0.08	0.07	0.44	0.08	0.22	0.11	0.12	0.18	0.08	0.13	0.80	0.12	0.17	0.15	0.07	0.07	0.07	0.07	-
64	1.48	0.04	0.07	0.01	0.05	0.04	0.22	0.08	0.07	0.05	0.04	0.12	0.15	0.19	0.18	0.08	0.12	0.09	0.09	0.13	0.07	0.08	0.58	0.07	0.07	H
66	1.30	0.04	0.10	0.01	0.05	0.05	0.25	0.09	0.07	0.04	0.04	0.17	0.16	0.18	0.21	0.08	0.16	0.14	0.08	0.21	0.08	0.08	0.62	0.06	0.08	H
72	1.70	0.05	0.09	0.05	0.05	0.05	0.65	0.09	0.08	0.05	0.05	0.36	0.16	0.19	0.08	0.07	0.17	0.34	0.17	0.18	0.07	0.08	0.71	0.06	0.08	H
73	1.71	0.05	0.08	0.01	0.91	0.05	0.63	0.08	0.07	0.04	0.05	0.23	0.13	0.17	0.28	0.08	0.15	0.34	0.12	0.16	0.08	0.08	0.74	0.06	0.08	H
75	1.65	0.04	0.07	0.01	0.65	0.04	0.38	0.08	0.07	0.05	0.04	0.18	0.14	0.18	0.21	0.07	0.15	0.15	0.11	0.16	0.07	0.08	0.79	0.06	0.07	H


FIG. 14C

81	1.49	1.74	0.09	0.07	0.01	0.85	0.08	0.09	0.06	0.07	0.07	0.20	0.13	0.15	0.21	0.08	0.13	0.12	0.11	0.16	0.06	0.08	0.08	0.08	0.07	-
88	1.87	0.00	0.09	0.06	0.10	0.07	0.09	0.08	0.07	0.24	0.08	0.18	0.15	0.17	0.25	0.07	0.15	0.12	0.12	0.17	0.07	0.08	0.07	0.06	0.07	-
89	0.80	0.08	0.09	0.07	0.08	0.08	0.08	0.09	0.07	0.12	0.15	0.14	0.24	0.08	0.14	1.17	0.12	0.18	0.12	0.18	0.07	0.07	0.08	0.07	0.07	-

11	1.88	0.53	0.06	0.06	0.55	0.24	0.58	0.61	0.17	0.40	0.06	1.63	0.15	0.11	0.39	0.09	0.26	1.50	0.28	0.96	0.13	0.40	0.60	0.59	0.63	Head
18	1.65	0.51	0.41	0.50	0.50	0.30	0.71	0.63	0.18	0.40	0.09	1.79	1.27	0.43	0.74	0.08	1.30	1.78	0.89	1.18	0.34	0.52	0.61	0.54	0.59	
30	1.44	0.11	1.79	0.96	2.08	0.11	0.61	0.65	1.08	1.21	0.97	1.40	1.22	0.42	1.86	0.51	1.11	0.96	1.32	1.86	0.51	0.43	0.63	0.58	0.55	
43	1.61	1.82	1.57	0.88	2.49	1.45	0.70	0.74	0.71	1.29	1.02	1.33	1.47	1.51	1.88	0.59	1.60	1.37	1.43	1.91	0.68	0.71	0.74	0.54	0.59	
46	1.96	0.84	1.50	1.12	1.69	0.17	0.68	0.77	0.96	1.27	1.07	1.74	1.44	1.65	2.06	0.58	1.71	1.61	1.41	1.95	0.68	0.70	0.70	0.70	0.63	
86	1.60	1.81	1.51	0.58	2.08	1.65	0.34	0.43	0.45	0.56	0.77	0.96	0.76	0.90	1.48	0.38	1.13	0.60	0.74	1.29	0.15	0.11	0.58	0.26	0.33	
98	1.80	0.52	0.18	0.48	0.50	0.53	0.65	0.69	0.47	0.52	0.51	2.22	1.83	1.96	2.13	0.52	2.05	1.86	1.72	1.88	0.58	0.63	0.61	0.55	0.63	

12	1.64	0.27	0.21	0.25	0.42	0.26	0.55	0.62	0.19	0.20	0.36	1.29	1.47	1.55	1.87	0.52	1.42	1.45	1.39	1.84	0.58	0.56	0.62	0.58	0.54	Stem
24	1.70	0.41	0.40	0.25	0.50	0.37	0.62	0.68	0.30	0.50	0.42	1.64	1.51	1.64	2.04	0.56	1.52	1.56	1.64	1.92	0.63	0.64	0.66	0.54	0.54	
45	1.63	1.99	1.76	0.50	1.50	1.53	0.64	0.71	0.82	1.31	1.24	1.72	1.43	1.41	1.95	0.57	1.50	1.35	1.58	1.97	0.63	0.67	0.68	0.65	0.53	
47	1.39	0.58	1.84	1.29	2.13	0.07	0.67	0.70	0.86	1.43	1.17	1.56	1.38	1.31	1.96	0.56	1.30	1.35	1.41	1.87	0.57	0.47	0.62	0.60	0.53	
61	1.53	0.21	0.18	0.19	0.30	0.13	0.56	0.60	0.14	0.20	0.26	1.54	0.99	1.60	2.00	0.57	1.30	1.21	1.33	1.83	0.55	0.56	0.58	0.55	0.53	
92	1.43	0.36	0.30	0.29	0.52	0.24	0.66	0.69	0.21	0.33	0.32	1.40	1.15	1.29	1.99	0.63	1.56	1.25	1.26	1.83	0.65	0.60	0.63	0.56	0.55	

FIG. 14D



POSITION	MUTANTS																													
	WT	1	2	4	5	6	9	10	11	12	14	15	16	17	22	23	24	25	26	28	29	30								
1	N	Y	M	K	Q	V	V	R	T	I	V	A	V	V	S	V	L	R	V	F	S	F								
2	T	V	V	R	R	R	K	V	G	T	M	K	C	C	S	Q	R	R	R	D	R	V								
3	T	V	G	G	T	R	V	K	L	N	3	S	N	L	T	V	N	I	Y	S	K	W								
4	A	K	D	A	K	F	T	W	R	K	4	R	I	L	K	R	T	V	K	K	T	S								
5	I	W	F	P	L	M	H	M	C	T	T	N	K	R	S	R	K	N	T	G	N	M								
6	R	S	T	D	N	N	E	G	S	Y	G	D	R	F	Q	E	T	G	A	N	R	H								
7	S	G	D	A	T	T	R	V	G	D	A	G	P	K	G	H	N	T	E	V	A	Q								
8	S	P	R	G	P	W	R	P	R	S	W	V	D	T	S	S	S	R	Q	K	P	P								
9	T	V	C	M	9	V	A	I	Y	R	Q	R	A	I	R	V	Q	W	T	P	Q	Q								
10	H	G	A	T	P	A	S	G	P	S	S	S	A	P	P	T	K	P	L	T	H	G								
11	L	V	N	S	D	L	P	P	L	S	R	R	G	S	I	L	R	S	W	R	M	R								
12	N	R	G	P	R	H	V	V	Q	S	L	F	A	P	K	R	F	P	G	R	K	C								
13	N	D	R	K	T	T	R	F	T	F	Q	T	L	Q	E	H	S	R	R	L	F	T								
14	K	N	E	D	A	I	R	T	F	A	L	E	A	N	P	L	F	S	Y	S	T	S								
15	F	A	G	G	Q	S	T	R	A	Q	R	A	P	S	N	T	T	S	Q	00	N	E								
16	A	Q	N	L	V	R	I	R	R	Q	R	Y	S	T	V	M	V	M	P	F	A									
17	D	K	K	E	L	P	S	P	T	C	E	G	S	S	Q	G	S	R	N	S	C	Y								

FIG. 15A

WT ←————— 17 AAmutants —————→

Antibodies	1	1.98	0.04	0.06	0.01	0.05	0.04	0.09	0.08	0.06	0.04	0.04	0.09	0.07	0.11	0.12	0.08	0.08	0.10	0.08	0.13	0.07	0.08	0.09	0.07	0.08	-
	2	1.96	0.04	0.06	0.05	0.04	0.08	0.11	0.08	0.06	0.04	0.05	0.10	0.26	0.13	0.11	0.08	0.08	0.15	0.08	0.14	0.07	0.08	0.08	0.07	0.08	H
	5	2.06	0.04	0.06	0.11	0.04	0.04	0.11	0.09	0.07	0.04	0.05	0.11	0.13	0.12	0.15	0.09	0.10	0.10	0.10	0.16	0.07	0.09	0.07	0.08	0.08	-
	10	1.96	0.05	0.08	0.06	0.06	0.06	0.12	0.10	0.08	0.06	0.06	0.21	0.16	0.20	0.21	0.11	0.13	0.17	0.13	0.24	0.09	0.10	0.10	0.08	0.09	-
	16	1.88	0.04	0.04	0.05	0.06	0.04	0.08	0.09	0.06	0.04	0.05	0.08	0.08	0.09	0.10	0.09	0.07	0.13	0.07	0.11	0.07	0.08	0.07	0.07	0.07	-
	25	1.32	0.24	0.07	0.01	0.25	0.04	0.10	0.09	0.06	0.04	0.05	0.13	0.13	0.15	0.16	0.08	0.10	0.13	0.10	0.15	0.07	0.08	0.09	0.06	0.07	-
	40	1.93	0.34	0.06	0.01	0.01	0.04	0.10	0.08	0.06	0.04	0.05	0.16	0.11	0.15	0.18	0.08	0.12	0.12	0.00	0.18	0.08	0.08	0.09	0.07	0.08	-
	54	1.95	0.24	0.05	0.01	0.25	0.05	0.09	0.09	0.06	0.04	0.05	0.24	0.15	0.17	0.23	0.08	0.15	0.15	0.15	0.22	0.08	0.07	0.08	0.07	0.07	-
	71	1.61	0.35	0.09	0.05	0.25	0.05	0.11	0.09	0.07	0.04	0.05	0.18	0.22	0.15	0.21	0.07	0.14	0.18	0.00	0.19	0.08	0.08	0.08	0.06	0.08	H
	95	1.67	0.34	0.05	0.01	0.01	0.04	0.07	0.08	0.05	0.05	0.04	0.09	0.08	0.10	0.11	0.09	0.08	0.18	0.09	0.12	0.07	0.07	0.07	0.06	0.07	-
	4	1.66	1.39	0.09	1.10	0.05	0.09	0.07	0.10	0.07	0.07	0.06	0.12	0.08	0.12	0.11	0.07	0.08	0.10	0.08	0.17	0.07	0.07	0.09	0.06	0.09	-
	6	1.91	0.04	0.07	0.05	0.04	0.05	0.11	0.10	0.06	0.04	0.05	0.14	0.14	0.15	0.20	0.09	0.11	0.90	0.11	0.24	0.08	0.09	0.08	0.09	0.07	-
	7	1.94	0.04	0.06	0.05	0.06	0.07	0.09	0.08	0.07	0.04	0.05	0.10	0.09	0.13	0.15	0.08	1.09	0.10	0.00	0.18	0.07	0.09	0.09	0.07	0.06	-
	13	1.85	0.04	0.05	0.05	0.00	0.06	0.09	0.09	0.06	0.20	0.06	0.27	0.09	0.11	0.13	0.09	0.11	1.02	0.00	0.15	0.08	0.08	0.08	0.07	0.07	H
	15	1.83	0.04	0.05	0.05	0.00	0.05	0.09	0.09	0.06	0.14	0.06	0.11	0.09	0.12	0.15	0.08	0.09	1.30	0.00	0.15	0.08	0.07	0.08	0.07	0.07	H

FIG. 15B

17	1.98	0.06	0.06	0.04	0.04	0.10	0.08	0.06	0.04	0.05	0.05	0.11	0.19	0.15	0.13	0.09	0.08	1.25	0.09	0.13	0.07	0.08	0.00	0.07	0.08	-
19	1.81	0.04	0.08	0.01	0.05	0.06	0.10	0.09	0.07	0.04	0.05	0.15	0.53	0.29	0.17	0.08	0.11	0.17	0.00	0.20	0.08	0.09	0.00	0.08	0.08	-
20	1.80	0.04	0.07	0.05	0.05	0.25	0.10	0.09	0.06	0.04	0.06	0.15	1.65	0.15	0.17	0.08	0.11	0.18	0.11	0.17	0.08	0.08	0.10	0.08	0.07	
21	1.94	0.97	0.09	0.09	0.10	0.17	0.10	0.08	0.07	0.08	0.06	0.12	0.12	0.14	0.15	0.08	0.12	0.13	0.10	0.14	0.08	0.08	0.09	0.07	0.08	-
26	1.02	1.91	0.54	0.25	1.00	1.42	0.11	0.11	0.20	0.14	0.18	0.30	0.21	0.39	0.36	0.13	0.37	0.22	0.22	0.36	0.07	0.09	0.12	0.08	0.08	H
28	0.91	0.10	0.83	0.30	0.80	0.08	0.12	0.31	0.17	0.11	0.20	0.25	0.17	0.50	0.51	0.44	0.35	0.20	0.21	0.26	0.11	0.08	0.30	0.12	0.16	-
31	1.80	0.69	0.10	0.08	0.08	0.08	0.09	0.08	0.08	0.09	0.08	0.11	0.09	0.10	0.11	0.08	0.10	0.10	0.11	0.13	0.07	0.07	0.07	0.15	0.24	-
33	1.77	0.04	0.04	0.05	0.00	0.00	0.60	0.08	0.05	0.14	0.05	0.09	0.08	0.10	0.10	0.08	0.08	0.12	0.83	0.13	0.07	0.07	0.61	0.08	0.07	H
39	1.09	0.11	0.10	0.08	0.42	0.09	0.61	0.08	0.08	0.09	0.08	0.12	0.11	0.12	0.14	0.08	0.11	0.12	0.63	0.16	0.07	0.08	0.59	0.07	0.07	H
41	1.81	1.90	0.10	0.07	0.09	1.43	0.09	0.08	0.08	0.12	0.08	0.30	0.11	0.17	0.18	0.08	0.15	0.13	0.09	0.17	0.07	0.08	0.09	0.07	0.07	-
42	2.00	1.96	0.10	0.07	0.10	1.65	0.09	0.07	0.09	0.08	0.09	0.34	0.13	0.19	0.19	0.07	0.10	0.15	0.09	0.16	0.08	0.08	0.08	0.06	0.07	-
49	0.81	0.13	0.30	0.15	0.85	0.08	0.16	0.32	0.15	0.13	0.18	0.31	0.19	0.42	0.55	0.30	0.32	0.29	0.24	0.27	0.11	0.10	0.28	0.14	0.17	-
50	1.94	1.89	0.10	0.07	0.15	1.02	0.08	0.08	0.07	0.44	0.08	0.22	0.11	0.12	0.18	0.08	0.13	0.80	0.12	0.17	0.15	0.07	0.07	0.07	0.07	-
64	1.48	0.04	0.07	0.01	0.05	0.04	0.22	0.08	0.07	0.05	0.04	0.12	0.15	0.19	0.18	0.08	0.12	0.09	0.09	0.13	0.07	0.08	0.58	0.07	0.07	H
66	1.30	0.04	0.10	0.01	0.05	0.05	0.25	0.09	0.07	0.04	0.04	0.17	0.16	0.18	0.21	0.08	0.16	0.14	0.08	0.21	0.08	0.08	0.62	0.06	0.08	H
72	1.70	0.05	0.09	0.05	0.05	0.05	0.65	0.09	0.08	0.05	0.05	0.36	0.16	0.19	0.08	0.07	0.17	0.34	0.17	0.18	0.07	0.08	0.71	0.06	0.08	H
73	1.71	0.05	0.08	0.01	0.91	0.05	0.63	0.08	0.07	0.04	0.05	0.23	0.13	0.17	0.28	0.08	0.15	0.34	0.12	0.16	0.08	0.08	0.74	0.06	0.08	H
75	1.65	0.04	0.07	0.01	0.65	0.04	0.38	0.08	0.07	0.05	0.04	0.18	0.14	0.18	0.21	0.07	0.15	0.15	0.11	0.16	0.07	0.08	0.79	0.06	0.07	H

FIG. 15C

81	1.49	1.74	0.09	0.07	0.01	0.85	0.08	0.09	0.06	0.07	0.07	0.20	0.13	0.15	0.21	0.08	0.13	0.12	0.11	0.16	0.06	0.08	0.08	0.08	0.07	-
88	1.87	0.00	0.09	0.06	0.10	0.07	0.09	0.08	0.07	0.24	0.08	0.18	0.15	0.17	0.25	0.07	0.15	0.12	0.12	0.17	0.07	0.08	0.07	0.06	0.07	-
89	0.80	0.08	0.09	0.07	0.08	0.08	0.08	0.09	0.07	0.12	0.15	0.14	0.24	0.08	0.14	1.17	0.12	0.18	0.12	0.18	0.07	0.07	0.08	0.07	0.07	-

11	1.88	0.53	0.06	0.06	0.55	0.24	0.58	0.61	0.17	0.40	0.06	1.63	0.15	0.11	0.39	0.09	0.26	1.50	0.28	0.96	0.13	0.40	0.60	0.59	0.63	Head
18	1.65	0.51	0.41	0.50	0.50	0.30	0.71	0.63	0.18	0.40	0.09	1.79	1.27	0.43	0.74	0.08	1.30	1.78	0.89	1.18	0.34	0.52	0.61	0.54	0.59	
30	1.44	0.11	1.79	0.96	2.08	0.11	0.61	0.65	1.08	1.21	0.97	1.40	1.22	0.42	1.86	0.51	1.11	0.96	1.32	1.86	0.51	0.43	0.63	0.58	0.55	
43	1.61	1.82	1.57	0.88	2.49	1.45	0.70	0.74	0.71	1.29	1.02	1.33	1.47	1.51	1.88	0.59	1.60	1.37	1.43	1.91	0.68	0.71	0.74	0.54	0.59	
46	1.96	0.84	1.50	1.12	1.69	0.17	0.68	0.77	0.96	1.27	1.07	1.74	1.44	1.65	2.06	0.58	1.71	1.61	1.41	1.95	0.68	0.70	0.70	0.70	0.63	
86	1.60	1.81	1.51	0.58	2.08	1.65	0.34	0.43	0.45	0.56	0.77	0.96	0.76	0.90	1.48	0.38	1.13	0.60	0.74	1.29	0.15	0.11	0.58	0.26	0.33	
98	1.80	0.52	0.18	0.48	0.50	0.53	0.65	0.69	0.47	0.52	0.51	2.22	1.83	1.96	2.13	0.52	2.05	1.86	1.72	1.88	0.58	0.63	0.61	0.55	0.63	

12	1.64	0.27	0.21	0.25	0.42	0.26	0.55	0.62	0.19	0.20	0.36	1.29	1.47	1.55	1.87	0.52	1.42	1.45	1.39	1.84	0.58	0.56	0.62	0.58	0.54	Stem
24	1.70	0.41	0.40	0.25	0.50	0.37	0.62	0.68	0.30	0.50	0.42	1.64	1.51	1.64	2.04	0.56	1.52	1.56	1.64	1.92	0.63	0.64	0.66	0.54	0.54	
45	1.63	1.99	1.76	0.50	1.50	1.53	0.64	0.71	0.82	1.31	1.24	1.72	1.43	1.41	1.95	0.57	1.50	1.35	1.58	1.97	0.63	0.67	0.68	0.65	0.53	
47	1.39	0.58	1.84	1.29	2.13	0.07	0.67	0.70	0.86	1.43	1.17	1.56	1.38	1.31	1.96	0.56	1.30	1.35	1.41	1.87	0.57	0.47	0.62	0.60	0.53	
61	1.53	0.21	0.18	0.19	0.30	0.13	0.56	0.60	0.14	0.20	0.26	1.54	0.99	1.60	2.00	0.57	1.30	1.21	1.33	1.83	0.55	0.56	0.58	0.55	0.53	
92	1.43	0.36	0.30	0.29	0.52	0.24	0.66	0.69	0.21	0.33	0.32	1.40	1.15	1.29	1.99	0.63	1.56	1.25	1.26	1.83	0.65	0.60	0.63	0.56	0.55	

FIG. 15D




FIG. 16A

WT ←————— 17 AAmutants —————→

Antibodies	1	1.98	0.04	0.06	0.01	0.05	0.04	0.09	0.08	0.06	0.04	0.04	0.09	0.07	0.11	0.12	0.08	0.08	0.10	0.08	0.13	0.07	0.08	0.09	0.07	0.08	-
	2	1.96	0.04	0.06	0.05	0.04	0.08	0.11	0.08	0.06	0.04	0.05	0.10	0.26	0.13	0.11	0.08	0.08	0.15	0.08	0.14	0.07	0.08	0.08	0.07	0.08	H
	5	2.06	0.04	0.06	0.11	0.04	0.04	0.11	0.09	0.07	0.04	0.05	0.11	0.13	0.12	0.15	0.09	0.10	0.10	0.10	0.16	0.07	0.09	0.07	0.08	0.08	-
	10	1.96	0.05	0.08	0.06	0.06	0.06	0.12	0.10	0.08	0.06	0.06	0.21	0.16	0.20	0.21	0.11	0.13	0.17	0.13	0.24	0.09	0.10	0.10	0.08	0.09	-
	16	1.88	0.04	0.04	0.05	0.06	0.04	0.08	0.09	0.06	0.04	0.05	0.08	0.08	0.09	0.10	0.09	0.07	0.13	0.07	0.11	0.07	0.08	0.07	0.07	0.07	-
	25	1.32	0.24	0.07	0.01	0.25	0.04	0.10	0.09	0.06	0.04	0.05	0.13	0.13	0.15	0.16	0.08	0.10	0.13	0.10	0.15	0.07	0.08	0.09	0.06	0.07	-
	40	1.93	0.34	0.06	0.01	0.01	0.04	0.10	0.08	0.06	0.04	0.05	0.16	0.11	0.15	0.18	0.08	0.12	0.12	0.00	0.18	0.08	0.08	0.09	0.07	0.08	-
	54	1.95	0.24	0.05	0.01	0.25	0.05	0.09	0.09	0.06	0.04	0.05	0.24	0.15	0.17	0.23	0.08	0.15	0.15	0.15	0.22	0.08	0.07	0.08	0.07	0.07	-
	71	1.61	0.35	0.09	0.05	0.25	0.05	0.11	0.09	0.07	0.04	0.05	0.18	0.22	0.15	0.21	0.07	0.14	0.18	0.00	0.19	0.08	0.08	0.08	0.06	0.08	H
	95	1.67	0.34	0.05	0.01	0.01	0.04	0.07	0.08	0.05	0.05	0.04	0.09	0.08	0.10	0.11	0.09	0.08	0.18	0.09	0.12	0.07	0.07	0.07	0.06	0.07	-
	4	1.66	1.39	0.09	1.10	0.05	0.09	0.07	0.10	0.07	0.07	0.06	0.12	0.08	0.12	0.11	0.07	0.08	0.10	0.08	0.17	0.07	0.07	0.09	0.06	0.09	-
	6	1.91	0.04	0.07	0.05	0.04	0.05	0.11	0.10	0.06	0.04	0.05	0.14	0.14	0.15	0.20	0.09	0.11	0.90	0.11	0.24	0.08	0.09	0.08	0.09	0.07	-
	7	1.94	0.04	0.06	0.05	0.06	0.07	0.09	0.08	0.07	0.04	0.05	0.10	0.09	0.13	0.15	0.08	1.09	0.10	0.00	0.18	0.07	0.09	0.09	0.07	0.06	-
	13	1.85	0.04	0.05	0.05	0.00	0.06	0.09	0.09	0.06	0.20	0.06	0.27	0.09	0.11	0.13	0.09	0.11	1.02	0.00	0.15	0.08	0.08	0.08	0.07	0.07	H
	15	1.83	0.04	0.05	0.05	0.00	0.05	0.09	0.09	0.06	0.14	0.06	0.11	0.09	0.12	0.15	0.08	0.09	1.30	0.00	0.15	0.08	0.07	0.08	0.07	0.07	H

FIG. 16B

17	1.98	0.06	0.06	0.04	0.04	0.10	0.08	0.06	0.04	0.05	0.05	0.11	0.19	0.15	0.13	0.09	0.08	1.25	0.09	0.13	0.07	0.08	0.00	0.07	0.08	-
19	1.81	0.04	0.08	0.01	0.05	0.06	0.10	0.09	0.07	0.04	0.05	0.15	0.53	0.29	0.17	0.08	0.11	0.17	0.00	0.20	0.08	0.09	0.00	0.08	0.08	-
20	1.80	0.04	0.07	0.05	0.05	0.25	0.10	0.09	0.06	0.04	0.06	0.15	1.65	0.15	0.17	0.08	0.11	0.18	0.11	0.17	0.08	0.08	0.10	0.08	0.07	
21	1.94	0.97	0.09	0.09	0.10	0.17	0.10	0.08	0.07	0.08	0.06	0.12	0.12	0.14	0.15	0.08	0.12	0.13	0.10	0.14	0.08	0.08	0.09	0.07	0.08	-
26	1.02	1.91	0.54	0.25	1.00	1.42	0.11	0.11	0.20	0.14	0.18	0.30	0.21	0.39	0.36	0.13	0.37	0.22	0.22	0.36	0.07	0.09	0.12	0.08	0.08	H
28	0.91	0.10	0.83	0.30	0.80	0.08	0.12	0.31	0.17	0.11	0.20	0.25	0.17	0.50	0.51	0.44	0.35	0.20	0.21	0.26	0.11	0.08	0.30	0.12	0.16	-
31	1.80	0.69	0.10	0.08	0.08	0.08	0.09	0.08	0.08	0.09	0.08	0.11	0.09	0.10	0.11	0.08	0.10	0.10	0.11	0.13	0.07	0.07	0.07	0.15	0.24	-
33	1.77	0.04	0.04	0.05	0.00	0.00	0.60	0.08	0.05	0.14	0.05	0.09	0.08	0.10	0.10	0.08	0.08	0.12	0.83	0.13	0.07	0.07	0.61	0.08	0.07	H
39	1.09	0.11	0.10	0.08	0.42	0.09	0.61	0.08	0.08	0.09	0.08	0.12	0.11	0.12	0.14	0.08	0.11	0.12	0.63	0.16	0.07	0.08	0.59	0.07	0.07	H
41	1.81	1.90	0.10	0.07	0.09	1.43	0.09	0.08	0.08	0.12	0.08	0.30	0.11	0.17	0.18	0.08	0.15	0.13	0.09	0.17	0.07	0.08	0.09	0.07	0.07	-
42	2.00	1.96	0.10	0.07	0.10	1.65	0.09	0.07	0.09	0.08	0.09	0.34	0.13	0.19	0.19	0.07	0.10	0.15	0.09	0.16	0.08	0.08	0.08	0.06	0.07	-
49	0.81	0.13	0.30	0.15	0.85	0.08	0.16	0.32	0.15	0.13	0.18	0.31	0.19	0.42	0.55	0.30	0.32	0.29	0.24	0.27	0.11	0.10	0.28	0.14	0.17	-
50	1.94	1.89	0.10	0.07	0.15	1.02	0.08	0.08	0.07	0.44	0.08	0.22	0.11	0.12	0.18	0.08	0.13	0.80	0.12	0.17	0.15	0.07	0.07	0.07	0.07	-
64	1.48	0.04	0.07	0.01	0.05	0.04	0.22	0.08	0.07	0.05	0.04	0.12	0.15	0.19	0.18	0.08	0.12	0.09	0.09	0.13	0.07	0.08	0.58	0.07	0.07	H
66	1.30	0.04	0.10	0.01	0.05	0.05	0.25	0.09	0.07	0.04	0.04	0.17	0.16	0.18	0.21	0.08	0.16	0.14	0.08	0.21	0.08	0.08	0.62	0.06	0.08	H
72	1.70	0.05	0.09	0.05	0.05	0.05	0.65	0.09	0.08	0.05	0.05	0.36	0.16	0.19	0.08	0.07	0.17	0.34	0.17	0.18	0.07	0.08	0.71	0.06	0.08	H
73	1.71	0.05	0.08	0.01	0.91	0.05	0.63	0.08	0.07	0.04	0.05	0.23	0.13	0.17	0.28	0.08	0.15	0.34	0.12	0.16	0.08	0.08	0.74	0.06	0.08	H
75	1.65	0.04	0.07	0.01	0.65	0.04	0.38	0.08	0.07	0.05	0.04	0.18	0.14	0.18	0.21	0.07	0.15	0.15	0.11	0.16	0.07	0.08	0.79	0.06	0.07	H

FIG. 16C

81	1.49	1.74	0.09	0.07	0.01	0.85	0.08	0.09	0.06	0.07	0.07	0.20	0.13	0.15	0.21	0.08	0.13	0.12	0.11	0.16	0.06	0.08	0.08	0.08	0.07	-
88	1.87	0.00	0.09	0.06	0.10	0.07	0.09	0.08	0.07	0.24	0.08	0.18	0.15	0.17	0.25	0.07	0.15	0.12	0.12	0.17	0.07	0.08	0.07	0.06	0.07	-
89	0.80	0.08	0.09	0.07	0.08	0.08	0.08	0.09	0.07	0.12	0.15	0.14	0.24	0.08	0.14	1.17	0.12	0.18	0.12	0.18	0.07	0.07	0.08	0.07	0.07	-

11	1.88	0.53	0.06	0.06	0.55	0.24	0.58	0.61	0.17	0.40	0.06	1.63	0.15	0.11	0.39	0.09	0.26	1.50	0.28	0.96	0.13	0.40	0.60	0.59	0.63	Head
18	1.65	0.51	0.41	0.50	0.50	0.30	0.71	0.63	0.18	0.40	0.09	1.79	1.27	0.43	0.74	0.08	1.30	1.78	0.89	1.18	0.34	0.52	0.61	0.54	0.59	
30	1.44	0.11	1.79	0.96	2.08	0.11	0.61	0.65	1.08	1.21	0.97	1.40	1.22	0.42	1.86	0.51	1.11	0.96	1.32	1.86	0.51	0.43	0.63	0.58	0.55	
43	1.61	1.82	1.57	0.88	2.49	1.45	0.70	0.74	0.71	1.29	1.02	1.33	1.47	1.51	1.88	0.59	1.60	1.37	1.43	1.91	0.68	0.71	0.74	0.54	0.59	
46	1.96	0.84	1.50	1.12	1.69	0.17	0.68	0.77	0.96	1.27	1.07	1.74	1.44	1.65	2.06	0.58	1.71	1.61	1.41	1.95	0.68	0.70	0.70	0.70	0.63	
86	1.60	1.81	1.51	0.58	2.08	1.65	0.34	0.43	0.45	0.56	0.77	0.96	0.76	0.90	1.48	0.38	1.13	0.60	0.74	1.29	0.15	0.11	0.58	0.26	0.33	
98	1.80	0.52	0.18	0.48	0.50	0.53	0.65	0.69	0.47	0.52	0.51	2.22	1.83	1.96	2.13	0.52	2.05	1.86	1.72	1.88	0.58	0.63	0.61	0.55	0.63	

12	1.64	0.27	0.21	0.25	0.42	0.26	0.55	0.62	0.19	0.20	0.36	1.29	1.47	1.55	1.87	0.52	1.42	1.45	1.39	1.84	0.58	0.56	0.62	0.58	0.54	Stem
24	1.70	0.41	0.40	0.25	0.50	0.37	0.62	0.68	0.30	0.50	0.42	1.64	1.51	1.64	2.04	0.56	1.52	1.56	1.64	1.92	0.63	0.64	0.66	0.54	0.54	
45	1.63	1.99	1.76	0.50	1.50	1.53	0.64	0.71	0.82	1.31	1.24	1.72	1.43	1.41	1.95	0.57	1.50	1.35	1.58	1.97	0.63	0.67	0.68	0.65	0.53	
47	1.39	0.58	1.84	1.29	2.13	0.07	0.67	0.70	0.86	1.43	1.17	1.56	1.38	1.31	1.96	0.56	1.30	1.35	1.41	1.87	0.57	0.47	0.62	0.60	0.53	
61	1.53	0.21	0.18	0.19	0.30	0.13	0.56	0.60	0.14	0.20	0.26	1.54	0.99	1.60	2.00	0.57	1.30	1.21	1.33	1.83	0.55	0.56	0.58	0.55	0.53	
92	1.43	0.36	0.30	0.29	0.52	0.24	0.66	0.69	0.21	0.33	0.32	1.40	1.15	1.29	1.99	0.63	1.56	1.25	1.26	1.83	0.65	0.60	0.63	0.56	0.55	

FIG. 16D




FIG. 17A



FIG. 17B




FIG. 17C



FIG. 17D

EXEMPLARY ANTIGENIC SITES IN H3 HA

A		B		C		D		E	
122	T	128	T	44	Q	96	N	57	R
124	G	129	G	45	S	102	V	59	L
126	T	155	T	46	S	103	P	62	I
130	V	156	K	47	S	117	T	63	D
131	T	157	S	48	T	121	I	67	I
132	Q	158	G	80	K	167	T	75	H
133	N	159	S	51	I	170	N	78	V
135	R	160	T	53	N	171	N	80	Q
137	N	163	V	54	N	172	D	81	N
138	A	164	L	273	P	173	N	82	E
140	K	165	N	275	D	174	F	165	T
142	G	186	S	276	T	175	D	86	L
143	P	187	T	278	I	176	K	87	F
144	G	188	N	279	S	177	L	88	V
145	S	189	Q	280	E	179	I	91	S
146	G	190	E	294	F	182	I	92	K
150	R	192	T	297	V	201	R	109	R
152	N	193	S	299	K	203	T	260	M
168	M	194	L	300	I	207	R	261	R
		196	V	304	A	208	R	262	T
		197	Q	305	C	209	S	265	S
		198	A	307	K	212	T		
				308	Y	213	I		
				309	V	214	I		
				310	K	215	P		
				311	Q	216	N		
				312	N	217	I		
						218	G		
						219	S		
						226	L		
						227	S		
						228	S		
						229	R		
						230	I		
						238	K		
						240	G		
						242	V		
						244	V		
						246	N		
						247	S		
						248	N		

FIG. 18

1

**VECTORS FOR ELICITING IMMUNE  
RESPONSES TO NON-DOMINANT  
EPITOPES IN THE HEMAGGLUTININ (HA)  
PROTEIN**

CROSS-REFERENCE TO RELATED  
APPLICATIONS

This application claims the benefit of the filing date of U.S. application No. 62/719,952, filed on Aug. 20, 2018, the disclosure of which is incorporated by reference herein.

STATEMENT OF GOVERNMENT RIGHTS

This invention was made with government support under HHSN272201400008C awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

Influenza outbreaks in humans are a major public health concern. Annual epidemics (outbreaks of influenza viruses circulating in humans) and sporadic pandemics (outbreaks of novel influenza viruses to which people lack protective immunity) increase morbidity and mortality in human populations and create considerable economic costs. Infections with influenza viruses and vaccination with current vaccines elicit antibodies against highly variable major antigenic epitopes in the head region of the viral surface glycoprotein hemagglutinin (HA). High mutation rates and immune pressure lead to the accumulation of mutations in these epitopes, resulting in viral ‘escape’ from the antibodies circulating in an individual; hence, the individual becomes infected again. As a consequence of viral ‘escape’ from immune responses elicited upon infection or vaccination, the vaccine strains must be replaced frequently. Recently, the National Institute of Allergy and Infectious Diseases (MAID) therefore announced a strategic plan for the development of a ‘universal’ influenza vaccine that protects against multiple, antigenically diverse strains.

Immunodominance describes the phenomenon whereby strong immune responses are directed towards a subset of antigenic epitopes (i.e., immunodominant antigenic epitopes), while much weaker immune responses are directed against the remaining, immune-subdominant epitopes. The immunodominant epitopes of influenza viruses are located in the highly variable regions of the HA head (i.e., most antibodies elicited after infection or vaccination are directed against these major antigenic epitopes). Immune-subdominant epitopes are located in conserved regions of the HA head and in the conserved HA stem. Antibodies elicited to these subdominant, conserved regions are typically reactive against a broad range of influenza viruses; however, since the epitopes are immune-subdominant, the levels of these broadly reactive antibodies are low.

Several studies have shown that the first exposure to an antigenically unique influenza virus generates relatively high levels of antibodies to immune-subdominant epitopes in the HA stem, in addition to high levels of antibodies to the immunodominant major epitopes in the highly variable regions of the HA head. Palese and colleagues demonstrated that repeat immunization with chimeric HAs that possess the same stem region but head regions derived from different HA subtypes increased the levels of stem-reactive antibodies compared to repeat vaccination with HAs possessing the same head (Chen et al., 2016; Krammer et al., 2013; Margine

2

et al., 2013; Nachbagauer et al., 2017 and 2015; Krammer et al., 2012 and 2014; Goff et al., 2013).

Despite the promising data obtained with chimeric HAs, this approach has drawbacks: (i) the number of HA subtypes that can be used to swap the head region is limited (and not all combinations of stems and heads are stable); and (ii) the current approach of exchanging the HA head does not exploit the subtype-specific conserved, immune-subdominant epitopes in the head.

Human influenza virus infections pose a considerable burden on individual health, the public health sector, and the global economy. Influenza viruses circulating in humans (i.e., ‘seasonal’ influenza viruses) typically cause annual epidemics that have resulted in the US alone in 9.2-35.6 million illnesses, 140,000-710,000 hospitalizations, and 12,000-56,000 deaths per year since 2010. Epidemics are caused by influenza viruses of type A and B. Influenza viruses of type A are further divided into subtypes based on the antigenicity of the viral surface glycoproteins HA and neuraminidase (NA). To date, 18 HA (H1-18) and 11 NA (N1-11) subtypes have been identified; based on their phylogenetic relationships, the HAs are categorized into two super-groups (group 1, H1, H2, H5, H6, H8, H9, H11-H13, H16-18; group 2, H3, H4, H7, H10, H14, H15). However, only viruses of the H1N1, H2N2, and H3N2 subtypes have extensively circulated in humans. Global outbreaks (pandemics) are caused by viruses possessing an HA that is antigenically distinct from that of viruses previously circulating in humans, so they encounter immunologically naïve populations, resulting in rapid spread around the globe. Four pandemics have occurred in the last 100 years. The 1918 pandemic was caused by H1N1 viruses, which were replaced by H2N2 viruses in 1957, causing the ‘Asian’ pandemic. In 1968, H3N2 viruses replaced the H2N2 viruses, causing the ‘Hong Kong’ pandemic. H1N1 viruses similar to those circulating in the 1950’s re-emerged in 1977 and co-circulated with H3N2 viruses until 2009, when the H1N1 viruses were replaced by H1N1 viruses with an antigenically distinct HA (2009 pandemic).

Wild aquatic birds are the natural reservoir of influenza A viruses and harbor influenza viruses of most subtypes. Sporadic transmission of avian influenza viruses to humans can cause severe respiratory disease with high fatality rates. Highly pathogenic avian influenza of the H5 subtype have infected 840 people and caused 454 deaths; human infections with H7N9 viruses (which emerged in 2013) have resulted in 1,625 reported human cases with a case fatality rate of 38% (as of May 24, 2018). These avian influenza viruses do not efficiently transmit among humans and have not (yet) caused a pandemic, although H7N9 viruses transmit via respiratory droplets among ferrets (1-4) (the commonly used animal model for influenza virus transmission studies) and H5 viruses with a small number of mutations can become transmissible among ferrets via respiratory droplets (5, 6). Any universal vaccine strategy should ideally be applicable/adaptable to these types of viruses.

SUMMARY

Disclosed herein is a method to redirect immune responses in an avian or a mammal from the immunodominant epitopes (which mutate frequently) towards non-dominant (sub-dominant) epitopes, which are more conserved. Immunization with one or more viruses produced by the method produce higher amounts of antibodies targeting the conserved non-dominant epitopes which in turn increases broadly-protective immunity. The method outdilutes

immune responses to the immunodominant epitopes, resulting in higher levels of antibodies directed against the conserved, non-dominant epitopes. Influenza vaccines having one or more of the influenza viruses with modified HAs that elicit immune responses to non-dominant epitopes, epitopes that are more conserved than the dominant antigenic epitopes on the hemagglutinin (HA) head of influenza viruses, e.g., human influenza viruses, may provide protection against antigenically drifted viruses. Thus, the need to vaccinate may be extended beyond 1-3 years. The vaccines may include mixtures of different HA proteins, each with mutated. e.g., non-naturally occurring, immunodominant antigenic epitopes, in order to dilute the immune responses to the immunodominant epitopes, thereby boosting the levels of antibodies directed against immune-subdominant epitopes.

As described herein, an influenza virus 'library' (e.g., a mixture of millions of variants) is generated with random mutations at selected positions of the highly variable immunodominant antigenic epitopes in the HA head, e.g., from any of the HA subtypes. For example, in a H3 HA, influenza viruses with up to 17 mutations in the immunodominant antigenic epitopes of HA were prepared and found to be viable. The virus library is incubated with different sera, e.g., ferret and/or human sera, to eliminate variants that are antigenically similar to wild-type virus(es). The individual modified HA sequences (Individual ID-EpiMut HAs) may be cloned, sequenced, and tested for their reactivity with monoclonal antibodies directed against immunodominant or sub-dominant epitopes of HA. ID-EpiMut HAs with high reactivity to antibodies directed against conserved, immune subdominant epitopes and low reactivity to antibodies directed against immunodominant epitopes are then isolated and optionally pooled in a vaccine formulation.

In one embodiment, for immunization studies in mice, the ID-EpiMut HAs are incorporated into virus-like particles (VLPs) composed of the Ebola virus VP40 matrix protein, hence eliminating potential contributions to immunity conferred by other influenza viral proteins. The mouse sera is tested for the levels of antibodies directed against immunodominant or -subdominant epitopes. Vaccination and challenge studies in ferrets are carried out with inactivated influenza vaccines possessing ID-EpiMut HAs. Naïve or pre-exposed animals are vaccinated, the levels of antibodies to immune subdominant epitopes assessed, and animals challenged with homologous and heterologous influenza viruses. ID-EpiMut based vaccines are likely to be more cross-protective than vaccines based on wild-type HA.

Thus, the disclosure provides a method to elicit broadly protective antibodies to immune-subdominant epitopes in HA of any subtype. Mixtures of influenza viruses or mixtures of other vectors, e.g., mixtures of isolated nucleic acid including mRNA and DNA encoding the altered HAs, including other viral vectors, e.g., filoviruses, adenoviruses, and the like, or virus-like particles including Ebola VLPs and influenza VLPs, or mixtures of polypeptides having altered influenza hemagglutinins (HAs), altered with a non-naturally occurring immunodominant antigenic head, as a result of substitutions and/or deletions in residues that form the immunodominant epitope, and conserved, immune subdominant epitopes (FIG. 2) provide a vaccine that may elicit high amounts of Abs to the conserved, immune subdominant epitopes in the head and in the stem, resulting in broader protection than that elicited by current vaccines. A composition having an individual recombinant virus, e.g., influenza virus, filovirus, adenovirus, or a VLP thereof, comprising HA having one or more of the altered residues, isolated

nucleic acid encoding HA having one or more of the altered residues, or isolated HA having one or more of the altered residues, is envisioned.

In one embodiment, a recombinant influenza virus produced by the method has a HA that has one or more altered residues in one or more immunodominant epitopes of HA (residues in an epitope do not need to be contiguous or in close proximity in the primary amino acid sequence) resulting in altered epitopes that do not, for example, bind antibodies specific for the one or more immunodominant epitopes as efficiently as the (unaltered) immunodominant epitopes in the parental HA, and/or once administered, the HA with the one or more altered residues in the immunodominant epitopes elicit antibodies to conserved, immune subdominant epitopes in the head and/or in the stem of HA. In one embodiment, a recombinant influenza virus produced by the method has 20 or fewer unaltered residues that are part of one or more immunodominant epitopes, e.g., 15, 10, 5, 4, 3, 2, 1 or 0 residues are unaltered in one or more naturally occurring immunodominant epitope, for instance, in a specific parental influenza virus. In one embodiment, a recombinant influenza virus produced by the method has 1 to 10 or 10 to 20 altered immunodominant residues in two or more immunodominant epitopes. In one embodiment, a recombinant influenza virus produced by the method has 10 or fewer, e.g., 5 or 3, unaltered immunodominant residues in one or two immunodominant epitopes. For example, a recombinant influenza H3 virus produced by the method has 5 or fewer immunodominant residues at positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225. For example, a recombinant influenza H5 virus produced by the method has 5 or fewer immunodominant residues at positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189 in H5.

In one embodiment, a recombinant influenza virus produced by the method has 2 or more residues, e.g., has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or more residues, that result in decreased antibody binding with antibodies that recognize immunodominant epitopes. Thus, residues in immunodominant epitopes are replaced (substituted) with residues that, if present in a HA in an influenza virus that infects an animal that has been infected with the HA with the immunodominant epitope, does not result in a memory response (immunological memory) as a result of the substitutions but instead redirects the immune response to subdominant epitopes in the HA head or stem, allowing for a broader immune response, e.g., to a specific HA subtype or a specific clade in a HA subtype. In one embodiment, a recombinant influenza virus produced by the method has 2 to 5, 5 to 10, 10 to 15, 15 to 20, or more substitutions in residues in immunodominant epitopes. In one embodiment, a recombinant influenza virus produced by the method has about 10 to 17 substitutions in residues in immunodominant epitopes. For example, a recombinant influenza H3 virus produced by the method has 2 to 5, 5 to 10, 10 to 15, or 10 to 17 non-dominant residues at a combination of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225. For example, a recombinant influenza H5 virus produced by the method has 2 to 5, 5 to 10, 10 to 15, or 10 to 17 substitutions (to non-dominant residues) at a combination of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189 in H5. In one embodiment, a recombinant influenza virus produced by the method has 1 to 2, 2 to 5, or up to 10 residues deleted, including for example positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225 in H3, or positions 119, 123, 125, 126, 127,

129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189 in H5, which deletion(s) in HA result in decreased antibody binding with antibodies that recognize immunodominant epitopes

In one embodiment, a vaccine comprises a plurality of recombinant influenza viruses having substitutions (or deletions) at immunodominant positions (substitutions to “non-immunodominant residues”). In one embodiment, the vaccine comprises 2 to 5, 5 to 10, 10 to 20, 20 to 30, 30 to 40, or 40 to 50 distinct recombinant influenza viruses having substitutions (or deletions) at immunodominant epitope positions. In one embodiment, the vaccine comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 distinct recombinant influenza viruses having substitutions at immunodominant epitope positions. In one embodiment, the vaccine comprises 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 distinct recombinant influenza viruses having substitutions at immunodominant epitope positions.

In one embodiment, combinations of vectors with altered HAs in Tables 1 or 6 are employed in a composition that is administered to a mammal or an avian.

#### BRIEF DESCRIPTION OF FIGURES

FIG. 1. X-ray structure of a human H3 HA protein. The positions targeted by mutagenesis are show in red.

FIG. 2. Ebola VP40-based VLPs possessing wild-type HA (left), or HA with randomized amino acid changes at up to 17 amino acid positions (right).

FIGS. 3A-D. Three-dimensional structure of H3 HA (4O5N). Shown are the head (dark gray) and stem (light gray) regions (A); the five major epitopes A (red), B (blue), C (orange), D (yellow), and E (green) (B); the amino acid positions selected for mutagenesis (wheat, see C.1.2.1 (C)); and the sequence conservation of >13,000 unique human H3N2 HA sequences downloaded from the Influenza Research Database (D); the color scale indicates the amino acid sequence conservation at the respective position from 85.5% (gold) to 100% (purple). Shown in magenta is the highly conserved tyrosine residue at position 98 in the receptor-binding pocket.

FIGS. 4A-4B. Schematic overview of the proposed strategy to elicit increased amounts of broadly-reactive Abs to immune-subdominant epitopes. (A) Subsequent infections or vaccinations with seasonal influenza viruses result in large amounts of Abs to the highly variable, immunodominant epitopes (shown in blue, dark green, and light green for three consecutive clusters), but consecutively lower amounts of Abs to the immune-subdominant epitopes in the stem (black) and head (dark gray). (B) New concept in which (repeat) immunizations with mixtures of HA proteins (shown here is only one mutant HA) with highly mutated, non-naturally occurring immunodominant antigenic epitopes are used to dilute the immune responses to the immunodominant epitopes, thereby boosting the levels of antibodies directed against immune-subdominant epitopes.

FIG. 5. Flowchart.

FIGS. 6A-6B. Exemplary HA sequences of H3N2 viruses and a H5N8 virus (SEQ ID Nos. 1 and 6-9).

FIG. 7. HA sequence of an exemplary H5 (SEQ ID NO:2).

FIG. 8. HA sequences of an exemplary H1 (SEQ ID NO:3).

FIG. 9. HA sequence of an exemplary H2 (SEQ ID NO:4).

FIG. 10. HA sequence of an exemplary H7 (SEQ ID NO:5).

FIGS. 11A-11B. H3 variants with substitutions in immunodominant epitope residues.

FIGS. 12A-12M. Antibody reactivities for clusters, wild-type and H3 variants with substitutions in immunodominant epitope residues.

FIGS. 13A-13D. Antibody reactivities for wild-type and H3 variants with substitutions in immunodominant epitope residues.w

FIGS. 14A-14D. Antibody reactivities for wild-type and selected H3 variants with substitutions in immunodominant epitope residues.

FIGS. 15A-15D. Combining sets of 10 independent (distinct) H3 variants with substitutions in immunodominant epitope residues.

FIGS. 16A-16D. Mixtures of H3 variants with substitutions in immunodominant epitope residues react with antibodies to sub-dominant epitopes.

FIGS. 17A-17D. Alignment of HA subtypes (see, e.g., Burke et al., *PLoS One*, 9:e112302 (2014)).

FIG. 18. Exemplary antigenic sites in H3 HA.

#### DETAILED DESCRIPTION

##### Definitions

As used herein, the term “isolated” refers to in vitro preparation and/or isolation of a nucleic acid molecule, e.g., vector or plasmid, peptide or polypeptide (protein), or virus, so that it is not associated with in vivo substances, or is substantially purified from in vitro substances. An isolated virus preparation is generally obtained by in vitro culture and propagation, and/or via passage in eggs, and is substantially free from other infectious agents.

As used herein, “substantially purified” means the object species is the predominant species, e.g., on a molar basis it is more abundant than any other individual species in a composition, and preferably is at least about 80% of the species present, and optionally 90% or greater, e.g., 95%, 98%, 99% or more, of the species present in the composition.

As used herein, “substantially free” means below the level of detection for a particular infectious agent using standard detection methods for that agent.

A “recombinant” virus is one which has been manipulated in vitro, e.g., using recombinant DNA techniques, to introduce changes to the viral genome. Reassortant viruses can be prepared by recombinant or nonrecombinant techniques.

As used herein, the term “recombinant nucleic acid” or “recombinant DNA sequence or segment” refers to a nucleic acid, e.g., to DNA, that has been derived or isolated from a source, that may be subsequently chemically altered in vitro, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in the native genome. An example of DNA “derived” from a source, would be a DNA sequence that is identified as a useful fragment, and which is then chemically synthesized in essentially pure form. An example of such DNA “isolated” from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g., by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

As used herein, a “heterologous” influenza virus gene or viral segment is from an influenza virus source that is

different than a majority of the other influenza viral genes or viral segments in a recombinant, e.g., reassortant, influenza virus.

The terms “isolated polypeptide”, “isolated peptide” or “isolated protein” include a polypeptide, peptide or protein encoded by cDNA or recombinant RNA including one of synthetic origin, or some combination thereof.

The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule expressed from a recombinant DNA molecule. In contrast, the term “native protein” is used herein to indicate a protein isolated from a naturally occurring (i.e., a nonrecombinant) source. Molecular biological techniques may be used to produce a recombinant form of a protein with identical properties as compared to the native form of the protein.

Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent identity between any two sequences can be accomplished using a mathematical algorithm.

Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Alignments using these programs can be performed using the default parameters. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

The algorithm may involve first identifying high scoring sequence pairs (HSPs) by identifying short words of length *W* in the query sequence, which either match or satisfy some positive-valued threshold score *T* when aligned with a word of the same length in a database sequence. *T* is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters *M* (reward score for a pair of matching residues; always >0) and *N* (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity *X* from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached.

In addition to calculating percent sequence identity, the BLAST algorithm may also perform a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm may be the smallest sum probability (*P(N)*), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

The BLASTN program (for nucleotide sequences) may use as defaults a wordlength (*W*) of 11, an expectation (*E*) of 10, a cutoff of 100, *M*=5, *N*=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program may use as defaults a wordlength (*W*) of 3, an expectation (*E*) of 10, and the BLOSUM62 scoring matrix. Alignment may also be performed manually by inspection.

For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Immunodominant HA Epitopes and Methods to Alter Those Epitopes

Both the processes of infection and vaccination with influenza viruses elicit, primarily, antibodies against the immune-dominant epitopes in the ‘head’ region of the viral hemagglutinin (HA) protein, the major viral antigen. Mutations in the immune-dominant epitopes may confer ‘escape’ from the antibodies circulating in an individual, so that a person that gained immunity to the previous influenza virus becomes vulnerable to the mutated ‘escape variant’ virus. Several strategies are being tested to redirect a recipient’s immune response from the immune-dominant epitopes (which mutate frequently) in HA towards non-dominant epitopes in HA, which are more conserved. Targeting the conserved non-dominant epitopes should increase broadly-protective immunity.

Infections or vaccinations with influenza viruses elicit neutralizing antibodies that protect against infection with an antigenically closely related virus. Most neutralizing antibodies are directed against highly variable, immunodominant antigenic epitopes in the head of HA. For H3N2 viruses, early studies with antigenic escape mutants against mouse monoclonal antibodies identified five immunodominant antigenic epitopes (A-E) in the head of HA (Wiley et al., 1981 and 1987) (FIG. 1). The high mutation rate of influenza viruses and immune pressure in previously infected and/or vaccinated people result in the accumulation of mutations in these immunodominant antigenic epitopes, causing the antibodies circulating in an individual to no longer neutralize the virus. This so-called ‘antigenic drift’ is why humans get re-infected with seasonal influenza viruses. Current seasonal influenza vaccine strains are selected based on the antigenic properties of the highly variable immunodominant antigenic epitopes in the HA head. Therefore, the vaccine strain must be replaced for each new cluster or clade of antigenic drift variants. Moreover, antigenic drift may occur between the time the vaccine is selected (February for the northern hemisphere) and the start of the influenza season (fall in the northern hemisphere), rendering the vaccine largely ineffective (‘vaccine mismatch’).

Most antibodies (Abs) elicited upon influenza virus infection or vaccination are directed against the highly variable, immunodominant antigenic epitopes on the HA head; therefore, they only react with closely related viruses. In 1993, Okuno et al. reported a monoclonal Ab (mAb) that neutralized influenza viruses of two different subtypes. This finding was not fully appreciated at the time, and it was another decade before numerous studies reported mAbs that reacted with multiple HAs of the same subtype, with HAs of another subtype from the same group, with HAs from both groups 1 and 2, or with both influenza A and B virus HAs. Most of these broadly reactive mAbs bind to the HA stem (which anchors HA in the membrane and mediates the pH-induced membrane fusion event in late endosomes that releases the viral genome into the cytosol) (FIG. 1). However, some broadly reactive mAbs interact with conserved regions in the HA head. These mAbs fall into at least two main categories; broadly reactive mAbs that interact with a conserved,

immune-subdominant epitope in the center of the receptor-binding site (conserved among most HA subtypes), and broadly reactive mAbs that interact with conserved, immune-subdominant epitopes on the HA head outside the receptor-binding pocket (these epitopes may not be conserved among all subtypes). The conserved, immune-subdominant epitopes evolve at a much slower rate than the immunodominant epitopes, explaining why antibodies that bind to the conserved epitopes react with more diverse strains (compared with antibodies that interact with the major antigenic epitopes). Antibodies directed at the conserved, immune-subdominant epitopes may therefore provide protection against viruses of different antigenic clusters within the same subtype, or against viruses of different subtypes.

Broadly reactive Abs to conserved regions in HA may pave the way for the development of broadly protective influenza vaccines. However, the conserved epitopes are immune-subdominant and Abs to these epitopes are detected at much lower levels than Abs targeting the immunodominant, highly variable major antigenic epitopes in the HA head. Researchers have therefore tried to refocus immune responses from the immunodominant, highly variable major epitopes in the HA head towards the conserved, immune-subdominant epitopes of HA.

A study in the 1980s demonstrated that vaccination with an HA lacking the head region ('headless HA') elicited stem-reactive Abs that reacted with the HA protein of a different subtype (Graves et al., 1983). Removing the HA head appeared to be an appealing strategy to elicit Abs to the conserved stem, and various membrane-anchored or secreted versions of headless HAs have been tested. Some of these studies led to the generation of broadly protective antibodies upon vaccination, but headless HAs are of low stability and may not fold correctly; moreover, they lack the conserved, immune-subdominant epitopes in the HA head.

In 2011, Wilson and colleagues reported that infection with the pandemic 2009 H1N1 virus (an antigenically novel influenza virus that had not circulated in humans prior to 2009) elicited more broadly cross-reactive antibodies against conserved, immune-subdominant epitopes in the HA stem than typically detected after infection or vaccination with a seasonal influenza virus (Wrarmert et al., 2011). Others reported similar results. Moreover, vaccination with experimental vaccines to H5 (Ellebedy et al., 2014; Nachbagauer et al., 2014) or H7 viruses (Henry et al., 2016 and 2015; Liu et al., 2017; Krammer et al., 2014; Halliley et al., 2015), neither of which circulate in humans, elicited higher amounts of broadly reactive antibodies to conserved, immune-subdominant epitopes in the HA stem than typically detected after infection or vaccination with a seasonal influenza virus. This effect was strongest after the first encounter with a novel (not previously encountered) HA. For example, the first vaccination with a pandemic 2009 H1N1 vaccine elicited high levels of broadly reactive Abs to immune-subdominant epitopes in the HA stem (Andrews et al., 2015). However, after the second exposure to the pandemic 2009 H1N1 virus, most Abs were directed against immunodominant epitopes in the HA head, and the level of Abs directed against the immune-subdominant stem epitopes declined considerably compared with the levels measured after the first exposure (Andrews et al., 2015). Collectively, these findings indicate that the first encounter with a unique HA elicits appreciable amounts of broadly reactive Abs to conserved, immune-subdominant epitopes. In contrast, repeated infection or vaccination with seasonal influenza viruses (which differ by as little as one or two

amino acids in one major antigenic epitope but share the other major epitopes) primarily stimulates (recall) Abs to the immunodominant antigenic epitopes.

#### Exemplary Methods

The present disclosure relates to influenza vaccines based on a distinct 'outdilution' approach for improving the antigenic response to the non-dominant epitopes. Customized influenza viruses with strategically antigenically-distinct immunodominant epitopes (the residues in the immunodominant epitope are changed to residues that do not react with antibodies that recognize the immunodominant epitope) in the 'head' region of HA are pooled, so that the response of the body is to make small amounts of antibodies to the various antigenically-distinct immunodominant epitopes (also referred to as non-immunodominant epitope residues), whereas the large amount of conserved non-dominant epitopes shared by the entire pool strengthen the response to those non-dominant epitopes and thereby create an immune response that is more likely to prove protection against a range of circulating natural viruses, which can be predicted to share those conserved non-dominant epitopes, also.

In one embodiment, a plurality of positions in HA, e.g., up to 17 positions in H3 HA, that are known or suspected of being associated with an epitope, are randomly mutated. For H3, 60 viable viruses were recovered. Monoclonal antibodies are used to evaluate the antigenicity of the recovered viruses. Many of the viruses bind to a limited number of the tested mAbs, which apparently correspond to non-dominant epitopes. The same approach can be used for a range of subtypes or just one subtype (e.g., H3N2, H5N1, etc.) that makes up the vaccine cocktail. For human seasonal H3N2 viruses, the method resulted in viruses with 'heavily' mutated immunodominant antigenic epitopes, viruses that were viable, functional, and antigenically distinct from the parent virus.

In one embodiment, a pan-H3 vaccine is prepared from the modified HA containing viruses that confers protection against multiple antigenic clusters of seasonal human H3N2 viruses. Since the mixtures of immunodominant antigenic head epitopes that have not been detected in nature, the immune response is focused towards conserved, immune subdominant epitopes. Because the method can generate millions of HA variants with multiple non-naturally occurring mutations in the immunodominant epitopes, viable viruses that possess multiple amino acid changes in their immunodominant epitopes that alter their antigenic properties can be obtained. Unlike other approaches, vaccine candidates are prepared that (i) present non-naturally occurring immunodominant antigenic head epitopes, (ii) preserve the conserved, immune subdominant epitopes in the HA stem and the HA head; and (iii) maintain the structural and functional integrity of HA; as a result, our vaccine candidates should be more cross-protective than vaccines based on a wild-type virus.

#### Influenza Vaccines

A vaccine of the invention includes at least one of the isolated recombinant influenza viruses having the desired property, e.g., one or more of non-naturally occurring immunodominant antigenic head epitopes and/or conserved, immune subdominant epitopes in the HA stem and the HA head, as well as maintaining the structural and functional integrity of HA, and optionally one or more other isolated viruses including other isolated influenza viruses having the desired property, one or more immunogenic proteins or glycoproteins of one or more isolated influenza viruses or one or more other pathogens. e.g., an immunogenic protein

from one or more bacteria, non-influenza viruses, yeast or fungi, or isolated nucleic acid encoding one or more viral proteins (e.g., DNA vaccines) including one or more immunogenic proteins of the isolated influenza virus of the invention. In one embodiment, the influenza viruses of the invention may be vaccine vectors for influenza virus or other pathogens.

A complete virion vaccine may be concentrated by ultrafiltration and then purified by zonal centrifugation or by chromatography. Viruses other than the virus of the invention, such as those included in a multivalent vaccine, may be inactivated before or after purification using formalin or beta-propiolactone, for instance.

A subunit vaccine comprises purified glycoproteins. Such a vaccine may be prepared as follows: using viral suspensions fragmented by treatment with detergent, the surface antigens are purified, by ultracentrifugation for example. The subunit vaccines thus contain mainly HA protein, and also NA. The detergent used may be cationic detergent for example, such as hexadecyl trimethyl ammonium bromide (Bachmeyer, 1975), an anionic detergent such as ammonium deoxycholate (Laver & Webster, 1976); or a nonionic detergent such as that commercialized under the name TRITON X100. The hemagglutinin may also be isolated after treatment of the virions with a protease such as bromelin, and then purified. The subunit vaccine may be combined with an attenuated virus of the invention in a multivalent vaccine.

A split vaccine comprises virions which have been subjected to treatment with agents that dissolve lipids. A split vaccine can be prepared as follows: an aqueous suspension of the purified virus obtained as above, inactivated or not, is treated, under stirring, by lipid solvents such as ethyl ether or chloroform, associated with detergents. The dissolution of the viral envelope lipids results in fragmentation of the viral particles. The aqueous phase is recuperated containing the split vaccine, constituted mainly of hemagglutinin and neuraminidase with their original lipid environment removed, and the core or its degradation products. Then the residual infectious particles are inactivated if this has not already been done. The split vaccine may be combined with an attenuated virus of the invention in a multivalent vaccine.

Inactivated Vaccines. Inactivated influenza virus vaccines are provided by inactivating replicated virus using known methods, such as, but not limited to, formalin or  $\beta$ -propiolactone treatment. Inactivated vaccine types that can be used in the invention can include whole-virus (WV) vaccines or subvirion (SV) (split) vaccines. The WV vaccine contains intact, inactivated virus, while the SV vaccine contains purified virus disrupted with detergents that solubilize the lipid-containing viral envelope, followed by chemical inactivation of residual virus.

In addition, vaccines that can be used include those containing the isolated HA and NA surface proteins, which are referred to as surface antigen or subunit vaccines.

Live Attenuated Virus Vaccines. Live, attenuated influenza virus vaccines, such as those including a recombinant virus of the invention can be used for preventing or treating influenza virus infection. Attenuation may be achieved in a single step by transfer of attenuated genes from an attenuated donor virus to a replicated isolate or reassorted virus according to known methods. Since resistance to influenza A virus is mediated primarily by the development of an immune response to the HA and/or NA glycoproteins, the genes coding for these surface antigens come from the reassorted viruses or clinical isolates. The attenuated genes

are derived from an attenuated parent. In this approach, genes that confer attenuation generally do not code for the HA and NA glycoproteins.

Viruses (donor influenza viruses) are available that are capable of reproducibly attenuating influenza viruses, e.g., a cold adapted (ca) donor virus can be used for attenuated vaccine production. Live, attenuated reassortant virus vaccines can be generated by mating the ca donor virus with a virulent replicated virus. Reassortant progeny are then selected at 25° C. (restrictive for replication of virulent virus), in the presence of an appropriate antiserum, which inhibits replication of the viruses bearing the surface antigens of the attenuated ca donor virus. Useful reassortants are: (a) infectious, (b) attenuated for seronegative non-adult mammals and immunologically primed adult mammals, (c) immunogenic and (d) genetically stable. The immunogenicity of the ca reassortants parallels their level of replication. Thus, the acquisition of the six transferable genes of the ca donor virus by new wild-type viruses has reproducibly attenuated these viruses for use in vaccinating susceptible mammals both adults and non-adult.

Other attenuating mutations can be introduced into influenza virus genes by site-directed mutagenesis to rescue infectious viruses bearing these mutant genes. Attenuating mutations can be introduced into non-coding regions of the genome, as well as into coding regions. Such attenuating mutations can also be introduced into genes other than the HA or NA, e.g., the PB2 polymerase gene. Thus, new donor viruses can also be generated bearing attenuating mutations introduced by site-directed mutagenesis, and such new donor viruses can be used in the production of live attenuated reassortants vaccine candidates in a manner analogous to that described above for the ca donor virus. Similarly, other known and suitable attenuated donor strains can be reassorted with influenza virus to obtain attenuated vaccines suitable for use in the vaccination of mammals.

In one embodiment, such attenuated viruses maintain the genes from the virus that encode antigenic determinants substantially similar to those of the original clinical isolates. This is because the purpose of the attenuated vaccine is to provide substantially the same antigenicity as the original clinical isolate of the virus, while at the same time lacking pathogenicity to the degree that the vaccine causes minimal chance of inducing a serious disease condition in the vaccinated mammal.

The viruses in a multivalent vaccine can thus be attenuated or inactivated, formulated and administered, according to known methods, as a vaccine to induce an immune response in an animal, e.g., a mammal. Methods are well-known in the art for determining whether such attenuated or inactivated vaccines have maintained similar antigenicity to that of the clinical isolate or high growth strain derived therefrom. Such known methods include the use of antisera or antibodies to eliminate viruses expressing antigenic determinants of the donor virus; chemical selection (e.g., amantadine or rimantadine); HA and NA activity and inhibition; and nucleic acid screening (such as probe hybridization or PCR) to confirm that donor genes encoding the antigenic determinants (e.g., HA or NA genes) are not present in the attenuated viruses.

#### Pharmaceutical Compositions

Pharmaceutical compositions, suitable for inoculation, e.g., nasal, parenteral or oral administration, comprise one or more influenza virus isolates, e.g., one or more attenuated or inactivated influenza viruses, a subunit thereof, isolated protein(s) thereof, and/or isolated nucleic acid encoding one or more proteins thereof, optionally further comprising

sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The compositions can further comprise auxiliary agents or excipients, as known in the art. The composition of the invention is generally presented in the form of individual doses (unit doses).

Conventional vaccines generally contain about 0.1 to 200 µg, e.g., 30 to 100 µg, of HA from each of the strains entering into their composition. The vaccine forming the main constituent of the vaccine composition of the invention may comprise a single influenza virus, or a combination of influenza viruses, for example, at least two or three influenza viruses, including one or more reassortant(s).

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and/or emulsions, which may contain auxiliary agents or excipients known in the art. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring, or perfuming agents.

When a composition of the present invention is used for administration to an individual, it can further comprise salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. For vaccines, adjuvants, substances which can augment a specific immune response, can be used. Normally, the adjuvant and the composition are mixed prior to presentation to the immune system, or presented separately, but into the same site of the organism being immunized.

Heterogeneity in a vaccine may be provided by mixing replicated influenza viruses for at least two influenza virus strains, such as 2-20 strains or any range or value therein. Vaccines can be provided for variations in a single strain of an influenza virus, using techniques known in the art.

A pharmaceutical composition according to the present invention may further or additionally comprise at least one chemotherapeutic compound, for example, for gene therapy, immunosuppressants, anti-inflammatory agents or immune enhancers, and for vaccines, chemotherapeutics including, but not limited to, gamma globulin, amantadine, guanidine, hydroxybenzimidazole, interferon-α, interferon-β, interferon-γ, tumor necrosis factor-alpha, thiosemicarbazones, methisazone, rifampin, ribavirin, a pyrimidine analog, a purine analog, foscarnet, phosphonoacetic acid, acyclovir, dideoxynucleosides, a protease inhibitor, or ganciclovir.

The composition can also contain variable but small quantities of endotoxin-free formaldehyde, and preservatives, which have been found safe and not contributing to undesirable effects in the organism to which the composition is administered.

#### Pharmaceutical Purposes

The administration of the composition (or the antisera that it elicits) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the compositions of the invention which are vaccines are provided before any symptom or clinical sign of a pathogen infection becomes manifest. The prophylactic administration of the composition serves to prevent or attenuate any subsequent infection. When provided prophylactically, the gene therapy compo-

sitions of the invention, are provided before any symptom or clinical sign of a disease becomes manifest. The prophylactic administration of the composition serves to prevent or attenuate one or more symptoms or clinical signs associated with the disease.

When provided therapeutically, a viral vaccine is provided upon the detection of a symptom or clinical sign of actual infection. The therapeutic administration of the compound(s) serves to attenuate any actual infection. When provided therapeutically, a gene therapy composition is provided upon the detection of a symptom or clinical sign of the disease. The therapeutic administration of the compound(s) serves to attenuate a symptom or clinical sign of that disease.

Thus, a vaccine composition of the present invention may be provided either before the onset of infection (so as to prevent or attenuate an anticipated infection) or after the initiation of an actual infection. Similarly, for gene therapy, the composition may be provided before any symptom or clinical sign of a disorder or disease is manifested or after one or more symptoms are detected.

A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient mammal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. A composition of the present invention is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient, e.g., enhances at least one primary or secondary humoral or cellular immune response against at least one strain of an infectious influenza virus.

The "protection" provided need not be absolute, i.e., the influenza infection need not be totally prevented or eradicated, if there is a statistically significant improvement compared with a control population or set of mammals. Protection may be limited to mitigating the severity or rapidity of onset of symptoms or clinical signs of the influenza virus infection.

#### Pharmaceutical Administration

A composition having one or more influenza viruses with the desired properties may confer resistance to one or more pathogens, e.g., one or more influenza virus strains, by either passive immunization or active immunization. In active immunization, an attenuated live vaccine composition is administered prophylactically to a host (e.g., a mammal), and the host's immune response to the administration protects against infection and/or disease. For passive immunization, the elicited antisera can be recovered and administered to a recipient suspected of having an infection caused by at least one influenza virus strain. A gene therapy composition of the present invention may yield prophylactic or therapeutic levels of the desired gene product by active immunization.

In one embodiment, the vaccine is provided to a mammalian female (at or prior to pregnancy or parturition), under conditions of time and amount sufficient to cause the production of an immune response which serves to protect both the female and the fetus or newborn (via passive incorporation of the antibodies across the placenta or in the mother's milk).

The present invention thus includes methods for preventing or attenuating a disorder or disease, e.g., an infection by at least one strain of pathogen. As used herein, a vaccine is said to prevent or attenuate a disease if its administration results either in the total or partial attenuation (i.e., suppression) of a clinical sign or condition of the disease, or in the total or partial immunity of the individual to the disease. As

used herein, a gene therapy composition is said to prevent or attenuate a disease if its administration results either in the total or partial attenuation (i.e., suppression) of a clinical sign or condition of the disease, or in the total or partial immunity of the individual to the disease.

A composition having at least one influenza virus of the present invention, including one which is attenuated and one or more other isolated viruses, one or more isolated viral proteins thereof, one or more isolated nucleic acid molecules encoding one or more viral proteins thereof, or a combination thereof, may be administered by any means that achieve the intended purposes.

For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, oral or transdermal routes. Parenteral administration can be accomplished by bolus injection or by gradual perfusion over time.

A typical regimen for preventing, suppressing, or treating an influenza virus related pathology, comprises administration of an effective amount of a vaccine composition as described herein, administered as a single treatment, or repeated as enhancing or booster dosages, over a period up to and including between one week and about 24 months, or any range or value therein.

According to the present invention, an "effective amount" of a composition is one that is sufficient to achieve a desired effect. It is understood that the effective dosage may be dependent upon the species, age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect wanted. The ranges of effective doses provided below are not intended to limit the invention and represent dose ranges.

The dosage of a live, attenuated or killed virus vaccine for an animal such as a mammalian adult organism may be from about  $10^2$ - $10^{20}$ , e.g.,  $10^3$ - $10^{12}$ ,  $10^2$ - $10^{10}$ ,  $10^5$ - $10^{11}$ ,  $10^6$ - $10^{15}$ ,  $10^2$ - $10^{10}$ , or  $10^{15}$ - $10^{20}$  plaque forming units (PFU)/kg, or any range or value therein. The dose of one viral isolate vaccine, e.g., in an inactivated vaccine, may range from about 0.1 to 1000, e.g., 0.1 to 10  $\mu$ g, 1 to 20  $\mu$ g, 30 to 100  $\mu$ g, 10 to 50  $\mu$ g, 50 to 200  $\mu$ g, or 150 to 300  $\mu$ g, of HA protein. However, the dosage should be a safe and effective amount as determined by conventional methods, using existing vaccines as a starting point.

The dosage of immunoreactive HA in each dose of replicated virus vaccine may be standardized to contain a suitable amount, e.g., 30 to 100  $\mu$ g or any range or value therein, or the amount recommended by government agencies or recognized professional organizations. The quantity of NA can also be standardized, however, this glycoprotein may be labile during purification and storage.

The dosage of immunoreactive HA in each dose of replicated virus vaccine can be standardized to contain a suitable amount, e.g., 1-50  $\mu$ g or any range or value therein, or the amount recommended by the U.S. Public Health Service (PHS), which is usually 15  $\mu$ g, per component for older children >3 years of age, and 7.5  $\mu$ g per component for children <3 years of age. The quantity of NA can also be standardized, however, this glycoprotein can be labile during the processor purification and storage (Kendal et al., 1980; Kerr et al., 1975). Each 0.5-ml dose of vaccine may contain approximately 0.1 to 0.5 billion viral particles, 0.5 to 2 billion viral particles, 1 to 50 billion virus particles, 1 to 10 billion viral particles, 20 to 40 billion viral particles, 1 to 5 billion viral particles, or 40 to 80 billion viral particles.

#### EXEMPLARY EMBODIMENTS

In one embodiment, a method to prepare a plurality of influenza virus nucleic acid molecules encoding a hemag-

glutinin (HA) having a reduced number of immunodominant epitopes is provided. The method includes introducing random mutations at a plurality of codons in an isolated parental influenza virus nucleic acid molecule encoding a hemagglutinin having immunodominant epitopes, thereby providing a library of influenza virus nucleic acid molecules encoding a mutant hemagglutinin, wherein the mutations are at codons that encode a residue in an immunodominant epitope in the parental hemagglutinin; introducing the library into cells so as to provide a library of cells that express the mutant hemagglutinins; and identifying nucleic acid molecules encoding a mutant hemagglutinin with a reduced number of immunodominant epitopes as a result of substitutions and/or deletions at residues that form the immunodominant epitopes. In one embodiment, the cells are mammalian cells. In one embodiment, the hemagglutinin (HA) is H1, H2, H3, H5, H6, H7, or H9. In one embodiment, the mutant HA has non-immunodominant residues at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225 in H3. In one embodiment, the residue in H3 at position 121 is Q, R, I, L, V, S, F, Y or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, S, V, or P, position 138 is W, K, I, R, or L, position 140 is L, M, T, S, R, K, M, or P, position 142 is N, G, Y, Q, E, H, N, L, or P, position 144 is T, V, G, D, H, L or Q, position 145 is P, R, W or K, position 155 is C, I, R, A, V, S or N, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, R or T, position 158 is R, V, S, A, K, C, Q, position 171 is T, F, L, E, H, C or R, position 189 is A, P, T, L, A, S, Y, or R, position 193 is Q, R, N, T, E, V, or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F. In one embodiment, the residue in H3 at position 121 is not N, position 131 is not T, position 135 is not T, position 138 is not A, position 140 is not I, position 142 is not R, position 144 is not S, position 145 is not S, position 155 is not T, position 156 is not H, position 157 is not L, position 158 is not N, position 171 is not N, position 189 is not K, position 193 is not F, position 212 is not A, or position 225 is not D. In one embodiment, the residue in H1 at position 121 is N, position 131 is T, position 135 is T, position 138 is A, position 140 is I, position 142 is R, position 144 is S, position 145 is S, position 155 is T, position 156 is H, position 157 is L, position 158 is N, position 171 is N, position 189 is K, position 193 is F, position 212 is A, or position 225 is D. In one embodiment, the mutant HA has non-immunodominant residues at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189 in H5. In one embodiment, the residue in H5 at position 119 is not R, 123 is not P, 125 is not H, 126 is not E, 127 is not T, 129 is not L, 138 is not Q, 140 is not A, 141 is not S, 151 is not I, 152 is not K, 153 is not K, 154 is not N, 155 is not D, 156 is not A, 185 is not A, or 189 is not N. In one embodiment, the residue in H5 at position 119 is R, position 123 is P, position 125 is H, position 126 is E, position 127 is T, position 129 is L, position 138 is Q, position 140 is A, position 141 is S, position 151 is I, position 152 is K, position 153 is K, position 154 is N, position 155 is D, position 156 is A, position 185 is A, or position 189 is N. In one embodiment, the residue in H5 at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L,

Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K, position 154 L, T, D, R, P, S, or H, position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H. In one embodiment, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of the codons that encode residues that form the immunodominant epitope are mutated. In one embodiment, the mutant HA has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 non-immunodominant epitope residues. In one embodiment, the mutant HA has 10, 11, 12, 13, 14, 15, 16, or 17 non-immunodominant epitope residues. In one embodiment, the mutant HA has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, immunodominant epitope residues of the parent. In one embodiment, the mutant HA has 1, 2, 3, 4, or 5 immunodominant epitopes of the parent. In one embodiment, the nucleic acid molecules are identified using one or more antibodies that recognize conserved sub-dominant epitopes. In one embodiment, the cells encoding the nucleic acid molecules are identified as those that do not bind one or more antibodies that recognize immunodominant epitopes. In one embodiment, the nucleic acid molecule encoding the mutant hemagglutinin is sequenced.

In one embodiment, a method to prepare an influenza virus encoding a mutant hemagglutinin that has one or more altered residues in one or more immunodominant epitopes relative to a parental influenza virus is provided. The method includes introducing a plurality of mutations at residues that form an immunodominant domain of a HA of a parent influenza virus and isolating or preparing one or more influenza viruses with the mutated HA. In one embodiment, a plurality of mutations is introduced to antigenic sites A and/or B in HA, thereby forming a library of influenza viruses having mutant HAs. Viruses in the library having distinct mutations in antigenic sites A and/or B, e.g., those that have lower reactivity with sera that bind immunodominant epitopes in the parent HA, can be pooled to form a 'pan' HA sub-type specific vaccine. In one embodiment, a mutation is introduced in an H3 HA encoding nucleic acid molecule at two or more of residues 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, to encode a residue that is not a residue that is part of an immunodominant epitope in the parent virus, and one or more influenza viruses with the mutated H3 HA are prepared. In one embodiment, a mutation is introduced in an H5 HA encoding nucleic acid molecule at two or more of residues 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, wherein the mutations encode a residue that is not an immunodominant epitope; and to encode a residue that is not a residue that forms an immunodominant epitope for the parent virus, and one or more influenza viruses with the mutated H5 HA are prepared. In one embodiment, the residue in the mutated H3 HA at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T, position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or T, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F. In one embodiment, the residue in 113 at position 121 is not N, position 131 is

not T, position 135 is not T, position 138 is not A, position 140 is not I, position 142 is not R, position 144 is not S, position 145 is not S, position 155 is not T, position 156 is not H, position 157 is not L, position 158 is not N, position 171 is not N, position 189 is not K, position 193 is not F, position 212 is not A, or position 225 is not D. In one embodiment, the residue in H3 at position 121 is N, position 131 is T, position 135 is T, position 138 is A, position 140 is I, position 142 is R, position 144 is S, position 145 is S, position 155 is T, position 156 is H, position 157 is L, position 158 is N, position 171 is N, position 189 is K, position 193 is F, position 212 is A, or position 225 is D. In one embodiment, the residue at position 119 is not R, 123 is not P, 125 is not H, 126 is not E, 127 is not T, 129 is not L, 138 is not Q, 140 is not A, 141 is not S, 151 is not I, 152 is not K, 153 is not K, 154 is not N, 155 is not D, 156 is not A, 185 is not A, or 189 is not N. In one embodiment, the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H, position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H. In one embodiment, wherein the mutant HA has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 different residues (non-immunodominant epitope residues) at the immunodominant epitope positions of the parent.

In one embodiment, a composition is provided comprising a plurality of distinct recombinant influenza viruses each encoding a hemagglutinin comprising non-immunodominant epitope residues at immunodominant epitope residue sites, e.g., antigenic sites A and/or B. Thus, the distinct recombinant influenza viruses have distinct mutations in antigenic sites A and/or B, e.g., those that have lower reactivity with sera that bind immunodominant epitopes in the parent HA, can be pooled to form a 'pan' HA sub-type specific vaccine. In another embodiment, the composition has a plurality of distinct recombinant influenza viruses each encoding a hemagglutinin comprising non-immunodominant epitope residues at immunodominant epitope residue sites, e.g., antigenic sites A and/or B, where at least two of the plurality encode different subtypes of hemagglutinin. In one embodiment, one of the plurality of influenza viruses comprises a non-immunodominant epitope at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225 in H3. In one embodiment, one of the plurality of influenza viruses comprises a non-immunodominant epitope residue at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189 in H5. In one embodiment, the composition has at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more distinct recombinant influenza viruses.

Further provided is a method to immunize an animal, comprising: administering an effective amount of a composition comprising a plurality of the viruses described to an animal, e.g., a human, canine, feline, bovine, caprine, ovine, equine, swine, or avian.

In one embodiment, a method to prepare a plurality of influenza virus nucleic acid molecules encoding a hemag-

glutinin (HA) having one or more altered residues in one or more immunodominant epitopes is provided, comprising: introducing random mutations at a plurality of codons in one or more immunodominant epitopes in an isolated parental influenza virus nucleic acid molecule encoding an influenza virus hemagglutinin having at least two immunodominant epitopes, thereby providing a library of influenza virus nucleic acid molecules encoding a mutant influenza virus hemagglutinin; introducing the library into cells so as to provide a library of cells that express the mutant hemagglutinins; and identifying a mutant hemagglutinin encoded by the library with a reduced number of the immunodominant epitopes relative to the parental hemagglutinin as a result of one or more substitutions and/or deletions at residues that form the one or more immunodominant epitopes. In one embodiment, the mutations are introduced into immunodominant epitope (antigenic site) A, B, or A and B. In one embodiment, the mutations are introduced into immunodominant epitope C, D or E, or any combination thereof. In one embodiment, at least 5, 10, 15 or 20 codons, or any integer between 5 and 20, are mutated. In one embodiment, the mutant hemagglutinin is identified using antibodies or other hemagglutinin binding molecules. In one embodiment, at least one of the antibodies or other hemagglutinin binding molecules binds an immunodominant epitope in the parent hemagglutinin or a different influenza virus of the same HA sub-type. In one embodiment, the method includes contacting one or more members of the library with at least one antibody or other hemagglutinin binding molecule that binds a conserved region in the hemagglutinin stem. In one embodiment, the immunodominant epitope that is mutated corresponds to residues 121 to 146 in H3 HA (site A), residues 156 to 196 in H3 HA (site B), residues 50 to 57 or 275 to 279 in H3 HA (site C), residue 164, residue 182 or residues 208 to 217 in H3 HA (site D) or residues 62 to 83 in H3 HA (site E). In one embodiment, the cells are mammalian cells. In one embodiment, the hemagglutinin (HA) is H1, H2, H3, H5, H6, H7 or H9. In one embodiment the mutant HA has a substitution at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, or a deletion at one or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, in H3, or a combination thereof, relative to a parental HA. In one embodiment, the residue in H3 at position 121 is Q, R, I, L, V, S, F, Y or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, S, V, or P, position 138 is W, K, I, R, or L, position 140 is L, M, T, S, R, K, M, or P, position 142 is N, G, Y, Q, E, H, N, L, or P, position 144 is T, V, G, D, H, L or Q, position 145 is P, R, W or K, position 155 is C, I, R, A, V, S or N, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, R or T, position 158 is R, V, S, A, K, C, Q, position 171 is T, F, L, E, H, C or R, position 189 is A, P, T, L, A, S, Y, or R, position 193 is Q, R, N, T, E, V, or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F. In one embodiment, the mutant residue at position 121 is not N, position 131 is not T, position 135 is not T, position 138 is not A, position 140 is not I, position 142 is not R, position 144 is not S, position 145 is not S, position 155 is not T, position 156 is not H, position 157 is not L, position 158 is not N, position 171 is not N, position 189 is not K, position 193 is not F, position 212 is not A, or position 225 is not D. In one embodiment, the non-mutant residue at position 121 is N, position 131 is T, position 135 is T, position 138 is A, position 140 is I, position 142 is R, position 144 is S, position 145 is S, position 155 is T, position 156 is H, position 157 is L,

position 158 is N, position 171 is N, position 189 is K, position 193 is F, position 212 is A, or position 225 is D. In one embodiment, the mutant HA has a substitution at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, or a deletion in one or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 18, in H5, or any combination thereof. In one embodiment, the mutant residue at position 119 is not R, 123 is not P, 125 is not H, 126 is not E, 127 is not T, 129 is not L, 138 is not Q, 140 is not A, 141 is not S, 151 is not I, 152 is not K, 153 is not K, 154 is not N, 155 is not D, 156 is not A, 185 is not A, or 189 is not N. In one embodiment, the non-mutant residue at position 119 is R, position 123 is P, position 125 is EH, position 126 is E, position 127 is T, position 129 is L, position 138 is Q, position 140 is A, position 141 is S, position 151 is I, position 152 is K, position 153 is K, position 154 is N, position 155 is D, position 156 is A, position 185 is A, or position 189 is N. In one embodiment, the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q, position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S, or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H. In one embodiment, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the codons that encode residues that form the immunodominant epitope are mutated. In one embodiment, the mutant HA has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 substitutions. In one embodiment, the mutant HA has 10, 11, 12, 13, 14, 15, 16, or 17 substitutions. In one embodiment, the mutant HA has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues in the one or more immunodominant epitopes that are not substituted or deleted. In one embodiment, the mutant HA has at least 10, 15, 20, 25, 30, 35, 40 or 45 residues in the immunodominant epitope that are not substituted or deleted. In one embodiment, the nucleic acid molecule encoding the mutant hemagglutinin is sequenced.

In one embodiment, a method to prepare an influenza virus encoding a mutant hemagglutinin with altered immunodominant epitopes relative to a parental influenza virus is provided, comprising: introducing a mutation in a parental H3 HA nucleic acid molecule at two or more codons for residue 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, wherein the mutation encodes a residue that is not an immunodominant epitope residue in the parent H3 HA; and isolating or preparing one or more influenza viruses with the mutated H3 HA. In one embodiment, the mutated H3 is recognized by antibodies that bind sub-dominant epitopes but not antibodies that bind the immunodominant epitope. In one embodiment, the residue in the mutated H3 HA at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T,

position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or R, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F. In one embodiment, the residue in H3 at position 121 is not N, position 131 is not T, position 135 is not T, position 138 is not A, position 140 is not I, position 142 is not R, position 144 is not S, position 145 is not S, position 155 is not T, position 156 is not H, position 157 is not L, position 158 is not N, position 171 is not N, position 189 is not K, position 193 is not F, position 212 is not A, or position 225 is not D. In one embodiment, the residue in H3 at position 121 is N, position 131 is T, position 135 is T, position 138 is A, position 140 is I, position 142 is R, position 144 is S, position 145 is S, position 155 is T, position 156 is H, position 157 is L, position 158 is N, position 171 is N, position 189 is K, position 193 is F, position 212 is A, or position 225 is D.

In one embodiment, a method to prepare an influenza virus encoding a mutant hemagglutinin with altered immunodominant epitopes relative to a parental influenza virus is provided, comprising: introducing a mutation in a parental H5 HA nucleic acid molecule at two or more codons for residue 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, wherein the mutation encodes a residue that is not an immunodominant epitope residue in the parent H5HA; and isolating or preparing influenza viruses with the mutated H5 HA. In one embodiment, the mutated H5 is recognized by antibodies that bind sub-dominant epitopes but not antibodies that bind the immunodominant epitope. In one embodiment, the residue at position 119 is not R, 123 is not P, 125 is not H1, 126 is not E, 127 is not T, 129 is not L, 138 is not Q, 140 is not A, 141 is not S, 151 is not I, 152 is not K, 153 is not K, 154 is not N, 155 is not D, 156 is not A, 185 is not A, or 189 is not N. In one embodiment, the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H. In one embodiment, the mutant HA has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 substitutions.

In one embodiment, a composition is provided comprising a plurality of distinct recombinant influenza H3 viruses each encoding a hemagglutinin comprising a plurality of antigenically distinct residues relative to residues that form an immunodominant epitope in a parent virus, wherein each of the plurality of influenza viruses comprises substitutions at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, or one or more deletions of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, in H3, or any combination thereof. In one embodiment, the composition has at least three, four or five distinct viruses with the substitutions. In one embodiment, the composition has five to ten distinct viruses with the substitutions. In one embodiment, the composition has ten to twenty distinct viruses with the substitutions. In one

embodiment, each distinct virus has at least one to five substitutions in antigenic site A or site B. In one embodiment, each distinct virus has at least one to ten substitutions in antigenic sites A and B. In one embodiment, each distinct virus has altered binding to antibodies that bind the corresponding parental hemagglutinin.

In one embodiment, a composition is provided comprising a plurality of distinct recombinant influenza H5 viruses each encoding a hemagglutinin comprising antigenically distinct residues relative to residues that form an immunodominant epitope in a parent virus, wherein each of the plurality of influenza viruses comprises a substitution at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, or a deletion in one or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, in H5, or any combination thereof. In one embodiment, the composition has at least three, four or five distinct viruses with the substitutions. In one embodiment, the composition has five to ten distinct viruses with the substitutions. In one embodiment, the composition has ten to twenty distinct viruses with the substitutions. In one embodiment, each distinct virus has at least one to five substitutions in antigenic site A or site B. In one embodiment, each distinct virus has at least one to ten substitutions in antigenic sites A and B. In one embodiment, wherein each distinct virus has altered binding to antibodies that bind the corresponding parental virus. In one embodiment, the composition has at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more distinct recombinant influenza viruses.

In one embodiment a method to immunize an animal is provided, comprising: administering an effective amount of a composition described herein to an animal.

In one embodiment, an isolated influenza virus is provided comprising a H5 HA wherein the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or 11, or any combination of those residues at those positions.

In one embodiment, a composition is provided comprising a plurality of distinct influenza viruses comprising a H5 HA wherein the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H, position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N, position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H, or any combination of those residues at those positions.

In one embodiment, an isolated influenza virus is provided comprising a H3 HA wherein the residue at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T, position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or R, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F, or any combination of those residues at those positions.

In one embodiment, a composition is provided comprising a plurality of distinct influenza viruses comprising a H3 HA wherein the residue at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T, position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or R, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F, or any combination of those residues at those positions.

The invention will be described by the following non-limiting examples.

#### Example 1

VLPs can be generated by expressing influenza HA together with a single viral matrix protein, hence, the immune responses to the other influenza viral proteins, such as M1 and NA, will not affect the interpretation of the results. VLPs based on the Ebola virus VP40 matrix protein are employed because humans do not possess antibodies to VP40, and Ebola VP40-based VLPs expressing HA are efficiently formed.

17 amino acid positions were identified in human H3 HA proteins that are known or expected to affect antigenicity (e.g., positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, and 225; see FIG. 1) and gene 'libraries' were prepared that encode all 20 amino acids at each of the 17 positions (resulting in  $20^{17}$  theoretically possible variants) in the genetic background of A/Tokyo/UT-IMS2-1/2014 (a clade 3c.2a virus). Virus libraries possessing the up to '17-amino acid mutant HA' proteins were generated and screened with human sera to identify antigenic escape mutants. It was found that HA proteins with up to 17 amino acid changes in their antigenic epitopes were functional and antigenically distinct from the parental virus.

The '17-amino acid mutant HA' proteins may elicit broadly protective immune responses. Immunization with a mixture of HAs with up to 17 amino acid changes at positions responsible for the immune-dominance of the HA head, are unlikely to induce antibodies to the immune-dominant HA epitopes. Rather, stronger responses may be elicited to non-dominant epitopes, resulting in increased cross-protective immunity compared to current vaccines. The use of such vaccines may overcome immunological imprinting (immune response biased towards the first influenza virus encountered).

Specifically, VLP libraries with randomized sequences at 17 amino acid positions of the HA protein of the A/California/7/2004 (Cal/04) virus, a representative of the 'California/2004' antigenic cluster of human H3 viruses are prepared. As a control, VLPs containing wild-type HA protein are also generated. All VLPs are treated with sialidase to prevent self-aggregation. VLPs containing wild-type or '17-amino acid mutant HA' proteins are tested for their reactivity with monoclonal antibodies to the HA head and stalk (e.g., >20 and >10 monoclonal antibodies that react with the head or stalk, respectively, of Cal/04 virus). Compared with VLPs containing wild-type HA, VLPs containing the '17-amino acid mutant HA' proteins likely show reduced binding to antibodies that interact with the HA head, whereas the level of binding to antibodies that interact with the HA stalk is expected to be similar between the two VLPs.

To test the immunogenicity and protective efficacy of the H3 HA-VLPs against antigenically diverse human H3 viruses, ferrets are immunized twice with Cal/04 H3 HA-VLPs; four weeks after the second immunization, the antibody titers against VLPs containing wild-type HA or '17-amino acid mutant HA' proteins are tested. Ferrets are challenged with homologous Cal/04 virus or with three different human H3 influenza viruses belonging to more recent antigenic clusters (e.g., the 'Perth/2009', 'Victoria/2012', and current 3c.2a1 clades). Virus titers in nasal swabs are tested by using plaque assays. Alternatively, or in addition, ferrets are "pre-immunized" with VLPs containing the HA proteins of the 'Wuhan/1995', 'Sydney/1997', and 'Fujian/2002 cluster (ferrets are immunized sequentially with these VLPs; immunizations will be two weeks apart). After the three sequential 'pre-immunizations', animals are vaccinated with VLPs containing wild-type Cal/04 or '17-amino acid mutant Cal/04 HA' proteins and the animals are challenged as described above in order to establish whether a vaccine that elicits antibodies to non-dominant epitopes can overcome immunogenic imprinting.

Immunization with wild-type virus protects ferrets against infection with homologous virus, but not against infection with antigenic drift variants that belong to different antigenic clades. Ferrets immunized with '17-amino acid mutant' H3 HA-VLPs are better protected than those immunized with the wild-type virus against antigenically drifted human H3N2 influenza viruses which establishes that immunization with '17-amino acid mutant HA' proteins elicits broadly protective antibodies, perhaps because immune responses are 'refocused' towards non-dominant epitopes that are more conserved among human H3 viruses than the major immune-dominant epitopes.

Individual mutants and/or libraries in which fewer amino acid positions are randomized allow for the identification of specific mutant HA proteins that elicit cross-protective immune responses to non-dominant epitopes.

#### Example 2

##### Generation and In Vitro Characterization of HAs with Multiple Mutations in Immunodominant Epitopes (ID-EpiMut HAs)

Given that the first exposure to previously unencountered HAs elicits high levels of Abs to conserved, immune-subdominant HA epitopes, mixtures of viruses encoding non-naturally occurring immunodominant head epitopes (i.e., immunodominant epitope-mutated HA, ID-EpiMut HA) are prepared. Each of these variants is a unique HA to

the immune system, thereby boosting the levels of cross-protective antibodies to the conserved, immune-subdominant regions in HA.

Experimental Approach. Millions of mutant influenza viruses are generated ('virus libraries'), and variants with the desired properties, such as non-naturally occurring immunodominant head epitopes, are selected.

Generation and screening of virus libraries. Methods to generate influenza virus 'libraries', as well as other viral libraries including Ebola VIP libraries, that is, mixtures of viruses possessing random mutations at arbitrary or predetermined amino acid positions of an influenza viral protein, are available ((Li et al., 2016; Ping et al., 2015 and 2016; Taft et al., 2015). Briefly, mutations at predetermined positions of influenza viral cDNAs are introduced by PCR with degenerate oligonucleotides encoding 'NNN' at the targeted codon, or by commercial gene synthesis. The resulting PCR or gene mixtures are cloned into RNA polymerase I vectors for the transcription of influenza viral RNAs, resulting in so-called 'plasmid libraries'. Following established reverse genetics protocols, eukaryotic cells (e.g., 293T human embryonic fibroblast cells) are transfected with the plasmid library, seven RNA polymerase I plasmids for the transcription of the remaining seven viral RNA segments (the genome of influenza A viruses comprises eight segments of single-stranded RNA), and four protein expression plasmids synthesizing the viral polymerase proteins (PB2, PB1, PA) and nucleoprotein (NP), which are all essential to initiate viral replication and transcription. This approach results in the generation of virus libraries composed of millions of mutants.

While classic experimental approaches test one mutation at a time, the present approach allows the simultaneous testing of millions of mutants. Hence, the approach (i) recapitulates multiple steps of evolution in an experimental setting; (ii) covers a large 'sequence space' (including mutants that have not been isolated in nature; (iii) allows for competition among mutants (a critical aspect in virus evolution); and (iv) eliminates non-viable mutants at the stage of virus library generation. Virus libraries are then screened for different biological features including antigenicity, receptor-binding properties, polymerase activity, and virus titers. The power and versatility of this approach has been shown by modeling the antigenic evolution of seasonal human H1N1 and H3N2 influenza viruses (Li et al., 2016), isolating polymerase mutants that confer efficient replication to avian influenza viruses in mammalian cells (an important feature in the generation of pandemic influenza viruses)

(Taft et al., 2016), and by selecting mutations that increase the titers of influenza A and B vaccine viruses (Ping et al., 2015 and 2016).

Generation and screening of H5 HA virus libraries. To better understand the antigenic differences among pandemic H5N1 influenza viruses, random mutations were introduced at 17 amino acid positions that are known or suspected to affect the antigenic properties of these viruses (e.g., amino acid positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, and 189; numbers refer to the amino acid position of mature H5 protein after the signal peptide has been removed); these positions cluster in the highly variable, immunodominant major antigenic head epitopes of H5N1 viruses. Chemically synthesized gene libraries were obtained which, theoretically, encode all 20 amino acids at each of the 17 selected positions. Gene libraries were amplified by PCR, the PCR products cloned into an RNA polymerase I vector, and H5N1 virus libraries generated. In general, the size of the virus libraries ranges from  $\sim 10^4$ - $10^7$  plaque forming units (pfu)/ml of supernatant derived from transfected cells; they do not, therefore, contain all possible combinations of amino acids at the 17 selected positions (i.e.,  $20^{17}$  different amino acid combinations).

After generating H5 virus libraries with random mutations at 17 amino acid positions in HA, they were incubated with ferret sera raised against different H5 viruses. During this selection step, mutants with antigenic properties similar to recently circulating H5 viruses will be neutralized. The resulting antigenic escape variants were plaque-purified in Madin-Darby canine kidney (MDCK) cells (a cell line commonly used for influenza virus propagation), and individual viruses were amplified and sequenced to identify the amino acid changes that conferred antigenic escape. After antigenic selection, >50 H5 mutants with 13-17 amino acid differences from the parent virus were isolated (see Table 1 for examples of selected sequences), attesting to the sequence plasticity of the highly variable, immunodominant major antigenic head epitopes. Importantly, most of these mutants are antigenically different from the parent virus as demonstrated by hemagglutination inhibition assays. Likewise, studies with seasonal human H3N2 virus (see Example 1 and Table 1B-C) yielded mutants that possessed multiple amino acid changes in the highly variable, immunodominant antigenic head epitopes and are antigenically distinct from the parent virus. Collectively, these studies establish that seasonal H3N2 and pandemic H5 viruses with up to 17 amino acid mutations in immunodominant antigenic epitopes are viable, replicate efficiently, and are antigenically distinct from the parent virus.

TABLE 1

Sequences of H5 HA proteins with randomized amino acids at the indicated positions																	
WT	119	123	125	126	127	129	138	140	141	151	152	153	154	155	156	185	189
R	P	H	E	T	L	Q	A	S	I	K	K	N	D	A	A	N	
1	R	L	L	S	V	D	G	T	S	T	A	R	L	N	T	L	Y
2	L	Y	L	S	V	L	G	G	R	T	P	Q	T	D	F	D	S
3	L	I	D	R	V	S	D	S	P	S	A	Q	N	G	R	D	L
4	K	M	N	S	V	G	E	R	P	T	T	T	N	K	A	N	L
5	R	N	D	S	A	K	L	R	P	T	Y	T	N	H	S	G	R
6	S	M	G	I	S	K	A	R	S	L	T	N	T	T	D	N	L
7	R	L	G	S	M	W	M	D	W	Y	H	T	T	L	P	E	R
8	S	L	L	S	V	R	L	K	K	K	E	S	D	N	H	F	L
9	G	S	W	G	L	E	L	R	R	N	S	F	N	S	P	S	Y
10	G	V	W	N	L	V	L	Q	S	T	S	T	L	I	P	L	K
11	T	Y	M	S	L	R	V	Q	E	I	P	S	R	D	R	Q	E
12	E	Y	I	S	L	L	D	R	A	T	A	P	R	P	T	L	G
13	S	K	R	S	V	L	M	R	E	T	A	V	P	T	G	P	S

TABLE 1-continued

Sequences of H5 HA proteins with randomized amino acids at the indicated positions																	
	119	123	125	126	127	129	138	140	141	151	152	153	154	155	156	185	189
WT	R	P	H	E	T	L	Q	A	S	I	K	K	N	D	A	A	N
14	A	G	K	Q	L	Q	F	R	A	Q	S	K	R	P	A	S	F
15	L	G	F	A	M	A	L	R	M	K	P	K	T	P	N	V	D
16	V	G	G	S	K	R	R	E	M	T	S	T	S	D	R	L	G
17	F	S	A	N	A	I	S	E	E	I	F	K	N	Q	T	M	V
18	R	T	F	G	A	F	A	C	D	T	I	T	H	P	T	R	E
19	N	R	D	R	F	L	A	V	L	L	P	K	S	D	T	A	I
20	T	R	S	G	Y	F	M	G	Q	Q	D	Q	S	Q	H	S	H

TABLE 1B

Sequence of TK/2 17AA (H3) mutants																			
Short	Position (H3 Numbering)																Note	FFU/50 ul	
name	121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225		
TK2	N	T	T	A	I	R	S	S	T	H	L	N	N	K	F	A	D		
TK2-17AA-mut-1	Y	V	V	K	W	S	G	P	V	G	V	R	D	N	A	Q	K		8.05E+04
TK2-17AA-mut-2	M	V	G	D	F	T	D	R	C	A	N	G	R	E	G	N	K		1.08E+05
TK2-17AA-mut-4	K	R	G	.	P	D	A	G	M	T	S	P	K	D	G	L	E		7.91E+04
TK2-17AA-mut-5	Q	R	Y	K	L	N	T	P	C	P	D	R	T	A	Q	V	L		2.92E+06
TK2-17AA-mut-6	V	R	R	F	M	N	T	W	V	A	.	H	T	I	S	R	P		4.46E+04
TK2-17AA-mut-7	F	G	V	.	K	A	M	L	I	L	S	G	.	—	—	S	.	Plus deletion of additional amino acids	1.85E+05
TK2-17AA-mut-9	V	K	V	T	H	E	R	R	A	S	P	V	R	R	T	I	S		1.12E+05
TK2-17AA-mut-10	R	V	K	W	M	G	V	P	I	G	P	V	F	T	R	R	P		6.16E+05
TK2-17AA-mut-11	T	G	L	R	C	S	G	R	Y	P	.	Q	T	F	A	R	T		4.37E+04
TK2-17AA-mut-12	I	.	N	K	T	Y	D	.	R	S	S	S	F	A	Q	G	C		2.37E+05
TK2-17AA-mut-14	V	M	L	K	T	G	A	W	Q	S	R	L	Q	L	R	R	E		3.03E+04
TK2-17AA-mut-15	A	K	S	R	N	D	G	V	R	S	R	F	T	E	A	Y	G		1.17E+05
TK2-17AA-mut-16	V	C	N	I	K	.	P	D	A	A	G	A	L	A	P	S	S		2.34E+05
TK2-17AA-mut-17	V	C	L	L	R	F	K	T	I	P	S	P	Q	N	S	T	S		1.91E+04
TK2-17AA-mut-21	V	R	V	V	V	D	P	R	G	S	C	I	I	—	—	—	—	Plus deletion of additional amino acids	5.51E+04
TK2-17AA-mut-22	S	S	.	K	S	Q	G	.	R	P	I	K	E	P	N	V	Q		3.59E+05
TK2-17AA-mut-23	V	Q	V	R	R	E	H	.	V	T	.	R	H	L	T	M	G		1.16E+06

TABLE 1B-continued

Sequence of TK2/17AA (H3) mutants														Note	FFU/50 ul				
Short name	Position (H3 Numbering)																		
	121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225		
TK2	N	T	T	A	I	R	S	S	T	H	L	N	N	K	F	A	D		
TK2-17AA-mut-24	L	R	N	T	K	T	N	.	Q	K	R	F	S	.	T	V	S		1.65E+05
TK2-17AA-mut-25	R	R	I	V	N	G	T	R	W	P	S	P	R	S	S	V	R		1.11E+05
TK2-17AA-mut-26	V	R	Y	K	T	A	E	Q	.	L	W	G	R	Y	Q	M	N		1.13E+05
TK2-17AA-mut-28	F	D	S	K	G	N	V	K	P	T	R	R	L	S	—	P	S		3.79E+04
TK2-17AA-mut-29	S	R	K	T	N	.	A	P	Q	.	M	K	F	T	N	F	C		8.16E+04
TK2-17AA-mut-30	F	V	W	S	M	H	Q	P	Q	G	R	C	T	S	E	.	Y		3.35E+05
TK2-17AA-mut-31	R	V	V	.	T	A	E	G	S	I	P	M	C	S	G	L	C		1.02E+05
TK2-17AA-mut-32	F	D	G	F	.	N	.	W	R	A	S	Q	V	Y	R	V	L		6.94E+05
TK2-17AA-mut-34	I	Y	S	R	Y	.	L	.	S	C	S	.	L	R	V	S	S		3.13E+05
TK2-17AA-mut-35	I	M	Q	W	A	V	E	K	E	K	E	C	G	T	S	P	S		1.29E+05
TK2-17AA-mut-36	H	G	S	R	K	M	G	E	K	R	K	Q	K	A	K	C	S		5.46E+03
TK2-17AA-mut-37	R	A	V	R	N	N	K	Q	V	R	I	S	S	G	S	T	A		4.05E+04
TK2-17AA-mut-38	I	E	R	G	D	P	P	N	V	G	E	H	R	R	.	S	C		1.01E+05
TK2-17AA-mut-39	V	E	A	E	L	A	I	N	S	E	E	C	L	N	S	C	H		1.47E+05
TK2-17AA-mut-40	T	I	A	R	C	S	K	P	R	N	R	T	R	V	K	T	V		5.09E+04
TK2-17AA-mut-41	V	D	C	S	L	G	Q	F	P	L	R	R	L	N	S	W	C		4.81E+04
TK2-17AA-mut-43	V	K	A	Q	M	.	.	K	S	S	A	I	R	A	M	S	.		1.57E+05
TK2-17AA-mut-44	I	G	G	R	.	D	.	P	I	P	P	G	L	E	V	L	.		8.63E+04
TK2-17AA-mut-45	M	N	S	T	R	H	K	.	C	D	T	Q	V	S	P	I	P		2.33E+05
TK2-17AA-mut-46	Y	L	Q	T	F	.	G	A	A	C	A	H	T	N	L	F	C		4.31E+04
TK2-17AA-mut-47	V	N	L	L	A	T	T	.	K	R	A	R	R	V	P	P	P		1.03E+05
TK2-17AA-mut-48	F	R	S	V	V	Q	R	P	D	G	N	T	M	T	G	R	M		2.04E+05
TK2-17AA-mut-50	V	C	P	L	W	H	Q	P	G	S	T	H	T	R	K	R	C		3.43E+04

TABLE 1B-continued

Sequence of TK2 17AA (H3) mutants														Note	FFU/50 ul				
Short name	Position (H3 Numbering)																		
TK2	121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225		
TK2-	M	K	Y	Q	Y	I	N	H	S	P	F	R	F	I	D	F	C		1.05E+05
17AA-mut-51	T	N	C	R	W	N	K	C	I	.	P	L	K	H	N	V	Q		1.45E+05
TK2-	V	R	N	C	F	N	T	P	L	I	P	K	R	H	A	R	L		4.86E+04
17AA-mut-53	Y	R	P	.	N	K	T	R	N	.	P	A	T	H	N	E	L	C139A	1.98E+05
TK2-	R	.	Q	S	C	Q	T	T	A	P	.	S	R	G	N	V	S		4.18E+04
17AA-mut-54	T	S	D	.	G	N	Y	A	P	F	S	G	L	I	D	V	C		3.35E+04
TK2-	F	H	M	R	L	N	N	T	R	R	C	G	H	T	K	G	A		2.87E+04
17AA-mut-55	H	R	R	R	M	G	N	D	Y	S	R	P	I	L	T	V	A		6.30E+04
TK2-	T	Q	S	Q	E	Q	I	R	.	S	K	G	I	T	R	L	W		7.46E+04
17AA-mut-56	V	S	K	D	H	K	A	G	R	D	R	K	T	V	K	W	S	G209D	6.47E+04
TK2-	L	G	A	Q	R	Q	E	A	S	D	R	R	E	R	G	V	M		2.31E+05
17AA-mut-57	F	R	V	.	Q	.	E	P	M	T	T	H	T	Q	T	R	F		1.95E+05
TK2-	Y	E	P	L	L	Q	.	N	.	S	T	G	R	S	P	D	P		3.34E+05
17AA-mut-58	L	E	S	V	R	Y	N	D	R	G	P	P	T	A	R	E	I		1.33E+05
TK2-	I	S	G	L	R	P	G	V	S	W	D	P	.	N	R	E	T		2.79E+05
17AA-mut-59	W	E	S	W	K	H	R	P	L	T	T	K	V	I	R	L	P		6.00E+04
TK2-	E	Q	E	L	Q	D	M	A	V	P	Q	G	F	P	M	.	E		3.88E+05
17AA-mut-60	T	R	M	R	Q	N	Y	P	W	I	S	K	W	E	R	S	P		1.25E+04
TK2-	S	L	S	R	L	E	W	P	G	Q	R	T	L	T	S	R	A		2.10E+05
17AA-mut-61	F	R	N	E	R	N	P	T	I	P	V	S	L	S	A	S	C		2.02E+05
TK2-	E	R	K	L	L	N	N	G	.	Q	.	S	A	S	D	.	A		9.73E+04
17AA-mut-62	A	L	V	I	P	.	K	.	S	T	Q	Q	L	R	P	E	F		6.92E+05
TK2-	L	G	L	D	D	A	.	P	D	K	P	C	R	S	N	R	A		1.52E+05
17AA-mut-63																			

\*,? Same amino acid as wild-type; ‘—’ Deletion.

TABLE 1C

		Sequence of H3 mutants with deletions																						
Virus	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202						
Tokyo 2	P	G	T	D	K	D	Q	I	F	L	Y	A	Q	S	S	G	R	I						
TK2-28	.	.	.	.	S	A	N	L	—	A	V	.	.	.	.	.	.	.	.					
TK2-7	.	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	.	.	.			
TK2-21	.	.	T	D	—	—	—	—	—	—	—	—	—	—	—	—	—	—	.	.	K			

	Virus	203	204	205	206	207	208	209	210	211	212	213	214	215
	Tokyo 2	T	V	S	T	K	R	S	Q	Q	A	V	I	P
	TK2-28	.	.	.	.	.	.	.	.	.	P	.	.	.
	TK2-7	.	.	.	.	.	.	.	.	.	S	.	.	.
	TK 2-21	N	H	.	I	Y	Q	K	K	—	—	—	—	.

‘.’ Same amino acid as wild-type; ‘—’ Deletion.

Selection of HA positions for mutagenesis. H3N2 HA variants with non-naturally occurring immunodominant antigenic head epitopes are generated so that vaccination with mixtures of these viruses dilutes the antibody responses to the immunodominant epitopes and focus the immune responses towards more conserved immune-subdominant epitopes in the head and stem regions of HA.

Random mutations at 15 amino acid positions. Based on published and unpublished data, random mutations are introduced at the following 15 amino acid positions of HA, which have been shown or are suspected to affect the antigenicity of H3 HA (all amino acid position numbers refer to the ‘mature’ H3 HA, after removal of the signal peptide): 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 158, 159, 189, 193, and 212 (FIG. 3). These sites are primarily located in the highly variable, immunodominant antigenic head epitopes A (positions 131, 135, 138, 140, 142, 144, 145), B (positions 155, 156, 158, 159, 189, 193), and C (positions 121, 193), and include the seven amino acid positions at which most seasonal H3N2 cluster changes have occurred (e.g., positions 145, 155, 156, 158, 159, 189, and 193 (84)). Random mutations at the selected positions are introduced into the HA protein of A/California/7/2004 (CA04) virus, the prototype of the California 2004 (CA04) antigenic cluster of humans H3N2 viruses. This older strain was selected so that the protective efficacy of the ID-EpiMut CA04-based vaccines could be tested against recent human H3N2 influenza viruses.

Briefly, a chemically synthesized cDNA library possessing random mutations at the selected positions of CA04 HA is prepared, the cDNA library is PCR amplified, and cloned into an RNA polymerase I vector, resulting in a plasmid library.

Generation of virus libraries. The plasmid library of mutant HAs is used to generate a virus library in the genetic background of a high-yield A/Puerto Rico/8/34 (PR8) virus, which confers high virus titers in cultured cells (Ping et al., 2015). Specifically, w 10<sup>6</sup> 293T cells (in 6-well plates) are transfected with 1 µg of the mutant HA plasmid library, with 0.1 µg each of the RNA polymerase I plasmids for the transcription of the remaining viral RNAs (all derived from high-yield PR8 virus), and with 0.1 µg each of polymerase protein expression plasmids for the polymerase and NP proteins. Forty-eight hours later, aliquots of supernatants are collected from transfected cells and plaque assays performed in MDCK cells to assess the titers of the virus library. As stated earlier, typically about ~10<sup>4</sup>-10<sup>7</sup> pfu of mutant viruses per ml of cell culture supernatant is obtained. Libraries are amplified in AX-4 cells (MDCK cells overexpressing α2,6-

linked sialic acids on the cell surface, to which human influenza viruses bind efficiently).

Selection of ID-EpiMut HA Variants with Immunodominant Head Epitopes that are Antigenically Distinct from Those of (Most) Influenza Viruses

To increase the levels of antibody responses to immune-subdominant epitopes in the stem and head of HA, HA variants with non-naturally occurring immunodominant antigenic head epitopes are generated. To select such mutants, the virus library is incubated with mixtures of ferret sera raised against viruses of different antigenic clades, and with mixtures of human sera from donors of different age groups who have been exposed to different viruses and vaccines during their lifetime.

Specifically, the virus library is incubated with different concentrations of serum mixtures, and then plaque assays in AX-4 cells are performed. Virus plaques are picked from the highest serum concentration at which plaques are detected. Individual viruses are amplified in AX-A cells and their HA genes sequenced. >100 individual HA genes are sequenced for each serum type (human or ferret) and serum concentration.

Viruses with amino acids that are not commonly found at the respective amino acid position (e.g., in <1% of sequences in the Influenza Research Database) are of particular interest. Highest priority is given to HAs with amino acids that have not been frequently detected at the respective position of any HA subtype (e.g., in <1% of sequences in the Influenza Research Database). For all mutants, the entire HA gene is sequenced to determine whether additional mutations emerged (outside of the targeted amino acid positions) that may have compensatory functions such as stabilizing effects on HA. The 100 ID-EpiMut HA variants with the least sequence homology to known influenza viruses at the targeted positions) are selected for further analysis (FIG. 5).

Reactivity of ID-EpiMut HA Variants with H3 HA- and Stem-Specific mAbs

After isolating ID-EpiMut HA variants with diverse sequences in the immunodominant antigenic head epitopes, reactivity of these HA proteins is tested with a panel of H3 HA-specific Abs. A panel may include >100 antibodies (Yamayoshi et al., 2017; Epstein et al., 2002). The ability of these mAbs to neutralize representative human H3N2 influenza viruses of all of the major antigenic clades was tested (Table 2) and it was found that most of them neutralized only

subsets of the test viruses, indicating that they react with the highly variable, immunodominant antigenic head epitopes A-E. Several of these mAbs, however, did not neutralize viruses from most of the major antigenic clusters of human H3N2 viruses (Table 2). Based on competition studies with known stem-reacting mAbs, these mAbs were found to interact with the HA head.

plasmid and transfected into 293T cells. Wild-type CA04 HA protein serves as a control. At 24 h post-transfection, the cells are fixed with 4% paraformaldehyde. The HA-expressing cells are incubated with mAbs (1 µg/ml) followed by a peroxidase-conjugated goat anti-human IgG, Fcγ Fragment-specific antibody (Jackson Immuno-Research). TMB (3,3', 5,5'-Tetramethylbenzidine) solution is added for 5 min at

TABLE 2

IC <sub>50</sub> values (µg/ml) of selected mAbs measured by micro-neutralization assay <sup>1</sup>								
Antigenic Cluster								
Name	HK68	EN72	VI75	TX77	BK79	SI87	BE89	BE92
#1	25.00**	25.00**	12.50***	25.00*	12.50***	25.00*	12.50***	12.50***
#2	>50	>50	>50	6.25***	0.78****	0.39****	1.56****	1.56****
#3	>50	>50	0.20****	3.13***	0.20****	0.20****	>50	1.56****
#4	>50	>50	25.00*	12.50***	1.56****	12.50***	0.78****	3.13***
#5	25.00**	>50	0.78****	1.56****	0.78****	1.56****	>50	3.13***
Antigenic Cluster								
Name	WH95	SY97	FU02	CA04	WI05	PE09	TX12	HK14
#1	12.50****	12.50***	25.00*	>50	6.25***	12.50**	>50	>50
#2	3.13****	3.13****	12.50**	12.50**	12.50**	3.13****	6.25****	12.50***
#3	0.78****	0.20****	1.56****	0.20****	0.20****	0.20****	1.56****	1.56****
#4	3.13****	6.25***	0.78****	6.25***	0.39****	6.25***	>50	12.50***
#5	3.13****	12.50**	3.13****	6.25***	12.50**	6.25***	6.25***	25.00*

<sup>1</sup>Shown are the IC<sub>50</sub> values of the indicated mAbs with viruses representing different antigenic clusters of human H3N2 viruses (HK68, Hong Kong '68; EN72, England '72; VI75, Victoria '75; TX77, Texas '77; BK79, Bangkok '79; SI87, Sichuan '87; BE89, Beijing '89; BE92, Beijing '92; WH95, Wuhan '95; SY97, Sydney '97; FU02, Fujian '02; CA04, California '04; WI05, Wisconsin '05; PE09, Perth '09; TX12, Texas '12; HK14, Hong Kong '14. The \*, \*\*, \*\*\*, \*\*\*\* indicate the level of reactivity (that is, \*, \*\*, \*\*\*, \*\*\*\* indicate higher reactivity).

In addition, the reactivity of ID-EpiMut HAs to a panel of stem-reactive mAbs (see, Yamayoshi et al., 2017 and 2018) or synthesized based on the published sequence (Corti et al., 2011) (Table 3) were tested. These mAbs recognize HAs of group 2 (1417infC10), or of group 1 and 2 HAs.

TABLE 3

Reactivity of stem-reactive mAbs with HAs of the indicated subtypes					
mAbs	Group 1		Group 2		Reference
	H1	H5	H3	H7	
S9-1-10/5-1 <sup>1</sup>	✓	✓	✓	✓	Yamayoshi et al., 2017
3352E69	✓	✓	✓	✓	Yamayoshi et al., 2017
10-4-7/1	✓	✓	✓	✓	Yamayoshi et al., 2017
4-8-6/4	✓	✓	✓	✓	Yamayoshi et al., 2017
3381E12	✓	✓	✓	✓	Yamayoshi et al., 2017
3381A11	✓	✓	✓	✓	Yamayoshi et al., 2017
3352E71	✓	✓	✓	✓	Yamayoshi et al., 2017
1417infE21 <sup>2</sup>	✓	✓	✓	✓	Yamayoshi et al., 2018
1417infC10 <sup>3</sup>	✓	✓	✓	✓	Yamayoshi et al., 2018
FI6V3 <sup>1</sup>	✓	✓	✓	✓	Corti et al., 2011

<sup>1</sup>Reacts with HAs of all 18 subtypes

<sup>2</sup>Reacts with H1, H5, H6, H8 (all group 1) & H3, H4, H7, H10, H14, H15 (all group 2) HAs

<sup>3</sup>Reacts with H3, H4, H7, H10, H14, H15 (all group 2) HAs

Hemagglutination inhibition (HI) assays measure the ability of antibodies to inhibit HA binding to red blood cells. HI assays are frequently used to distinguish between antibodies that bind to the head (where the receptor-binding pocket is located that mediates binding to sialic acids on red blood cells) and antibodies that bind to the stem and do not interfere with hemagglutination. However, recent H3N2 viruses do not bind to commonly used red blood cells.

To test the reactivity of the selected 100 ID-EpiMut HA variants, their HA genes are cloned into a protein expression

room temperature before the reaction is stopped by the addition of H<sub>2</sub>SO<sub>4</sub>. The optical density at 450 nm (OD<sub>450</sub>) is measured by using a VersaMax plate reader (Molecular Devices). The OD<sub>450</sub> values of mock-transfected wells incubated with each mAb is subtracted as background.

The reactivity of the ID-EpiMut HA variants is compared with that of wild-type HA. Mutants that lose their reactivity with cluster-specific Abs (directed against highly variable, immunodominant antigenic head epitopes), but retain their reactivity with broadly-reactive H3-specific Abs and with stem-specific Abs (directed against conserved, immune-subdominant antigenic epitopes), are identified. Up to 50 ID-EpiMut HA proteins that fulfill these criteria (FIG. 5) are collected.

Example 3

Immunogenicity and protective efficacy of ID-EpiMut vaccines. Each of the variants produced by the method likely have a unique antigen to the immune system; by mixing them, the vaccine contains low amounts of each of the non-naturally occurring immunodominant antigenic head epitopes, but high amounts of the immune-subdominant epitopes (which are the same in all ID-EpiMut HAs). Such a vaccine elicits higher amounts of antibodies directed at the conserved immune-subdominant epitopes compared with a vaccine presenting only one wild-type HA (which is the current practice with influenza vaccines); the higher levels of antibodies to conserved immune-subdominant epitopes result in cross-protection.

Experimental Approach. Mouse antisera to individual and mixed ID-EpiMut HA variants is generated and tested for reactivity. Vaccination and challenge studies are conducted in mice and ferrets to assess whether mixtures of non-naturally occurring immunodominant epitopes dilute the

responses to these epitopes and increase the levels of antibodies to immune-subdominant epitopes, resulting in more broadly protective immunity.

Generation of virus-like particles possessing individual ID-EpiMut HA variants. In addition to HA (the major influenza viral antigen), other influenza viral proteins including NA, NP, and the matrix (M1) and ion channel (M2) proteins contribute to viral antigenicity; in fact, immunity to NP and M1 are protective in the mouse model. To avoid any confounding effects from these proteins, ID-EpiMut HA variants are presented on VLPs of Ebola virus. Co-expression of Ebola virus VP40 and influenza virus HA results in the highly efficient generation of VLPs decorated with HA. Moreover, a 293T cell line that stably expresses VP40 may be employed for highly efficient VLP formation. VP40-expressing 293T cells are transfected with protein expression plasmids encoding each of the 50 ID-EpiMut HA variants. Two-to-three days later, cells are treated with bacterial neuraminidase to efficiently release the VLPs from the cells. The cell culture supernatant with the released VLPs is harvested, purified through a sucrose gradient, concentrated by ultracentrifugation, and the total protein yield measured by using the BCA assay (Thermo Scientific). The resulting 50 ID-EpiMut-HA/VP40 VLPs (each decorated with a single HA mutant) (FIG. 5) is used to immunize mice.

Generation of virus-like particles possessing multiple ID-EpiMut HA variants. In addition to VLPs decorated with a single ID-EpiMut HA variant, eight different ID-EpiMut-HA/VP40 VLPs that are decorated with different ID-EpiMut HAs (FIG. 5) are generated. Specifically, five ID-EpiMut-HA/VP40 VLPs are tested that are decorated with 10 ID-EpiMut HA variants each, two ID-EpiMut-HA/VP40 VLPs are tested that are decorated with all 25 ID-EpiMut HA variants each, and one ID-EpiMut-HA/VP40 VLP is tested that is decorated with all 50 ID-EpiMut HA variants (for the first two sets, ID-EpiMut HA mutants are randomly sorted into groups of 10 or 25, respectively). VP40-expressing 293T cells are cotransfected with the respective number of different protein expression plasmids expressing different ID-EpiMut HAs. The presentation of different HA mutants on the same VLP will likely reduce the B cell populations that are specific to one particular mutant.

Generation and characterization of mouse sera directed against ID-EpiMut-HA/VP40 VLPs. Mice (BALB/c female mice, Jackson Laboratories: three per group) are intramuscularly immunized with 10-20  $\mu$ g of total protein of ID-EpiMut-HA/VP40 VLPs and two weeks later are intramuscularly boosted with the same amount of protein of ID-EpiMut-HA/VP40 VLPs. Three weeks after the second immunization, blood is collected.

The mouse sera is tested for reactivity against the following groups of HA proteins: (1) Human H3N2 virus HA proteins representing all of the major antigenic clades, derived from viruses that have not been amplified in embryonated chicken eggs (thus eliminating the risk of egg-adapting HA mutations that affect antigenicity); (2) ID-EpiMut HA variants; and (3) HA proteins representing several other HA subtypes, including H1, H5, and H7 (for each of these subtypes, a panel of HA proteins representing the major antigenic clades and sub-clades are used).

An ELISA is employed with purified HA protein using protocol to express secreted forms of HA that are stabilized by a trimerization motif ('foldon') (Stevens et al., 2004). The interaction of mouse sera with purified HA proteins is detected as described above. To assess the relative contributions of antibodies binding to highly variable, immunodominant antigenic head epitopes, conserved immune-

subdominant antigenic stem epitopes, and conserved immune-subdominant antigenic head epitopes, competition assays are performed with human Abs known to bind to these epitopes. Controls include wild-type HA protein and antiserum raised against it, as well as antigenically distant influenza B virus HA protein and antiserum raised against it.

From the 50 ID-EpiMut-HA/VP40 VLPs decorated with one EpiMut HA, the top 30 candidates with the highest proportions of antibodies reactive against the conserved, immune-subdominant antigenic epitopes in the stem and head regions of HA are selected (FIG. 5).

For the eight ID-EpiMut-HA/VP40 VLPs decorated with multiple EpiMut HAs, candidates are eliminated if they do not elicit increased amounts of antibodies to immune-subdominant epitopes (compared to wild-type HA) (FIG. 5). Immunization of Mice with Mixtures of ID-EpiMut-HA/VP40 VLPs

Immunization with mixtures of ID-EpiMut HAs with multiple mutations in the immunodominant antigenic head epitopes likely results in relatively low antibody responses to each of the unique, immunodominant antigens, while boosting responses to the shared epitopes (e.g., the conserved immune-subdominant epitopes in the HA stem and head). To assess this, w different vaccination strategies are tested in which mice (e.g., groups of five animals) are primed with mixtures of 10, 15, or 30 ID-EpiMut-HA/VP40 VLPs, each decorated with a single ID-EpiMut HA (Table 4a). Mice are unboosted, boosted with the same ID-EpiMut-HA/VP40 VLPs used for the prime immunization, or boosted with a different set of 10 or 15 ID-EpiMut-HA/VP40 VLPs.

Likewise, mice are primed with a single ID-EpiMut-HA/VP40 VLP decorated with multiple different mutants (Table 4b), and then mock-boost, boost with the same ID-EpiMut-HA/VP40 VLP, or boost with a different ID-EpiMut-HA/VP40 VLP (this does not apply for animals vaccinated with the ID-EpiMut-HA/VP40 VLP decorated with all 50 EpiMut HA mutants). In addition, controls are primed or primed and boosted with HA/VP40 VLPs decorated with the wild-type HA protein.

Sera is collected 28 days after the last immunization and tested for antibody levels to immune-subdominant antigenic epitopes as described above. Comparison of the different vaccination strategies reveals if two immunizations with the same mixture of ID-EpiMut-HA/VP40 VLPs increase the amount of antibodies to immune-subdominant epitopes compared with a single immunization. Comparison of the different vaccination strategies also reveals if a prime/boost regimen with different ID-EpiMut-HA/VP40 VLPs increases the amount of antibodies to immune-subdominant epitopes compared with a prime/boost regimen with the same ID-EpiMut-HA/VP40 VLPs. Moreover, comparisons of the different vaccination strategies reveal if one VLP decorated with multiple HA mutants (see Table 4b) elicits higher amounts of antibodies to immune-subdominant epitopes than multiple VLPs decorated with one HA mutant each (see Table 4a). The comparison of VLPs decorated with 10, 25, or 50 HA mutants also provides information on the number of different HAs needed to dilute immune response to the immune-dominant epitopes in the HA head.

If mixtures of ten ID-EpiMut HAs (provided from one or ten VLPs) dilute the immune response to the immunodominant epitopes, similar experiments are performed with mixtures of five or three ID-EpiMut HAs to determine the lowest number of different ID-EpiMut HAs needed for the dilution effect.

39

From the different vaccination regimen tested here, the top 10 are selected (e.g., those with the highest levels of antibodies to immune-subdominant epitopes) for protection studies in mice (FIG. 5).

TABLE 4a

Overview of vaccination strategies		
Vaccination Strategy	ID-EpiMut HA/VP40 VLPs (Prime) #	ID-EpiMut HA/VP40 VLPs (Boost) #
VLPs decorated with individual EpiMut HAs	1-10	None 1-10 11-20 21-30
	11-20	None 1-10 11-20 21-30

40

TABLE 4a-continued

Overview of vaccination strategies		
Vaccination Strategy	ID-EpiMut HA/VP40 VLPs (Prime) #	ID-EpiMut HA/VP40 VLPs (Boost) #
	21-30	None 1-10 11-20 21-30
	1-15	None 1-15 16-30
	16-30	None 1-15 16-30
	1-30	None 1-30

TABLE 4b

Overview of vaccination strategies (cont.)		
Vaccination Strategy	ID-EpiMut HA/VP40 VLPs (Prime) #	ID-EpiMut HA/VP40 VLPs (Boost) #
VLPs decorated with multiple EpiMut HAs	1 VLP with ID-EpiMut HAs 1-10	None 1 VLP with ID-EpiMut HAs 1-10 1 VLP with ID-EpiMut HAs 11-20 1 VLP with ID-EpiMut HAs 21-30 1 VLP with ID-EpiMut HAs 31-40 1 VLP with ID-EpiMut HAs 41-50
	1 VLP with ID-EpiMut HAs 11-20	None 1 VLP with ID-EpiMut HAs 1-10 1 VLP with ID-EpiMut HAs 11-20 1 VLP with ID-EpiMut HAs 21-30 1 VLP with ID-EpiMut HAs 31-40 1 VLP with ID-EpiMut HAs 41-50
	1 VLP with ID-EpiMut HAs 21-30	None 1 VLP with ID-EpiMut HAs 1-10 1 VLP with ID-EpiMut HAs 11-20 1 VLP with ID-EpiMut HAs 21-30 1 VLP with ID-EpiMut HAs 31-40 1 VLP with ID-EpiMut HAs 41-50
	1 VLP with ID-EpiMut HAs 31-40	None 1 VLP with ID-EpiMut HAs 1-10 1 VLP with ID-EpiMut HAs 11-20 1 VLP with ID-EpiMut HAs 21-30 1 VLP with ID-EpiMut HAs 31-40 1 VLP with ID-EpiMut HAs 41-50
	1 VLP with ID-EpiMut HAs 41-50	None 1 VLP with ID-EpiMut HAs 1-10 1 VLP with ID-EpiMut HAs 11-20 1 VLP with ID-EpiMut HAs 21-30 1 VLP with ID-EpiMut HAs 31-40 1 VLP with ID-EpiMut HAs 41-50
	1 VLP with ID-EpiMut HAs 1-25	None 1 VLP with ID-EpiMut HAs 1-25 1 VLP with ID-EpiMut HAs 26-50
	1 VLP with ID-EpiMut HAs 26-50	None 1 VLP with ID-EpiMut HAs 1-25 1 VLP with ID-EpiMut HAs 26-50
	1 VLP with ID-EpiMut HAs 1-50	None 1 VLP with ID-EpiMut HAs 1-50

Challenge Studies in Mice Vaccinated with ID-EpiMut-HA/VP40 VLPs

After establishing that mixtures of highly mutated immunodominant antigenic head epitopes dilute the immune responses to these epitopes and boost the antibody levels to conserved, immune-subdominant epitopes, it is determined whether the increased levels of antibodies to the immune-subdominant epitopes provide broader protection against seasonal human H3N2 viruses than the protection elicited by a wild-type virus-based vaccine.

For the top 10 vaccination regimen that elicit increased levels of antibodies to conserved, immune-subdominant epitopes, the protective efficacy of the antibodies raised to ID-EpiMut-HAs is evaluated. First, 48 mice each are vaccinated with the selected vaccination regimen. Recent human H3N2 influenza viruses do not replicate efficiently in mice. Mouse-adapted variants of CA04 (for homologous challenge) and of viruses representing the Perth 2009 (PE09), Victoria 2011 (VI11), and Hong Kong 2014 (HK14) antigenic clusters are generated for heterologous challenges, using established strategies for the generation of mouse-adapted viruses. To rule out effects of mouse-adapting mutations on antigenicity, the reactivity of wild-type and mouse-adapted viruses is compared with sera directed against wild-type HAs. If the mouse-adapted variants are antigenically similar to wild-type viruses, the four mouse-adapted viruses are used at a dose of 10<sup>6</sup> pfu to challenge 12 vaccinated mice each. Four mice per challenge group are observed for weight loss; the remaining eight animals are euthanized on days 3 and 6 post-challenge (four animals per timepoint) to assess virus titers in the lungs and nasal turbinates. Vaccination with ID-EpiMut-HAs elicits Abs that are more broadly protective than Abs elicited after vaccination with wild-type HA.

Immunogenicity of ID-EpiMut HA Influenza Vaccines in Ferrets

The top 3 vaccination regimen are tested for their immunogenicity in ferrets (FIG. 5). In ferrets, like humans, the contribution of the 'internal' influenza viral proteins is less pronounced than in mice. Therefore, the vaccination and challenge experiments in ferrets are carried out with influenza virus-based vaccine (e.g., viruses that possess the respective ID-EpiMut HAs are generated in the genetic background of PR8 virus). The recombinant viruses possessing ID-EpiMut HAs are inactivated with beta-propiolactone (an established procedure for the inactivation of influenza viruses) and the equivalent of 15 µg of HA protein is used for vaccination.

Protective Efficacy of ID-EpiMut HA Influenza Vaccines in Ferrets

Next, it is tested whether vaccination of ferrets with ID-EpiMut-HA influenza vaccine confers broader protection than that elicited by a vaccine based on wild-type HA. Ferrets (groups of 5) are immunized with the top 3 vaccination regimens (determined as stated above) (FIG. 5). Twenty-eight days after the last immunization, ferrets are intranasally infected with 10<sup>6</sup> pfu of the homologous CA04 virus, or viruses representing the more recent Perth 2009 (PE09), Victoria 2011 (VI11), and Hong Kong 2014 (HK14) antigenic clusters (heterologous challenges). Starting one day after challenge, the infected animals are weighed every day and nasal wash samples collected every other day to determine virus titers. Vaccination with inactivated influenza vaccine possessing wild-type HA is expected to protect against challenge with the homologous CA04 virus, but provide incomplete protection against the heterologous viruses (which belong to different antigenic clusters). The

finding that vaccination with ID-EpiMut HA influenza vaccine protects against infection with antigenic drift variants establishes the feasibility of the concept for universal influenza vaccines.

TABLE 5

Vaccination/challenge groups to test the broadly protective efficacy of EpiMut HA influenza vaccines			
Group	Influenza virus infections	Vaccination with ID-EpiMut HA influenza vaccine	Challenge
1	Sequential infection with WU95, SY97, and FU02 viruses	ID-EpiMut HA vaccine 1*	CA 04 (homol.)
2			PE09 (heterol.)
3			VI11 (heterol.)
4	ID-EpiMut HA vaccine 2*	ID-EpiMut HA vaccine 2*	CA 04 (homol.)
5			PE09 (heterol.)
6			VI11 (heterol.)
7	ID-EpiMut HA vaccine 3*	ID-EpiMut HA vaccine 3*	CA 04 (homol.)
8			PE09 (heterol.)
9			VI11 (heterol.)
10	Wt-HA vaccine (single vaccination)	Wt-HA vaccine (single vaccination)	CA 04 (homol.)
11			PE09 (heterol.)
12			VI11 (heterol.)
13	Wt-HA vaccine (two vaccinations)	Wt-HA vaccine (two vaccinations)	CA 04 (homol.)
14			PE09 (heterol.)
15			VI11 (heterol.)
16	Wt-HA vaccine (two vaccinations)	Wt-HA vaccine (two vaccinations)	CA 04 (homol.)
17			PE09 (heterol.)
18			VI11 (heterol.)
19			HK14 (heterol.)
20			HK14 (heterol.)

\*Vaccines 1, 2, and 3 indicate the top 3 vaccination regimen based on the data obtained in C.2.3.

Five ferrets (4-6-month-old females) per group are immunized intramuscularly. Twenty-eight days after the last immunization, sera is collected and the reactivity of the sera tested as described above. Control animals are immunized with inactivated influenza vaccine possessing wild-type HA protein. Immunization with ID-EpiMut HA influenza vaccine elicits higher amounts of antibodies directed against conserved, immune-subdominant epitopes than vaccination with a vaccine possessing wild-type HA. Protective Efficacy of ID-EpiMut HA Influenza Vaccines in Ferrets

Next, it is tested whether vaccination of ferrets with ID-EpiMut-HA influenza vaccine confers broader protection than that elicited by a vaccine based on wild-type HA. Ferrets (groups of 5) are immunized with the top 3 vaccination regimen (determined as stated above) (FIG. 5). Twenty-eight days after the last immunization, ferrets are intranasally infected with 10<sup>6</sup> pfu of the homologous CA04 virus, or viruses representing the more recent Perth 2009 (PE09), Victoria 2011 (VI11), and Hong Kong 2014 (HK14) antigenic clusters (heterologous challenges). Starting one day after challenge, the infected animals are weighed every day and nasal wash samples collected every other day to determine virus titers. Vaccination with inactivated influenza vaccine possessing wild-type HA protects against challenge with the homologous CA04 virus, but provides incomplete protection against the heterologous viruses (which belong to different antigenic clusters). The finding that vaccination with ID-EpiMut HA influenza vaccine protects against infection with antigenic drift variants establishes that vaccine as a universal influenza vaccine.

Protective Efficacy of ID-EpiMut HA Influenza Vaccine in Ferrets Pre-Exposed to Human Influenza Viruses

Humans are repeatedly exposed to influenza viruses through natural infection and/or vaccination. To mimic this

exposure to multiple influenza viruses, ferrets are sequentially infected with seasonal human H3N2 viruses representing three past antigenic clusters: the Wuhan 1995 (WU95), Sydney 1997 (SY97), and Fujian 2002 (FU02) clusters (Table 5). Next, animals are vaccinated with each of the top three vaccination approaches. Twenty-eight days after the last immunization, serum samples are collected from vaccinated animals and the reactivity of the sera tested. Sera from ferrets vaccinated with ID-EpiMut HA influenza vaccine are more cross-reactive than those obtained from ferrets immunized with influenza vaccine possessing wild-type HA.

Next, the pre-exposed and vaccinated animals are intranasally infected with 10<sup>6</sup> pfu of the homologous CA04 virus, or with the heterologous PE09, VI11, or HK14 viruses (5 animals per group, Table 5). As described previously, body weight measurements are carried out every day and nasal

washes are collected every other day, starting on day 1 after challenge. ID-EpiMut HA influenza vaccine provides broader protection against viruses of different antigenic clusters than influenza vaccine based on wild-type HA.

In summary, the reactivity and neutralizing properties of mouse sera raised against ID-EpiMut HA variants show that these sera are more broadly reactive and neutralizing than sera raised to wild-type HA. Vaccination/challenge studies establish that the disclosed vaccine approach provides more broadly protective immunity than that afforded by current vaccines based on wild-type HAs.

Thus, mixtures of non-naturally occurring immunodominant head epitopes dilute the immune responses to these epitopes and refocus immune responses towards conserved, immune-subdominant epitopes in HA, thereby increasing the amounts of cross-protective antibodies, thereby providing universal influenza vaccines.

TABLE 6

		TK/2 (H3) Mutants																				
		Amino acid position																				
Name		121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225				
Tokyo 2		N	T	T	A	I	R	S	S	T	H	L	N	N	K	F	A	D		Genotype		
TK/2-177 Hck-41_14		.	.	M	S	F	H	.	P	.	M	S	G	D	R	S	R	.		1		
TK/2-177 Hck-41_69		.	.	M	S	F	H	.	P	.	M	S	G	D	R	S	R	.				
TK/2-177 Hck-41_9		.	.	M	S	F	H	.	P	.	M	S	G	D	R	S	R	.				
TK/2-177 Hck-37_87		A	R	G	S	R	L	D	P	.	N	D	A	Y	N	R	N	E		2		
TK/2-177 Hck-37_73		E	K	.	T	P	D	R	M	Y	K	S	A	T	L	E	S	G		3		
TK/2-177 Hck-37_84		E	K	.	T	P	D	R	M	Y	K	S	A	T	L	E	S	G				
TK/2-177 Hck-37_68		E	L	N	S	K	K	A	P	F	S	T	S	Q	A	R	L	T		4		
TK/2-177 Hck-37_101		E	S	S	.	T	F	G	A	F	A	R	G	R	M	H	Q	.		5		
TK/2-177 Hck-41_3		F	M	G	S	.	E	M	P	F	S	Q	M	R	T	D	L	G		6		
TK/2-177 Hck-41_34		F	M	G	S	.	E	M	P	F	S	Q	M	R	T	D	L	G				
TK/2-177 Hck-37_70-3		F	M	G	S	.	E	M	P	F	S	Q	M	R	T	D	L	G				
TK/2-177 Hck-37_11		F	R	N	.	T	N	I	N	Y	I	R	E	K	D	G	S	E		7		
TK/2-177 Hck-37_19		F	R	S	S	P	M	G	N	.	L	P	D	K	D	A	.	A		8		
TK/2-177 Hck-37_10		F	S	G	S	L	H	R	A	W	S	R	T	F	F	S	S	L		9		
TK/2-177 Hck-37_1		F	S	H	S	S	T	N	P	F	A	S	R	M	A	Q	S	C		10		
TK/2-177 Hck-37_98		F	V	G	S	K	T	G	Q	I	R	S	T	L	N	S	I	R		11		
TK/2-177 Hck-37_71		F	Y	H	S	W	N	K	L	.	A	.	P	S	E	R	T	R		12		
TK/2-177 Hck-37_90		H	A	V	.	R	I	Q	P	Y	Q	S	R	V	S	R	S	.		13		
TK/2-177 Hck-41_H50		H	E	V	.	V	N	V	P	H	R	H	E	M	N	W	T	S		14		
TK/2-177 Hck-37_70-2		H	K	S	S	K	.	G	P	S	Q	G	R	M	A	.	L	G		15		
TK/2-177 Hck-41_H96		H	K	V	S	P	L	R	T	S	A	W	D	R	S	A	H	A		16		
TK/2-177 Hck-37_12		H	R	V	.	R	S	M	T	V	S	S	S	R	N	N	S	G		17		
TK/2-177 Hck-37_16		I	E	H	S	D	.	K	P	V	T	R	K	S	R	S	W	G		18		
TK/2-177 Hck-37_74 2and3		I	E	K	S	Y	T	G	N	V	R	R	G	F	R	D	F	S		19		

TABLE 6-continued

		TK/2 (H3) Mutants																				
		Amino acid position																				
Name	121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225	Genotype				
Tokyo 2	N	T	T	A	I	R	S	S	T	H	L	N	N	K	F	A	D					
TK/2-177 Hek-41_58	I	L	S	S	D	Y	K	K	R	A	R	.	P	N	A	T	R	20				
TK/2-177 Hek-37_81	I	R	M	S	L	A	N	.	.	N	R	V	V	S	R	G	.	21				
TK/2-177 Hek-37_102	I	R	Q	S	N	A	M	P	.	K	H	L	L	H	S	T	K	22				
TK/2-177 Hek-37_49	K	N	.	.	H	N	M	P	F	R	S	.	T	T	L	S	H	23				
TK/2-177 Hek-37_22-1	L	.	G	.	M	D	K	.	I	R	R	Q	M	E	G	T	R	24				
TK/2-177 Hek-37_31	L	.	G	.	M	D	K	.	I	R	R	Q	M	E	G	T	R					
TK/2-177 Hek-37_56	L	.	G	.	M	D	K	.	I	R	R	Q	M	E	G	T	R					
TK/2-177 Hek-41_75	L	.	G	.	M	D	K	.	I	R	R	Q	M	E	G	T	R					
TK/2-177 Hek-37_95	L	.	G	.	M	D	K	.	I	R	R	Q	M	E	G	T	R					
TK/2-177 Hek-41_H48	L	A	.	S	P	D	F	P	H	S	R	L	A	S	T	Q	Q	25				
TK/2-177 Hek-41_H51	L	A	.	S	P	D	F	P	H	S	R	L	A	S	T	Q	Q					
TK/2-177 Hek-41_H58	L	A	.	S	P	D	F	P	H	S	R	L	A	S	T	Q	Q					
TK/2-177 Hek-37_64	L	A	A	S	L	K	N	Y	.	S	M	D	C	F	A	T	S	26				
TK/2-177 Hek-37_74-1	L	A	A	S	L	K	N	Y	.	S	M	D	C	F	A	T	S					
TK/2-177 Hek-41_79	L	A	F	.	S	H	R	.	Y	A	V	G	T	M	M	T	S	27				
TK/2-177 Hek-37_59	L	I	.	S	L	I	G	N	.	.	S	G	V	H	Q	T	L	28				
TK/2-177 Hek-41_89	L	L	D	S	S	.	G	P	H	A	Q	A	A	R	S	N	H	29				
TK/2-177 Hek-37_33	L	L	R	S	L	.	R	E	H	S	P	M	.	M	A	N	H	30				
TK/2-177 Hek-37_35	L	S	Q	.	N	F	A	P	F	S	E	S	.	N	G	.	S	31				
TK/2-177 Hek-37_39	M	.	N	S	P	T	N	Q	F	S	R	R	H	V	N	S	T	32				
TK/2-177 Hek-37_45	M	.	V	S	M	G	V	P	H	V	M	S	L	Y	K	S	S	33				
TK/2-177 Hek-41_76	M	N	.	S	G	E	E	E	Y	A	R	E	R	M	T	H	G	34				
TK/2-177 Hek-41_21	M	Q	A	S	T	N	.	R	F	V	S	R	.	D	S	L	T	35				
TK/2-177 Hek-37_17-1	R	G	S	S	L	S	I	P	K	A	A	A	S	I	H	F	R	36				
TK/2-177 Hek-41_93	R	L	V	S	A	G	R	A	S	S	Q	S	Y	D	.	S	R	37				
TK/2-177 Hek-41_53	R	L	V	S	A	K	M	P	.	A	S	L	E	T	L	S	M	38				
TK/2-177 Hek-37_36	R	N	H	S	R	G	M	M	.	A	S	L	F	S	T	V	C	39				
TK/2-177 Hek-37_60	R	N	H	S	R	G	M	M	.	A	S	L	F	S	T	V	C					
TK/2-177 Hek-37_H5	R	N	S	.	M	Q	Q	V	.	K	F	R	M	E	S	W	?	40				
TK/2-177 Hek-37_96	S	A	V	S	N	K	H	A	F	S	D	S	Q	E	A	Q	.	41				
TK/2-177 Hek-41_48	S	G	R	S	R	N	.	N	W	S	G	K	L	T	S	I	G	42				
TK/2-177 Hek-37_67	S	H	V	S	.	Q	Q	W	.	L	H	D	T	G	A	S	.	43				
TK/2-177 Hek-41_7	S	K	S	S	Y	L	E	.	H	A	D	Q	G	.	A	R	S	44				
TK/2-177 Hek-37_37	T	E	G	C	M	H	T	M	F	K	P	R	E	R	S	V	G	45				
TK/2-177 Hek-37_28	T	G	V	S	.	T	R	.	V	A	N	V	K	S	D	H	T	46				

TABLE 6-continued

Name	TK/2 (H3) Mutants																Genotype	
	Amino acid position																	
Tokyo 2	121	131	135	138	140	142	144	145	155	156	157	158	171	189	193	212	225	
TK/2-177 Hek-41_54	T	K	Q	S	N	G	K	Q	S	S	D	E	L	T	W	I	S	47
TK/2-177 Hek-37_40	T	N	W	S	S	N	A	G	.	S	A	L	L	N	H	S	S	48
TK/2-177 Hek-37_86	T	R	G	T	V	.	E	R	V	Q	R	G	S	A	G	M	S	49
TK/2-177 Hek-37_85	T	V	A	S	K	I	G	V	.	R	S	L	L	V	K	V	G	50
TK/2-177 Hek-37_97	T	V	A	S	K	I	G	V	.	R	S	L	L	V	K	V	G	
TK/2-177 Hek-37_94	V	?	V	S	S	S	G	M	.	A	S	E	I	T	S	L	L	51
TK/2-177 Hek-37_17-2and3	V	A	.	.	L	C	E	A	V	S	T	R	S	G	S	S	G	52
TK/2-177 Hek-41_4	V	K	.	S	P	G	.	D	F	T	P	I	Y	N	Y	V	E	53
TK/2-177 Hek-37_5	V	K	.	S	P	G	.	D	F	T	P	I	Y	N	Y	V	E	
TK/2-177 Hek-37_42	V	K	V	.	P	G	D	Y	.	S	W	K	R	Q	.	G	Q	54
TK/2-177 Hek-41_55	V	K	V	S	Q	.	R	H	.	S	T	S	R	L	N	.	L	55
TK/2-177 Hek-37_57	V	L	V	S	L	S	.	H	V	V	S	K	E	S	H	T	R	56
TK/2-177 Hek-41_78	V	L	V	S	L	S	.	H	V	V	S	K	E	S	H	T	R	
TK/2-177 Hek-37_2	V	N	C	S	A	A	M	N	.	Q	S	Q	T	R	N	V	R	57
TK/2-177 Hek-37_65	V	N	C	S	A	A	M	N	.	Q	S	Q	T	R	N	V	R	
TK/2-177 Hek-41_51	V	Q	.	S	K	T	K	R	W	K	G	H	R	E	Q	S	T	58
TK/2-177 Hek-37_100	V	R	.	.	S	G	I	R	.	W	V	G	M	V	A	W	A	59
TK/2-177 Hek-37_20	V	R	G	S	C	V	K	F	.	A	K	S	L	E	I	L	E	60
TK/2-177 Hek-41_41	V	R	K	S	P	E	.	K	V	M	E	Q	H	R	S	Q	H	61
TK/2-177 Hek-41_26	W	K	.	S	H	Y	T	P	S	A	Q	E	A	R	A	?	Q	62
TK/2-177 Hek-41_38	W	K	.	S	H	Y	T	P	S	A	Q	E	A	R	A	T	Q	
TK/2-177 Hek-41_66	W	K	.	S	H	Y	T	P	S	A	Q	E	A	R	A	T	Q	
TK/2-177 Hek-37_22-3	Y	K	S	S	K	M	N	P	.	M	?	L	W	T	L	L	R	63
TK/2-177 Hek-37_32	Y	L	R	S	L	H	E	R	S	R	.	R	M	A	E	H	.	64
TK/2-177 Hek-41_50	Y	L	R	S	L	H	E	R	S	R	.	R	M	A	E	H	.	
TK/2-177 Hek-41_8	Y	L	R	S	L	H	E	R	S	R	.	R	M	A	E	H	.	
TK/2-177 Hek-41_52	Y	L	R	S	M	A	H	Q	Y	A	W	R	E	Q	R	V	W	65
TK/2-177 Hek-37_62	Y	M	S	.	.	E	R	M	V	K	.	G	S	S	D	F	A	66

## REFERENCES

- Andrews et al., *Sci. Transl. Med.*, 7:316ra192 (2015).  
 Belser et al., *J. Virol.*, 90:4647 (2016).  
 Bommakanti et al., *J. Virol.*, 86:13434 (2012).  
 Bommakanti et al., *Proc. Natl. Acad. Sci. USA*, 107:13701 (2010).  
 Chen et al., *J. Virol.*, 90:3789 (2016).  
 Clementi et al., *PLoS One*, 6:e28001 (2011).  
 Corti et al., *Science*, 333:850 (2011).  
 DiLillo et al., *J. Clin. Invest.*, 126:605 (2016).  
 Dreyfus et al., *Science*, 2:1343 (2012).  
 Ekiert et al., *Curr. Opin. Virol.*, 2:134 (2012).  
 Ekiert et al., *Nature*, 489:526 (2011).  
 Ekiert et al., *Science*, 324:246 (2009).  
 Ekiert et al., *Science*, 333:843 (2011).  
 Ellebedy et al., *Proc. Natl. Acad. Sci. USA*, 111:13133 (2014).  
 Epstein et al., *Emerg. Infect. Dis.*, 8:796 (2002).  
 Erbeling et al., *J. Infect. Dis.*, \_\_\_\_\_; \_\_\_\_\_doi:10.1093/infdis/jiy103 (2018).  
 Fleury et al., *Nat. Struct. Biol.*, 1:119 (1998).  
 Friesen et al., *Proc. Natl. Acad. Sci. USA*, 111:445 (2014).  
 Fu et al., *Nat. Commun.*, 7:12780 (2016).

Goff et al., *PLoS One*, 8:e79194 (2013).  
 Graves et al., *Virology*, 126:106 (1983).  
 Halliley et al., *J. Infect. Dis.*, 212:1270 (2015).  
 Henry et al., *Cell Host Microbe*, 92:800 (2016).  
 Henry et al., *J. Clin. Invest.*, 125-1255 (2015).  
 Herfst et al., *Science*, 336:1534 (2012).  
 Hong et al., *J. Virol.*, 87:12471 (2013).  
 Iba et al., *J. Virol.*, 88:7130 (2014).  
 Imai et al., *Nature*. 486:420 (2012).  
 Impagliazzo et al., *Science*, 349:1301 (2015).  
 Joyce et al., *Cell*, 166:609 (2016).  
 Kallewaard et al., *Cell*, 166:596 (2016).  
 Koel et al., *Science*, 342:976 (2013).  
 Krammer et al., *Clin. Vaccine Immunol.*, 21:1153 (2014).  
 Krammer et al., *J. Virol.*, 86:10302 (2012).  
 Krammer et al., *J. Virol.*, 87:6542 (2013).  
 Krammer et al., *J. Virol.*, 88:2340 (2014).  
 Krammer et al., *J. Virol.*, 88:3432 (2014).  
 Krause et al., *J. Virol.*, 85:10905 (2011).  
 Krause et al., *J. Virol.*, 86:6334 (2012).  
 Lee et al., *Nat. Commun.*, 5:3614 (2014).  
 Lee et al., *Proc. Natl. Acad. Sci. USA*, 109:17040 (2012).  
 Li et al., *Nat. Microbiol.*, 1:16058 (2016).  
 Li et al., *Proc. Natl. Acad. Sci. USA*, 109:9047 (2012).  
 Liu et al., *J. Infect. Dis.*, 215:518 (2017).  
 Luo et al., *J. Virol. Methods*, 154:121 (2008).  
 Mallajosyula et al., *Front. Immunol.*, 6:329 (2015).  
 Mallajosyula et al., *Proc. Natl. Acad. Sci. USA*, 111:E2514 (2014).  
 Margine et al., *J. Virol.*, 87:10435 (2013).  
 Margine et al., *J. Virol.*, 87:4728 (2013).  
 Miller et al., *J. Infect. Dis.*, 207:98 (2009).  
 Nachbagauer et al., *J. Virol.*, 88:13260 (2014).  
 Nachbagauer et al., *J. Virol.*, 90:3268 (2015).  
 Nachbagauer et al., *MBio*, 7:e01996 (2016).  
 Nachbagauer et al., *NPJ Vaccines*, 1:e00018 (2016).  
 Nachbagauer et al., *NPJ Vaccines*, 2:26 (2017).  
 Nakamura et al., *Cell Host Microbe*, 14:93 (2013).  
 Neumann et al., *Proc. Natl. Acad. Sci. USA*, 96:9345 (1999).  
 Ohshima et al., *J. Virol.*, 85:11048 (2011).  
 Okuno et al., *J. Virol.*, 67:2552 (1993).  
 Pica et al., *Proc. Natl. Acad. Sci. USA*, 109:2573 (2012).  
 Ping et al., *Nat. Commun.*, 6:8148 (2015).

Ping et al., *Proc. Natl. Acad. Sci. USA*, 113:E8296 (2016).  
 Raymond et al., *Proc. Natl. Acad. Sci. USA*, 115:168 (2018).  
 Sakabe et al., *Virus Res.*, 158:124 (2009).  
 Sangster et al., *Clin. Vaccine Immunol.* 20:867 (2009).  
 5 Schmidt et al., *Proc. Natl. Acad. Sci. USA*, 110:264 (2013).  
 Steel et al., *MBio*, 1:e00018 (2010).  
 Steinbruck et al., *J. Virol.*, 88:12123 (2014).  
 Stevens et al., *Science*, 303:1866 (2004).  
 Sui et al., *Nat. Struct. Mol. Biol.*, 16:265 (2009).  
 10 Sun et al., *MBio*, :e00230 (2013).  
 Sutton et al., *NPJ Vaccines*, 2:35 (2017).  
 Taft et al., *Nat. Commun.*, 6:7491 (2015).  
 Tan et al., *J. Virol.*, 86:6179 (2012).  
 Thomson et al., *Front. Immunol.*, 3:87 (2012).  
 15 Throsby et al., *PLoS One*, 3:e3942 (2008).  
 Tsibane et al., *PLoS Pathog.*, 8:e1003067 (2012).  
 Valkenburg et al., *Sci. Rep.*, 6:22666. (2016)  
 Watanabe et al., *Nature*, 501:551 (2013).  
 Whittle et al., *Proc. Natl. Acad. Sci. USA*, 108:14216 (2011).  
 20 Wiley et al., *Annu. Rev. Biochem.*, 56:365 (1987).  
 Wiley et al., *Nature*. 289:373 (1981).  
 Wohlbold et al., *Vaccine* 33:3314 (2015).  
 Wrammert et al., *J. Exp. Med.*, 208:181 (2009).  
 Wu et al., *Nat. Commun.*, 6:7708 (2015).  
 25 Xu et al., *Nat. Struct. Mol. Biol.*, \_\_\_\_\_:\_\_\_\_\_doi:  
 10.1038/nsmb.2500 (2013).  
 Yamayoshi et al., *EBioMedicine*, 17:182 (2017).  
 Yamayoshi et al., *J. Infect.*, 76:177 (2018).  
 Yang et al., *PLoS One*, 9:e106660 (2014).  
 30 Yao et al., *Sci. Rep.*, 7:1545 (2017).  
 Yassine et al., *Nat. Med.*, 21:1065 (2015).  
 Yoshida et al., *PLoS Pathog.*, 5:e1000350 (2009)  
 Zhang et al., *Science*, 341:410 (2013).  
 Zhu et al., *Science*, doi:10.1126/science.1239844 (2013).  
 35 All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.  
 40

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 51

<210> SEQ ID NO 1

<211> LENGTH: 329

<212> TYPE: PRT

<213> ORGANISM: Influenza A

<400> SEQUENCE: 1

Gln Lys Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly  
 1 5 10 15

His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp  
 20 25 30

Gln Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Ser Ser Ser Thr  
 35 40 45

Gly Gly Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys  
 50 55 60

Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln  
 65 70 75 80



-continued

115					120					125					
Lys	Thr	Leu	Ile	Ile	Pro	Arg	Ser	Ser	Trp	Pro	Asn	His	Glu	Thr	Ser
130						135					140				
Leu	Gly	Val	Ser	Ala	Ala	Cys	Pro	Tyr	Gln	Gly	Ala	Ser	Ser	Phe	Phe
145				150						155					160
Arg	Asn	Val	Val	Trp	Leu	Ile	Lys	Lys	Asn	Asp	Ala	Tyr	Pro	Thr	Ile
				165					170					175	
Lys	Ile	Ser	Tyr	Asn	Asn	Thr	Asn	Arg	Glu	Asp	Leu	Leu	Ile	Leu	Trp
			180					185					190		
Gly	Ile	His	His	Ser	Asn	Asn	Ala	Ala	Glu	Gln	Thr	Asn	Leu	Tyr	Lys
		195					200					205			
Asn	Pro	Asp	Thr	Tyr	Val	Ser	Val	Gly	Thr	Ser	Thr	Leu	Asn	Gln	Arg
	210					215					220				
Leu	Val	Pro	Lys	Ile	Ala	Thr	Arg	Ser	Gln	Val	Asn	Gly	Gln	Ser	Gly
225					230					235					240
Arg	Met	Asp	Phe	Phe	Trp	Thr	Ile	Leu	Lys	Pro	Asn	Asp	Ala	Ile	His
			245						250					255	
Phe	Glu	Ser	Asn	Gly	Asn	Phe	Ile	Ala	Pro	Glu	Tyr	Ala	Tyr	Lys	Ile
			260					265					270		
Val	Lys	Lys	Gly	Asp	Ser	Thr	Ile	Met	Lys	Ser	Glu	Met	Glu	Tyr	Gly
		275					280					285			
His	Cys	Asn	Thr	Lys	Cys	Gln	Thr	Pro	Ile	Gly	Ala	Ile	Asn	Ser	Ser
	290					295					300				
Met	Pro	Phe	His	Asn	Ile	His	Pro	Leu	Thr	Ile	Gly	Glu	Cys	Pro	Lys
305					310					315					320
Tyr	Val	Lys	Ser	Asn	Lys	Leu	Val	Leu	Ala	Thr	Gly	Leu	Arg	Asn	Ser
				325					330					335	
Pro	Leu	Arg	Glu	Arg	Arg	Arg	Lys	Arg	Gly	Leu	Phe	Gly	Ala	Ile	Ala
			340					345					350		
Gly	Phe	Ile	Glu	Gly	Gly	Trp	Gln	Gly	Met	Val	Asp	Gly	Trp	Tyr	Gly
		355					360					365			
Tyr	His	His	Ser	Asn	Glu	Gln	Gly	Ser	Gly	Tyr	Ala	Ala	Asp	Lys	Glu
	370					375					380				
Ser	Thr	Gln	Lys	Ala	Ile	Asp	Gly	Val	Thr	Asn	Lys	Val	Asn	Ser	Ile
385					390					395					400
Ile	Asp	Lys	Met	Asn	Thr	Gln	Phe	Glu	Ala	Val	Gly	Arg	Glu	Phe	Asn
				405					410					415	
Asn	Leu	Glu	Arg	Arg	Ile	Glu	Asn	Leu	Asn	Lys	Lys	Met	Glu	Asp	Gly
			420					425					430		
Phe	Leu	Asp	Val	Trp	Thr	Tyr	Asn	Ala	Glu	Leu	Leu	Val	Leu	Met	Glu
		435					440					445			
Asn	Glu	Arg	Thr	Leu	Asp	Phe	His	Asp	Ser	Asn	Val	Lys	Asn	Leu	Tyr
	450					455					460				
Asp	Lys	Val	Arg	Leu	Gln	Leu	Arg	Asp	Asn	Ala	Lys	Glu	Leu	Gly	Asn
465					470					475					480
Gly	Cys	Phe	Glu	Phe	Tyr	His	Lys	Cys	Asp	Asn	Glu	Cys	Met	Glu	Ser
				485					490					495	
Val	Arg	Asn	Gly	Thr	Tyr	Asp	Tyr	Pro	Lys	Tyr	Ser	Glu	Glu	Ala	Ile
			500					505						510	
Leu	Lys	Arg	Glu	Glu	Ile	Ser	Gly	Val	Lys	Leu	Glu	Ser	Ile	Gly	Thr
			515				520						525		
Tyr	Gln	Ile	Leu	Ser	Ile	Tyr	Ser	Thr	Val	Ala	Ser	Ser	Leu	Ala	Leu
	530					535							540		

-continued

Ala Ile Ile Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser  
545 550 555 560

Leu Gln Cys Arg Ile Cys Ile  
565

<210> SEQ ID NO 3

<211> LENGTH: 564

<212> TYPE: PRT

<213> ORGANISM: Influenza A

<400> SEQUENCE: 3

Met Lys Ala Asn Leu Leu Val Leu Leu Cys Ala Leu Ala Ala Asp  
1 5 10 15

Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr  
20 25 30

Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn  
35 40 45

Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys Gly Ile  
50 55 60

Ala Pro Leu Gln Leu Gly Lys Cys Asn Ile Ala Gly Trp Leu Leu Gly  
65 70 75 80

Asn Pro Glu Cys Asp Pro Leu Leu Pro Val Arg Ser Trp Ser Tyr Ile  
85 90 95

Val Glu Thr Pro Asn Ser Glu Asn Gly Ile Cys Tyr Pro Gly Asp Phe  
100 105 110

Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe  
115 120 125

Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Asn  
130 135 140

Thr Asn Gly Val Thr Ala Ala Cys Ser His Glu Gly Lys Ser Ser Phe  
145 150 155 160

Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys Glu Gly Ser Tyr Pro Lys  
165 170 175

Leu Lys Asn Ser Tyr Val Asn Lys Lys Gly Lys Glu Val Leu Val Leu  
180 185 190

Trp Gly Ile His His Pro Pro Asn Ser Lys Glu Gln Gln Asn Leu Tyr  
195 200 205

Gln Asn Glu Asn Ala Tyr Val Ser Val Val Thr Ser Asn Tyr Asn Arg  
210 215 220

Arg Phe Thr Pro Glu Ile Ala Glu Arg Pro Lys Val Arg Asp Gln Ala  
225 230 235 240

Gly Arg Met Asn Tyr Tyr Trp Thr Leu Leu Lys Pro Gly Asp Thr Ile  
245 250 255

Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Met Tyr Ala Phe Ala  
260 265 270

Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser Asn Ala Ser Met  
275 280 285

His Glu Cys Asn Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Ser  
290 295 300

Ser Leu Pro Tyr Gln Asn Ile His Pro Val Thr Ile Gly Glu Cys Pro  
305 310 315 320

Lys Tyr Val Arg Ser Ala Lys Leu Arg Met Val Thr Gly Leu Arg Asn  
325 330 335

Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe

-continued

340					345					350					
Ile	Glu	Gly	Gly	Trp	Thr	Gly	Met	Ile	Asp	Gly	Trp	Tyr	Gly	Tyr	His
	355						360						365		
His	Gln	Asn	Glu	Gln	Gly	Ser	Gly	Tyr	Ala	Ala	Asp	Gln	Lys	Ser	Thr
	370					375					380				
Gln	Asn	Ala	Ile	Asn	Gly	Ile	Thr	Asn	Lys	Val	Asn	Thr	Val	Ile	Glu
	385					390					395				400
Lys	Met	Asn	Ile	Gln	Phe	Thr	Ala	Val	Gly	Lys	Glu	Phe	Asn	Lys	Leu
			405						410					415	
Glu	Lys	Arg	Met	Glu	Asn	Leu	Asn	Lys	Lys	Val	Asp	Asp	Gly	Phe	Leu
			420					425					430		
Asp	Ile	Trp	Thr	Tyr	Asn	Ala	Glu	Leu	Leu	Val	Leu	Leu	Glu	Asn	Glu
			435				440						445		
Arg	Thr	Leu	Asp	Phe	His	Asp	Ser	Asn	Val	Lys	Asn	Leu	Tyr	Glu	Lys
	450					455					460				
Val	Lys	Ser	Gln	Leu	Lys	Asn	Asn	Ala	Lys	Glu	Ile	Gly	Asn	Gly	Cys
	465					470					475				480
Phe	Glu	Phe	Tyr	His	Lys	Cys	Asp	Asn	Glu	Cys	Met	Glu	Ser	Val	Arg
			485						490					495	
Asn	Gly	Thr	Tyr	Asp	Tyr	Pro	Lys	Tyr	Ser	Glu	Glu	Ser	Lys	Leu	Asn
			500					505					510		
Arg	Glu	Lys	Val	Asp	Gly	Val	Lys	Leu	Glu	Ser	Met	Gly	Ile	Tyr	Gln
		515					520					525			
Ile	Leu	Ala	Ile	Tyr	Ser	Thr	Val	Ala	Ser	Ser	Leu	Val	Leu	Leu	Val
	530					535					540				
Ser	Leu	Gly	Ala	Ile	Ser	Phe	Trp	Met	Cys	Ser	Asn	Gly	Ser	Leu	Gln
	545					550					555				560
Cys	Arg	Ile	Cys												

<210> SEQ ID NO 4  
 <211> LENGTH: 562  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 4

Met	Ala	Ile	Ile	Tyr	Leu	Ile	Leu	Leu	Phe	Thr	Ala	Val	Arg	Gly	Asp
1				5					10					15	
Gln	Ile	Cys	Ile	Gly	Tyr	His	Ala	Asn	Asn	Ser	Thr	Glu	Lys	Val	Asp
			20					25					30		
Thr	Ile	Leu	Glu	Arg	Asn	Val	Thr	Val	Thr	His	Ala	Lys	Asp	Ile	Leu
		35					40					45			
Glu	Lys	Thr	His	Asn	Gly	Lys	Leu	Cys	Lys	Leu	Asn	Gly	Ile	Pro	Pro
		50				55					60				
Leu	Glu	Leu	Gly	Asp	Cys	Ser	Ile	Ala	Gly	Trp	Leu	Leu	Gly	Asn	Pro
				70					75					80	
Glu	Cys	Asp	Arg	Leu	Leu	Ser	Val	Pro	Glu	Trp	Ser	Tyr	Ile	Met	Glu
				85					90					95	
Lys	Glu	Asn	Pro	Arg	Asp	Gly	Leu	Cys	Tyr	Pro	Gly	Ser	Phe	Asn	Asp
			100					105					110		
Tyr	Glu	Glu	Leu	Lys	His	Leu	Leu	Ser	Ser	Val	Lys	His	Phe	Glu	Lys
			115				120					125			
Val	Lys	Ile	Leu	Pro	Lys	Asp	Arg	Trp	Thr	Gln	His	Thr	Thr	Thr	Gly
	130					135						140			
Gly	Ser	Arg	Ala	Cys	Ala	Val	Ser	Gly	Asn	Pro	Ser	Phe	Phe	Arg	Asn



-continued

---

```

<210> SEQ ID NO 5
<211> LENGTH: 562
<212> TYPE: PRT
<213> ORGANISM: Influenza A

<400> SEQUENCE: 5

Met Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly Asp
1           5           10           15

Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Lys Val Asp
20           25           30

Thr Ile Leu Glu Arg Asn Val Thr Val Thr His Ala Lys Asp Ile Leu
35           40           45

Glu Lys Thr His Asn Gly Lys Leu Cys Lys Leu Asn Gly Ile Pro Pro
50           55           60

Leu Glu Leu Gly Asp Cys Ser Ile Ala Gly Trp Leu Leu Gly Asn Pro
65           70           75           80

Glu Cys Asp Arg Leu Leu Ser Val Pro Glu Trp Ser Tyr Ile Met Glu
85           90           95

Lys Glu Asn Pro Arg Asp Gly Leu Cys Tyr Pro Gly Ser Phe Asn Asp
100          105          110

Tyr Glu Glu Leu Lys His Leu Leu Ser Ser Val Lys His Phe Glu Lys
115          120          125

Val Lys Ile Leu Pro Lys Asp Arg Trp Thr Gln His Thr Thr Thr Gly
130          135          140

Gly Ser Arg Ala Cys Ala Val Ser Gly Asn Pro Ser Phe Phe Arg Asn
145          150          155          160

Met Val Trp Leu Thr Glu Lys Gly Ser Asn Tyr Pro Val Ala Lys Gly
165          170          175

Ser Tyr Asn Asn Thr Ser Gly Glu Gln Met Leu Ile Ile Trp Gly Val
180          185          190

His His Pro Asn Asp Glu Thr Glu Gln Arg Thr Leu Tyr Gln Asn Val
195          200          205

Gly Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Lys Arg Ser Thr
210          215          220

Pro Glu Ile Ala Thr Arg Pro Lys Val Asn Gly Gln Gly Gly Arg Met
225          230          235          240

Glu Phe Ser Trp Thr Leu Leu Asp Met Trp Asp Thr Ile Asn Phe Glu
245          250          255

Ser Thr Gly Asn Leu Ile Ala Pro Glu Tyr Gly Phe Lys Ile Ser Lys
260          265          270

Arg Gly Ser Ser Gly Ile Met Lys Thr Glu Gly Thr Leu Glu Asn Cys
275          280          285

Glu Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Thr Thr Leu Pro
290          295          300

Phe His Asn Val His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr Val
305          310          315          320

Lys Ser Glu Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Val Pro Gln
325          330          335

Ile Glu Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly
340          345          350

Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His Ser Asn
355          360          365

Asp Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln Lys Ala
370          375          380

```

-continued

Phe Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile Glu Lys Met Asn  
 385 390 395 400

Thr Gln Phe Glu Ala Val Gly Lys Glu Phe Ser Asn Leu Glu Arg Arg  
 405 410 415

Leu Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp Val Trp  
 420 425 430

Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg Thr Leu  
 435 440 445

Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val Arg Met  
 450 455 460

Gln Leu Arg Asp Asn Val Lys Glu Leu Gly Asn Gly Cys Phe Glu Phe  
 465 470 475 480

Tyr His Lys Cys Asp Asp Glu Cys Met Asn Ser Val Lys Asn Gly Thr  
 485 490 495

Tyr Asp Tyr Pro Lys Tyr Glu Glu Glu Ser Lys Leu Asn Arg Asn Glu  
 500 505 510

Ile Lys Gly Val Lys Leu Ser Ser Met Gly Val Tyr Gln Ile Leu Ala  
 515 520 525

Ile Tyr Ala Thr Val Ala Gly Ser Leu Ser Leu Ala Ile Met Met Ala  
 530 535 540

Gly Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu Gln Cys Arg Ile  
 545 550 555 560

Cys Ile

<210> SEQ ID NO 6  
 <211> LENGTH: 512  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 6

Gln Lys Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly  
 1 5 10 15

His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp  
 20 25 30

Gln Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Ser Ser Thr  
 35 40 45

Gly Gly Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys  
 50 55 60

Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln  
 65 70 75 80

Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Lys Ala Tyr Ser Asn  
 85 90 95

Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val  
 100 105 110

Ala Ser Ser Gly Thr Leu Glu Phe Asn Asn Glu Ser Phe Asn Trp Thr  
 115 120 125

Gly Val Thr Gln Asn Gly Thr Ser Ser Ala Cys Lys Arg Arg Ser Asn  
 130 135 140

Asn Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Lys Phe Lys  
 145 150 155 160

Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Asn Glu Lys Phe Asp Lys  
 165 170 175

Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asn Asn Asp Gln Ile  
 180 185 190

-continued

Ser Leu Tyr Ala Gln Ala Ser Gly Arg Ile Thr Val Ser Thr Lys Arg  
 195 200 205  
 Ser Gln Gln Thr Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Val Arg  
 210 215 220  
 Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly  
 225 230 235 240  
 Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly  
 245 250 255  
 Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala  
 260 265 270  
 Pro Ile Gly Lys Cys Asn Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile  
 275 280 285  
 Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala  
 290 295 300  
 Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met  
 305 310 315 320  
 Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala  
 325 330 335  
 Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly  
 340 345 350  
 Phe Arg His Gln Asn Ser Glu Gly Ile Gly Gln Ala Ala Asp Leu Lys  
 355 360 365  
 Ser Thr Gln Ala Ala Ile Asn Gln Ile Asn Gly Lys Leu Asn Arg Leu  
 370 375 380  
 Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser  
 385 390 395 400  
 Glu Val Glu Gly Arg Ile Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr  
 405 410 415  
 Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu  
 420 425 430  
 Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe  
 435 440 445  
 Glu Arg Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn  
 450 455 460  
 Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser  
 465 470 475 480  
 Ile Arg Asn Gly Thr Tyr Asp His Asp Val Tyr Arg Asp Glu Ala Leu  
 485 490 495  
 Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys  
 500 505 510

&lt;210&gt; SEQ ID NO 7

&lt;211&gt; LENGTH: 512

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Influenza A

&lt;400&gt; SEQUENCE: 7

Gln Lys Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly  
 1 5 10 15  
 His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp  
 20 25 30  
 Gln Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Ser Ser Ser Thr  
 35 40 45  
 Gly Gly Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys

-continued

50					55					60					
Thr	Leu	Ile	Asp	Ala	Leu	Leu	Gly	Asp	Pro	Gln	Cys	Asp	Gly	Phe	Gln
65					70					75					80
Asn	Lys	Lys	Trp	Asp	Leu	Phe	Val	Glu	Arg	Ser	Lys	Ala	Tyr	Ser	Asn
				85					90					95	
Cys	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Leu	Arg	Ser	Leu	Val
			100					105					110		
Ala	Ser	Ser	Gly	Thr	Leu	Glu	Phe	Asn	Asn	Glu	Ser	Phe	Asn	Trp	Thr
			115				120					125			
Gly	Val	Thr	Gln	Asn	Gly	Thr	Ser	Ser	Ser	Cys	Lys	Arg	Arg	Ser	Asn
	130					135					140				
Asn	Ser	Phe	Phe	Ser	Arg	Leu	Asn	Trp	Leu	Thr	His	Leu	Lys	Phe	Lys
145					150					155					160
Tyr	Pro	Ala	Leu	Asn	Val	Thr	Met	Pro	Asn	Asn	Glu	Lys	Phe	Asp	Lys
				165					170					175	
Leu	Tyr	Ile	Trp	Gly	Val	His	His	Pro	Gly	Thr	Asn	Asn	Asp	Gln	Ile
			180					185					190		
Ser	Leu	Tyr	Thr	Gln	Ala	Ser	Gly	Arg	Ile	Thr	Val	Ser	Thr	Lys	Arg
			195				200					205			
Ser	Gln	Gln	Thr	Val	Ile	Pro	Asn	Ile	Gly	Ser	Arg	Pro	Arg	Val	Arg
	210					215					220				
Asp	Ile	Pro	Ser	Arg	Ile	Ser	Ile	Tyr	Trp	Thr	Ile	Val	Lys	Pro	Gly
225					230					235					240
Asp	Ile	Leu	Leu	Ile	Asn	Ser	Thr	Gly	Asn	Leu	Ile	Ala	Pro	Arg	Gly
				245					250					255	
Tyr	Phe	Lys	Ile	Arg	Ser	Gly	Lys	Ser	Ser	Ile	Met	Arg	Ser	Asp	Ala
			260					265					270		
Pro	Ile	Gly	Lys	Cys	Asn	Ser	Glu	Cys	Ile	Thr	Pro	Asn	Gly	Ser	Ile
			275				280					285			
Pro	Asn	Asp	Lys	Pro	Phe	Gln	Asn	Val	Asn	Arg	Ile	Thr	Tyr	Gly	Ala
	290					295					300				
Cys	Pro	Arg	Tyr	Val	Lys	Gln	Asn	Thr	Leu	Lys	Leu	Ala	Thr	Gly	Met
305					310					315					320
Arg	Asn	Val	Pro	Glu	Lys	Gln	Thr	Arg	Gly	Ile	Phe	Gly	Ala	Ile	Ala
				325					330					335	
Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly	Met	Val	Asp	Gly	Trp	Tyr	Gly
			340					345					350		
Phe	Arg	His	Gln	Asn	Ser	Glu	Gly	Ile	Gly	Gln	Ala	Ala	Asp	Leu	Lys
			355				360					365			
Ser	Thr	Gln	Ala	Ala	Ile	Asn	Gln	Ile	Asn	Gly	Lys	Leu	Asn	Arg	Leu
	370					375					380				
Ile	Gly	Lys	Thr	Asn	Glu	Lys	Phe	His	Gln	Ile	Glu	Lys	Glu	Phe	Ser
385					390					395					400
Glu	Val	Glu	Gly	Arg	Ile	Gln	Asp	Leu	Glu	Lys	Tyr	Val	Glu	Asp	Thr
				405					410					415	
Lys	Ile	Asp	Leu	Trp	Ser	Tyr	Asn	Ala	Glu	Leu	Leu	Val	Ala	Leu	Glu
			420					425					430		
Asn	Gln	His	Thr	Ile	Asp	Leu	Thr	Asp	Ser	Glu	Met	Asn	Lys	Leu	Phe
			435				440					445			
Glu	Arg	Thr	Lys	Lys	Gln	Leu	Arg	Glu	Asn	Ala	Glu	Asp	Met	Gly	Asn
	450					455					460				
Gly	Cys	Phe	Lys	Ile	Tyr	His	Lys	Cys	Asp	Asn	Ala	Cys	Ile	Gly	Ser
465					470					475					480

-continued

---

Ile Arg Asn Gly Thr Tyr Asp His Asp Val Tyr Arg Asp Glu Ala Leu  
485 490 495

Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys  
500 505 510

<210> SEQ ID NO 8  
<211> LENGTH: 566  
<212> TYPE: PRT  
<213> ORGANISM: Influenza A

<400> SEQUENCE: 8

Met Lys Thr Ile Ile Ala Leu Ser Cys Ile Leu Cys Leu Val Phe Thr  
1 5 10 15

Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly  
20 25 30

His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp  
35 40 45

Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile  
50 55 60

Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys  
65 70 75 80

Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln  
85 90 95

Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Asn Lys Ala Tyr Ser Asn  
100 105 110

Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val  
115 120 125

Ala Ser Ser Gly Thr Leu Glu Phe Asn Asn Glu Ser Phe Asn Trp Ala  
130 135 140

Gly Val Thr Gln Asn Gly Thr Ser Ser Ser Cys Ile Arg Gly Ser Lys  
145 150 155 160

Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Ser Lys  
165 170 175

Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Asn Glu Gln Phe Asp Lys  
180 185 190

Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile  
195 200 205

Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg  
210 215 220

Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg  
225 230 235 240

Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly  
245 250 255

Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly  
260 265 270

Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala  
275 280 285

Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile  
290 295 300

Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala  
305 310 315 320

Cys Pro Arg Tyr Val Lys Gln Ser Thr Leu Lys Leu Ala Thr Gly Met  
325 330 335

Arg Asn Val Pro Glu Arg Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala

-continued

340					345					350					
Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly	Met	Val	Asp	Gly	Trp	Tyr	Gly
	355						360					365			
Phe	Arg	His	Gln	Asn	Ser	Glu	Gly	Arg	Gly	Gln	Ala	Ala	Asp	Leu	Lys
	370					375					380				
Ser	Thr	Gln	Ala	Ala	Ile	Asp	Gln	Ile	Asn	Gly	Lys	Leu	Asn	Arg	Leu
385					390					395					400
Ile	Gly	Lys	Thr	Asn	Glu	Lys	Phe	His	Gln	Ile	Glu	Lys	Glu	Phe	Ser
				405					410					415	
Glu	Val	Glu	Gly	Arg	Ile	Gln	Asp	Leu	Glu	Lys	Tyr	Val	Glu	Asp	Thr
		420						425					430		
Lys	Ile	Asp	Leu	Trp	Ser	Tyr	Asn	Ala	Glu	Leu	Leu	Val	Ala	Leu	Glu
		435					440					445			
Asn	Gln	His	Thr	Ile	Asp	Leu	Thr	Asp	Ser	Glu	Met	Asn	Lys	Leu	Phe
	450					455					460				
Glu	Lys	Thr	Lys	Lys	Gln	Leu	Arg	Glu	Asn	Ala	Glu	Asp	Met	Gly	Asn
465					470					475					480
Gly	Cys	Phe	Lys	Ile	Tyr	His	Lys	Cys	Asp	Asn	Ala	Cys	Ile	Gly	Ser
			485						490					495	
Ile	Arg	Asn	Gly	Thr	Tyr	Asp	His	Asn	Val	Tyr	Arg	Asp	Glu	Ala	Leu
		500						505					510		
Asn	Asn	Arg	Phe	Gln	Ile	Lys	Gly	Val	Glu	Leu	Lys	Ser	Gly	Tyr	Lys
		515					520					525			
Asp	Trp	Ile	Leu	Trp	Ile	Ser	Phe	Ala	Ile	Ser	Cys	Phe	Leu	Leu	Cys
	530					535					540				
Val	Ala	Leu	Leu	Gly	Phe	Ile	Met	Trp	Ala	Cys	Gln	Lys	Gly	Asn	Ile
545					550					555					560
Arg	Cys	Asn	Ile	Cys	Ile										
				565											

&lt;210&gt; SEQ ID NO 9

&lt;211&gt; LENGTH: 567

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Influenza A

&lt;400&gt; SEQUENCE: 9

Met	Glu	Lys	Ile	Val	Leu	Leu	Leu	Ala	Val	Ile	Ser	Leu	Val	Lys	Ser
1				5					10					15	
Asp	Gln	Ile	Cys	Ile	Gly	Tyr	His	Ala	Asn	Asn	Ser	Thr	Lys	Gln	Val
			20					25					30		
Asp	Thr	Ile	Met	Glu	Lys	Asn	Val	Thr	Val	Thr	His	Ala	Gln	Asp	Ile
		35					40					45			
Leu	Glu	Lys	Thr	His	Asn	Gly	Lys	Leu	Cys	Asp	Leu	Asn	Gly	Val	Lys
	50					55					60				
Pro	Leu	Ile	Leu	Lys	Asp	Cys	Ser	Val	Ala	Gly	Trp	Leu	Leu	Gly	Asn
65					70					75					80
Pro	Met	Cys	Asp	Glu	Phe	Ile	Arg	Val	Pro	Glu	Trp	Ser	Tyr	Ile	Val
			85						90					95	
Glu	Arg	Ala	Asn	Pro	Ala	Asn	Asp	Leu	Cys	Tyr	Pro	Gly	Thr	Leu	Asn
			100					105						110	
Asp	Tyr	Glu	Glu	Leu	Lys	His	Leu	Leu	Ser	Arg	Ile	Asn	His	Phe	Glu
		115					120					125			
Lys	Thr	Leu	Ile	Ile	Pro	Arg	Ser	Ser	Trp	Pro	Asn	His	Glu	Thr	Ser
		130					135					140			

-continued

---

Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Ala Ser Ser Phe Phe  
 145 150 155 160  
 Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asp Ala Tyr Pro Thr Ile  
 165 170 175  
 Lys Ile Ser Tyr Asn Asn Thr Asn Arg Glu Asp Leu Leu Ile Leu Trp  
 180 185 190  
 Gly Ile His His Ser Asn Asn Ala Ala Glu Gln Thr Asn Leu Tyr Lys  
 195 200 205  
 Asn Pro Asp Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Gln Arg  
 210 215 220  
 Leu Val Pro Lys Ile Ala Thr Arg Ser Gln Val Asn Gly Gln Ser Gly  
 225 230 235 240  
 Arg Met Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile His  
 245 250 255  
 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile  
 260 265 270  
 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Met Glu Tyr Gly  
 275 280 285  
 His Cys Asn Thr Lys Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser  
 290 295 300  
 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys  
 305 310 315 320  
 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser  
 325 330 335  
 Pro Leu Arg Glu Arg Arg Arg Lys Arg Gly Leu Phe Gly Ala Ile Ala  
 340 345 350  
 Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly  
 355 360 365  
 Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu  
 370 375 380  
 Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile  
 385 390 395 400  
 Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn  
 405 410 415  
 Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly  
 420 425 430  
 Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu  
 435 440 445  
 Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr  
 450 455 460  
 Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn  
 465 470 475 480  
 Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser  
 485 490 495  
 Val Arg Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Ile  
 500 505 510  
 Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr  
 515 520 525  
 Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu  
 530 535 540  
 Ala Ile Ile Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser  
 545 550 555 560  
 Leu Gln Cys Arg Ile Cys Ile

-continued

565

<210> SEQ ID NO 10  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 10

Asn Thr Thr Ala Ile Arg Ser Ser Thr His Leu Asn Asn Lys Phe Ala  
 1                   5                   10                   15

Asp

<210> SEQ ID NO 11  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 11

Tyr Val Val Lys Trp Ser Gly Pro Val Gly Val Arg Asp Asn Glx Gln  
 1                   5                   10                   15

Lys

<210> SEQ ID NO 12  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 12

Met Val Gly Asp Phe Thr Asp Arg Cys Ala Asn Gly Arg Glu Gly Asn  
 1                   5                   10                   15

Lys

<210> SEQ ID NO 13  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 13

Lys Arg Gly Ala Pro Asp Ala Gly Met Thr Ser Pro Lys Asp Gly Leu  
 1                   5                   10                   15

Glu

<210> SEQ ID NO 14  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 14

Gln Arg Thr Lys Leu Asn Thr Pro Cys Pro Asp Arg Thr Ala Gln Val  
 1                   5                   10                   15

Leu

<210> SEQ ID NO 15

-continued

---

<211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 15

Val Arg Arg Phe Met Asn Thr Trp Val Ala Leu His Thr Ile Ser Arg  
 1           5                   10                   15

Pro

<210> SEQ ID NO 16  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 16

Val Lys Val Thr His Glu Arg Arg Ala Ser Pro Val Arg Arg Thr Ile  
 1           5                   10                   15

Ser

<210> SEQ ID NO 17  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 17

Arg Val Lys Trp Met Gly Val Pro Ile Gly Pro Val Phe Thr Arg Arg  
 1           5                   10                   15

Pro

<210> SEQ ID NO 18  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 18

Thr Gly Leu Arg Cys Ser Gly Arg Tyr Pro Leu Gln Thr Phe Ala Arg  
 1           5                   10                   15

Thr

<210> SEQ ID NO 19  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 19

Ile Thr Asn Lys Thr Tyr Asp Ser Arg Ser Ser Ser Phe Ala Gln Gly  
 1           5                   10                   15

Cys

<210> SEQ ID NO 20  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:

-continued

---

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 20

Val Met Leu Lys Thr Gly Ala Trp Gln Ser Arg Leu Gln Leu Arg Arg  
 1                    5                    10                    15

Glu

<210> SEQ ID NO 21

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 21

Ala Lys Ser Arg Asn Asp Gly Val Arg Ser Arg Phe Thr Glu Ala Tyr  
 1                    5                    10                    15

Gly

<210> SEQ ID NO 22

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 22

Val Cys Asn Ile Lys Arg Pro Asp Ala Ala Gly Ala Leu Ala Pro Ser  
 1                    5                    10                    15

Ser

<210> SEQ ID NO 23

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 23

Val Cys Leu Leu Arg Phe Lys Thr Ile Pro Ser Pro Gln Asn Ser Thr  
 1                    5                    10                    15

Ser

<210> SEQ ID NO 24

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 24

Ser Ser Thr Lys Ser Gln Gly Ser Arg Pro Ile Lys Glu Pro Asn Val  
 1                    5                    10                    15

Gln

<210> SEQ ID NO 25

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 25

-continued

---

Val Gln Val Arg Arg Glu His Ser Val Thr Leu Arg His Leu Thr Met  
1 5 10 15

Gly

<210> SEQ ID NO 26  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

&lt;400&gt; SEQUENCE: 26

Leu Arg Asn Thr Lys Thr Asn Ser Gln Lys Arg Phe Ser Phe Thr Val  
1 5 10 15

Ser

<210> SEQ ID NO 27  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

&lt;400&gt; SEQUENCE: 27

Arg Arg Ile Val Asn Gly Thr Arg Trp Pro Ser Pro Arg Ser Ser Val  
1 5 10 15

Arg

<210> SEQ ID NO 28  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

&lt;400&gt; SEQUENCE: 28

Val Arg Tyr Lys Thr Ala Glu Gln Thr Leu Trp Gly Arg Tyr Gln Met  
1 5 10 15

Asn

<210> SEQ ID NO 29  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

&lt;400&gt; SEQUENCE: 29

Phe Asp Ser Lys Gly Asn Val Lys Pro Thr Arg Arg Leu Ser Pro Ser  
1 5 10 15

<210> SEQ ID NO 30  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutant amino acid sequence

&lt;400&gt; SEQUENCE: 30

Ser Arg Lys Thr Asn Arg Ala Pro Gln His Met Lys Phe Thr Asn Phe  
1 5 10 15

Cys

-continued

---

```

<210> SEQ ID NO 31
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A mutant amino acid sequence

<400> SEQUENCE: 31
Phe Val Trp Ser Met His Gln Pro Gln Gly Arg Cys Thr Ser Glu Ala
1          5          10          15
Tyr

<210> SEQ ID NO 32
<211> LENGTH: 326
<212> TYPE: PRT
<213> ORGANISM: Influenza A

<400> SEQUENCE: 32
Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val
1          5          10          15
Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu
20          25          30
Leu Glu Asp Ser His Asn Gly Lys Leu Cys Leu Leu Lys Gly Ile Ala
35          40          45
Pro Leu Gln Leu Gly Asn Cys Ser Val Ala Gly Trp Ile Leu Gly Asn
50          55          60
Pro Glu Cys Glu Leu Leu Ile Ser Lys Glu Ser Trp Ser Tyr Ile Val
65          70          75          80
Glu Thr Pro Asn Pro Glu Asn Gly Thr Cys Tyr Pro Gly Tyr Phe Ala
85          90          95
Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu
100         105         110
Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr Val
115        120        125
Thr Gly Val Ser Ala Ser Cys Ser His Asn Gly Lys Ser Ser Phe Tyr
130        135        140
Arg Asn Leu Leu Trp Ile Thr Gly Lys Asn Gly Leu Tyr Pro Asn Leu
145        150        155        160
Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu Val Leu Val Leu Trp
165        170        175
Gly Val His His Pro Pro Asn Ile Gly Asn Gln Arg Ala Leu Tyr His
180        185        190
Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser His Tyr Ser Arg Arg
195        200        205
Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val Arg Asp Gln Glu Gly
210        215        220
Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile Ile
225        230        235        240
Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe Ala Leu
245        250        255
Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser Asn Ala Pro Met Asp
260        265        270
Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly Ala Ile Asn Ser Ser
275        280        285
Leu Pro Phe Gln Asn Val His Pro Val Thr Ile Gly Glu Cys Pro Lys
290        295        300

```

-continued

---

Tyr Val Arg Ser Ala Lys Leu Arg Met Val Thr Gly Leu Arg Asn Ile  
305 310 315 320

Pro Ser Ile Gln Ser Arg  
325

<210> SEQ ID NO 33  
<211> LENGTH: 327  
<212> TYPE: PRT  
<213> ORGANISM: Influenza A

<400> SEQUENCE: 33

Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val  
1 5 10 15

Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu  
20 25 30

Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val Ala  
35 40 45

Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly Asn  
50 55 60

Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp Ser Tyr Ile Val  
65 70 75 80

Glu Thr Pro Ser Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe Ile  
85 90 95

Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu  
100 105 110

Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp Ser  
115 120 125

Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser Phe  
130 135 140

Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro Lys  
145 150 155 160

Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val Leu  
165 170 175

Trp Gly Ile His His Pro Ser Thr Ser Ala Asp Gln Gln Ser Leu Tyr  
180 185 190

Gln Asn Ala Asp Thr Tyr Val Phe Val Gly Ser Ser Arg Tyr Ser Lys  
195 200 205

Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys Val Arg Asp Gln Glu  
210 215 220

Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys Ile  
225 230 235 240

Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe Ala  
245 250 255

Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro Val  
260 265 270

His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys Gly Ala Ile Asn Thr  
275 280 285

Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr Ile Gly Lys Cys Pro  
290 295 300

Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg Asn  
305 310 315 320

Ile Pro Ser Ile Gln Ser Arg  
325

<210> SEQ ID NO 34

-continued

&lt;211&gt; LENGTH: 325

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Influenza A

&lt;400&gt; SEQUENCE: 34

Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Lys Val  
 1 5 10 15  
 Asp Thr Ile Leu Glu Arg Asn Val Thr Val Thr His Ala Lys Asp Ile  
 20 25 30  
 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Lys Leu Asn Gly Ile Pro  
 35 40 45  
 Pro Leu Glu Leu Gly Asp Cys Ser Ile Ala Gly Trp Leu Leu Gly Asn  
 50 55 60  
 Pro Glu Cys Asp Arg Leu Leu Ser Val Pro Glu Trp Ser Tyr Ile Met  
 65 70 75 80  
 Glu Lys Glu Asn Pro Arg Asp Gly Leu Cys Tyr Pro Gly Ser Phe Asn  
 85 90 95  
 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Ser Val Lys His Phe Glu  
 100 105 110  
 Lys Val Lys Ile Leu Pro Lys Asp Arg Trp Thr Gln His Thr Thr Thr  
 115 120 125  
 Gly Gly Ser Arg Ala Cys Ala Val Ser Gly Asn Pro Ser Phe Phe Arg  
 130 135 140  
 Asn Met Val Trp Leu Thr Lys Lys Glu Ser Asn Tyr Pro Val Ala Lys  
 145 150 155 160  
 Gly Ser Tyr Asn Asn Thr Ser Gly Glu Gln Met Leu Ile Ile Trp Gly  
 165 170 175  
 Val His His Pro Asn Asp Glu Thr Glu Gln Arg Thr Leu Tyr Gln Asn  
 180 185 190  
 Val Gly Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Lys Arg Ser  
 195 200 205  
 Thr Pro Asp Ile Ala Thr Arg Pro Lys Val Asn Gly Leu Gly Ser Arg  
 210 215 220  
 Met Glu Phe Ser Trp Thr Leu Leu Asp Met Trp Asp Thr Ile Asn Phe  
 225 230 235 240  
 Glu Ser Thr Gly Asn Leu Ile Ala Pro Glu Tyr Gly Phe Lys Ile Ser  
 245 250 255  
 Lys Arg Gly Ser Ser Gly Ile Met Lys Thr Glu Gly Thr Leu Glu Asn  
 260 265 270  
 Cys Glu Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Thr Thr Leu  
 275 280 285  
 Pro Phe His Asn Val His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr  
 290 295 300  
 Val Lys Ser Glu Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Val Pro  
 305 310 315 320  
 Gln Ile Glu Ser Arg  
 325

&lt;210&gt; SEQ ID NO 35

&lt;211&gt; LENGTH: 326

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Influenza A

&lt;400&gt; SEQUENCE: 35

Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val  
 1 5 10 15

-continued

Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile  
                   20  25  30  
 Leu Glu Lys Ala His Asn Gly Lys Leu Cys Ser Leu Asn Gly Val Lys  
                   35  40  45  
 Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn  
                   50  55  60  
 Pro Met Cys Asp Glu Phe Leu Asn Val Pro Glu Trp Ser Tyr Ile Val  
                   65  70  75  80  
 Glu Lys Asp Asn Pro Ile Asn Gly Leu Cys Tyr Pro Gly Asp Phe Asn  
   85  90  95  
 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Ser Thr Asn His Phe Glu  
   100  105  110  
 Lys Ile Gln Ile Ile Pro Arg Ser Ser Trp Ser Asn His Glu Ala Ser  
   115  120  125  
 Ser Gly Val Ser Ser Ala Cys Pro Tyr Asn Gly Arg Ser Ser Phe Phe  
   130  135  140  
 Arg Asn Val Val Trp Ile Ile Lys Lys Asn Asn Ala Tyr Pro Thr Ile  
   145  150  155  160  
 Lys Arg Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp  
   165  170  175  
 Gly Ile His His Pro Asn Asp Ala Ala Glu Gln Thr Lys Leu Tyr Gln  
   180  185  190  
 Asn Pro Thr Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Gln Arg  
   195  200  205  
 Ser Val Pro Glu Ile Ala Thr Arg Pro Lys Val Asn Gly Gln Ser Gly  
   210  215  220  
 Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn  
   225  230  235  240  
 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile  
   245  250  255  
 Val Lys Lys Gly Asp Ser Ala Ile Met Lys Ser Gly Leu Glu Tyr Gly  
   260  265  270  
 Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser  
   275  280  285  
 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys  
   290  295  300  
 Tyr Val Lys Ser Asp Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Val  
   305  310  315  320  
 Pro Gln Arg Glu Thr Arg  
   325

<210> SEQ ID NO 36  
 <211> LENGTH: 329  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 36

Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val  
 1                  5  10  15  
 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile  
                   20  25  30  
 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asn Leu Asp Gly Val Lys  
                   35  40  45  
 Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn

-continued

---

```

50          55          60
Pro Met Cys Asp Glu Phe Leu Asn Val Pro Glu Trp Ser Tyr Ile Val
65          70          75          80
Glu Lys Ile Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn
85          90          95
Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu
100         105         110
Lys Ile Gln Ile Ile Pro Lys Asn Ser Trp Ser Asp His Glu Ala Ser
115         120         125
Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Arg Ser Ser Phe Phe Arg
130         135         140
Asn Val Val Trp Leu Thr Lys Lys Asp Asn Ala Tyr Pro Thr Ile Lys
145         150         155         160
Arg Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp Gly
165         170         175
Ile His His Pro Asn Asp Ala Ala Glu Gln Thr Arg Leu Tyr Gln Asn
180         185         190
Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg Leu
195         200         205
Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly Arg
210         215         220
Met Glu Phe Phe Trp Thr Ile Leu Lys Ser Asn Asp Ala Ile Asn Phe
225         230         235         240
Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Asn Ala Tyr Lys Ile Val
245         250         255
Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly Asn
260         265         270
Cys Asn Thr Lys Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser Met
275         280         285
Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr
290         295         300
Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser Pro
305         310         315         320
Gln Arg Glu Arg Arg Lys Lys Arg
325

```

```

<210> SEQ ID NO 37
<211> LENGTH: 329
<212> TYPE: PRT
<213> ORGANISM: Influenza A

```

```

<400> SEQUENCE: 37

```

```

Asp Lys Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Thr Gln Val
1          5          10          15
Asp Thr Ile Leu Glu Lys Asn Val Thr Val Thr His Ser Val Glu Leu
20         25         30
Leu Glu Asn Gln Lys Glu Glu Arg Phe Cys Lys Ile Met Asn Lys Ser
35         40         45
Pro Leu Asp Leu Arg Glu Cys Thr Ile Glu Gly Trp Ile Leu Gly Asn
50         55         60
Pro Lys Cys Asp Leu Leu Leu Gly Asp Gln Ser Trp Ser Tyr Ile Val
65         70         75         80
Glu Arg Pro Thr Ala Gln Asn Gly Ile Cys Tyr Pro Gly Ala Leu Asn
85         90         95

```

-continued

Glu Val Glu Glu Leu Lys Ala Leu Ile Gly Ser Gly Glu Arg Val Glu  
 100 105 110  
 Arg Phe Glu Met Phe Pro Lys Ser Thr Trp Ala Gly Val Asp Thr Ser  
 115 120 125  
 Ser Gly Val Thr Asn Ala Cys Pro Ser Tyr Thr Ile Gly Ser Ser Phe  
 130 135 140  
 Tyr Arg Asn Leu Val Trp Ile Ile Lys Thr Asn Ser Ala Ala Tyr Pro  
 145 150 155 160  
 Val Ile Lys Gly Thr Tyr Asn Asn Thr Gly Asn Gln Pro Ile Leu Tyr  
 165 170 175  
 Phe Trp Gly Val His His Pro Pro Asn Thr Gly Val Gln Asp Thr Leu  
 180 185 190  
 Tyr Gly Ser Gly Glu Arg Tyr Val Arg Met Gly Thr Asp Ser Met Asn  
 195 200 205  
 Phe Ala Lys Ser Pro Glu Ile Ala Glu Arg Pro Val Val Asn Gly Gln  
 210 215 220  
 Arg Gly Arg Ile Asp Tyr Tyr Trp Ser Val Leu Lys Pro Gly Glu Thr  
 225 230 235 240  
 Leu Asn Val Glu Ser Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Tyr  
 245 250 255  
 Lys Phe Val Ser Thr Asn Lys Lys Gly Ala Val Phe Lys Ser Asn Leu  
 260 265 270  
 Pro Ile Glu Asn Cys Asp Ala Thr Cys Gln Thr Ile Ala Gly Val Leu  
 275 280 285  
 Arg Thr Asn Lys Thr Phe Gln Asn Val Ser Pro Leu Trp Ile Gly Glu  
 290 295 300  
 Cys Pro Lys Tyr Val Lys Ser Glu Ser Leu Arg Leu Ala Thr Gly Leu  
 305 310 315 320  
 Arg Asn Ile Pro Gln Ile Lys Thr Arg  
 325

<210> SEQ ID NO 38  
 <211> LENGTH: 328  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 38

Tyr Asp Arg Ile Cys Ile Gly Tyr Gln Ser Asn Asn Ser Thr Asp Thr  
 1 5 10 15  
 Val Asn Thr Leu Ile Glu Gln Asn Val Pro Val Thr Gln Thr Met Glu  
 20 25 30  
 Leu Val Glu Thr Glu Lys His Pro Ala Tyr Cys Asn Thr Asp Leu Gly  
 35 40 45  
 Ala Pro Leu Glu Leu Arg Asp Cys Lys Ile Glu Ala Val Ile Tyr Gly  
 50 55 60  
 Asn Pro Lys Cys Asp Ile His Leu Lys Asp Gln Gly Trp Ser Tyr Ile  
 65 70 75 80  
 Val Glu Arg Pro Ser Ala Pro Glu Gly Met Cys Tyr Pro Gly Ser Val  
 85 90 95  
 Glu Asn Leu Glu Glu Leu Arg Phe Val Phe Ser Ser Ala Ala Ser Tyr  
 100 105 110  
 Lys Arg Ile Arg Leu Phe Asp Tyr Ser Arg Trp Asn Val Thr Arg Ser  
 115 120 125  
 Gly Thr Ser Lys Ala Cys Asn Ala Ser Thr Gly Gly Gln Ser Phe Tyr  
 130 135 140

-continued

Arg Ser Ile Asn Trp Leu Thr Lys Lys Lys Pro Asp Thr Tyr Asp Phe  
 145 150 155 160  
 Asn Glu Gly Ala Tyr Val Asn Asn Glu Asp Gly Asp Ile Ile Phe Leu  
 165 170 175  
 Trp Gly Ile His His Pro Pro Asp Thr Lys Glu Gln Thr Thr Leu Tyr  
 180 185 190  
 Lys Asn Ala Asn Thr Leu Ser Ser Val Thr Thr Asn Thr Ile Asn Arg  
 195 200 205  
 Ser Phe Gln Pro Asn Ile Gly Pro Arg Pro Leu Val Arg Gly Gln Gln  
 210 215 220  
 Gly Arg Met Asp Tyr Tyr Trp Gly Ile Leu Lys Arg Gly Glu Thr Leu  
 225 230 235 240  
 Lys Ile Arg Thr Asn Gly Asn Leu Ile Ala Pro Glu Phe Gly Tyr Leu  
 245 250 255  
 Leu Lys Gly Glu Ser Tyr Gly Arg Ile Ile Gln Asn Glu Asp Ile Pro  
 260 265 270  
 Ile Gly Asn Cys Asn Thr Lys Cys Gln Thr Tyr Ala Gly Ala Ile Asn  
 275 280 285  
 Ser Ser Lys Pro Phe Gln Asn Ala Ser Arg His Tyr Met Gly Glu Cys  
 290 295 300  
 Pro Lys Tyr Val Lys Lys Ala Ser Leu Arg Leu Ala Val Gly Leu Arg  
 305 310 315 320  
 Asn Thr Pro Ser Val Glu Pro Arg  
 325

<210> SEQ ID NO 39  
 <211> LENGTH: 320  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 39

Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu Thr Val  
 1 5 10 15  
 Asp Thr Leu Thr Glu Thr Asn Val Pro Val Thr His Ala Lys Glu Leu  
 20 25 30  
 Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Asn Leu Gly His  
 35 40 45  
 Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr Gly Asn  
 50 55 60  
 Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr Ile Val  
 65 70 75 80  
 Glu Arg Pro Ser Ala Val Asn Gly Met Cys Tyr Pro Gly Asn Val Glu  
 85 90 95  
 Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Ser Ser Tyr Gln  
 100 105 110  
 Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Ser Tyr Ser Gly  
 115 120 125  
 Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg Trp Leu  
 130 135 140  
 Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr Thr Asn  
 145 150 155 160  
 Asn Arg Gly Lys Ser Ile Leu Phe Met Trp Gly Ile Asn His Pro Pro  
 165 170 175  
 Thr Asp Thr Val Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr Thr Thr



-continued

---

Phe Glu Ser Asn Gly Ala Phe Leu Ala Pro Arg Tyr Ala Phe Glu Ile  
 245 250 255  
 Val Ser Val Gly Asn Gly Lys Leu Phe Arg Ser Glu Leu Asn Ile Glu  
 260 265 270  
 Ser Cys Ser Thr Lys Cys Gln Thr Glu Ile Gly Gly Ile Asn Thr Asn  
 275 280 285  
 Lys Ser Phe His Asn Val His Arg Asn Thr Ile Gly Asp Cys Pro Lys  
 290 295 300  
 Tyr Val Asn Val Lys Ser Leu Lys Leu Ala Thr Gly Pro Arg Asn Val  
 305 310 315 320  
 Pro Ala Ile Ala Ser Arg  
 325

<210> SEQ ID NO 41  
 <211> LENGTH: 326  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 41

Tyr Asp Lys Ile Cys Ile Gly Tyr Gln Thr Asn Asn Ser Thr Glu Thr  
 1 5 10 15  
 Val Asn Thr Leu Ser Glu Gln Asn Val Pro Val Thr Gln Val Glu Glu  
 20 25 30  
 Leu Val His Gly Gly Ile Asp Pro Ile Leu Cys Gly Thr Glu Leu Gly  
 35 40 45  
 Ser Pro Leu Val Leu Asp Asp Cys Ser Leu Glu Gly Leu Ile Leu Gly  
 50 55 60  
 Asn Pro Lys Cys Asp Leu Tyr Leu Asn Gly Arg Glu Trp Ser Tyr Ile  
 65 70 75 80  
 Val Glu Arg Pro Lys Glu Met Glu Gly Val Cys Tyr Pro Gly Ser Ile  
 85 90 95  
 Glu Asn Gln Glu Glu Leu Arg Ser Leu Phe Ser Ser Ile Lys Lys Tyr  
 100 105 110  
 Glu Arg Val Lys Met Phe Asp Phe Thr Lys Trp Asn Val Thr Tyr Thr  
 115 120 125  
 Gly Thr Ser Lys Ala Cys Asn Asn Thr Ser Asn Gln Gly Ser Phe Tyr  
 130 135 140  
 Arg Ser Met Arg Trp Leu Thr Leu Lys Ser Gly Gln Phe Pro Val Gln  
 145 150 155 160  
 Thr Asp Glu Tyr Lys Asn Thr Arg Asp Ser Asp Ile Val Phe Thr Trp  
 165 170 175  
 Ala Ile His His Pro Pro Thr Ser Asp Glu Gln Val Lys Leu Tyr Lys  
 180 185 190  
 Asn Pro Asp Thr Leu Ser Ser Val Thr Thr Asp Glu Ile Asn Arg Ser  
 195 200 205  
 Phe Lys Pro Asn Ile Gly Pro Arg Pro Leu Val Arg Gly Gln Gln Gly  
 210 215 220  
 Arg Met Asp Tyr Tyr Trp Ala Val Leu Lys Pro Gly Gln Thr Val Lys  
 225 230 235 240  
 Ile Gln Thr Asn Gly Asn Leu Ile Ala Pro Glu Tyr Gly His Leu Ile  
 245 250 255  
 Thr Gly Lys Ser His Gly Arg Ile Leu Lys Asn Asn Leu Pro Met Gly  
 260 265 270  
 Gln Cys Val Thr Glu Cys Gln Leu Asn Glu Gly Val Met Asn Thr Ser  
 275 280 285

-continued

---

Lys Pro Phe Gln Asn Thr Ser Lys His Tyr Ile Gly Lys Cys Pro Lys  
 290 295 300  
 Tyr Ile Pro Ser Gly Ser Leu Lys Leu Ala Ile Gly Leu Arg Asn Val  
 305 310 315 320  
 Pro Gln Val Gln Asp Arg  
 325  
  
 <210> SEQ ID NO 42  
 <211> LENGTH: 325  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A  
  
 <400> SEQUENCE: 42  
  
 Asp Arg Ile Cys Val Gly Tyr Leu Ser Thr Asn Ser Ser Glu Arg Val  
 1 5 10 15  
 Asp Thr Leu Leu Glu Asn Gly Val Pro Val Thr Ser Ser Ile Asp Leu  
 20 25 30  
 Ile Glu Thr Asn His Thr Gly Thr Tyr Cys Ser Leu Asn Gly Val Ser  
 35 40 45  
 Pro Val His Leu Gly Asp Cys Ser Phe Glu Gly Trp Ile Val Gly Asn  
 50 55 60  
 Pro Ala Cys Thr Ser Asn Phe Gly Ile Arg Glu Trp Ser Tyr Leu Ile  
 65 70 75 80  
 Glu Asp Pro Ala Ala Pro His Gly Leu Cys Tyr Pro Gly Glu Leu Asn  
 85 90 95  
 Asn Asn Gly Glu Leu Arg His Leu Phe Ser Gly Ile Arg Ser Phe Ser  
 100 105 110  
 Arg Thr Glu Leu Ile Pro Pro Thr Ser Trp Gly Glu Val Leu Asp Gly  
 115 120 125  
 Thr Thr Ser Ala Cys Arg Asp Asn Thr Gly Thr Asn Ser Phe Tyr Arg  
 130 135 140  
 Asn Leu Val Trp Phe Ile Lys Lys Asn Asn Arg Tyr Pro Val Ile Ser  
 145 150 155 160  
 Lys Thr Tyr Asn Asn Thr Thr Gly Arg Asp Val Leu Val Leu Trp Gly  
 165 170 175  
 Ile His His Pro Val Ser Val Asp Glu Thr Lys Thr Leu Tyr Val Asn  
 180 185 190  
 Ser Asp Pro Tyr Thr Leu Val Ser Thr Lys Ser Trp Ser Glu Lys Tyr  
 195 200 205  
 Lys Leu Glu Thr Gly Val Arg Pro Gly Tyr Asn Gly Gln Arg Ser Trp  
 210 215 220  
 Met Lys Ile Tyr Trp Ser Leu Ile His Pro Gly Glu Met Ile Thr Phe  
 225 230 235 240  
 Glu Ser Asn Gly Gly Phe Leu Ala Pro Arg Tyr Gly Tyr Ile Ile Glu  
 245 250 255  
 Glu Tyr Gly Lys Gly Arg Ile Phe Gln Ser Arg Ile Arg Met Ser Arg  
 260 265 270  
 Cys Asn Thr Lys Cys Gln Thr Ser Val Gly Gly Ile Asn Thr Asn Arg  
 275 280 285  
 Thr Phe Gln Asn Ile Asp Lys Asn Ala Leu Gly Asp Cys Pro Lys Tyr  
 290 295 300  
 Ile Lys Ser Gly Gln Leu Lys Leu Ala Thr Gly Leu Arg Asn Val Pro  
 305 310 315 320  
 Ala Ile Ser Asn Arg

-continued

325

```

<210> SEQ ID NO 43
<211> LENGTH: 325
<212> TYPE: PRT
<213> ORGANISM: Influenza A

<400> SEQUENCE: 43
Asp Lys Ile Cys Ile Gly Tyr Leu Ser Asn Asn Ser Ser Asp Thr Val
1           5           10           15
Asp Thr Leu Thr Glu Asn Gly Val Pro Val Thr Ser Ser Val Asp Leu
                20           25           30
Val Glu Thr Asn His Thr Gly Thr Tyr Cys Ser Leu Asn Gly Ile Ser
                35           40           45
Pro Ile His Leu Gly Asp Cys Ser Phe Glu Gly Trp Ile Val Gly Asn
50           55           60
Pro Ser Cys Ala Thr Asn Ile Asn Ile Arg Glu Trp Ser Tyr Leu Ile
65           70           75           80
Glu Asp Pro Asn Ala Pro Asn Lys Leu Cys Tyr Pro Gly Glu Leu Asp
                85           90           95
Asn Asn Gly Glu Leu Arg His Leu Phe Ser Gly Val Asn Ser Phe Ser
                100           105           110
Arg Thr Glu Leu Ile Asn Pro Ser Lys Trp Gly Asn Val Leu Asp Gly
                115           120           125
Val Thr Ala Ser Cys Leu Asp Arg Gly Ala Ser Ser Phe Tyr Arg Asn
130           135           140
Leu Val Trp Leu Val Lys Gln Lys Ile Gly Glu Tyr Pro Val Val Lys
145           150           155           160
Gly Glu Tyr Asn Asn Thr Thr Gly Arg Asp Val Leu Val Leu Trp Gly
                165           170           175
Ile His His Pro Asp Thr Glu Thr Thr Ala Thr Asn Leu Tyr Val Asn
                180           185           190
Lys Asn Pro Tyr Thr Leu Val Ser Thr Lys Glu Trp Ser Lys Arg Tyr
                195           200           205
Glu Leu Glu Ile Gly Thr Arg Ile Gly Asp Gly Gln Arg Ser Trp Met
210           215           220
Lys Leu Tyr Trp His Leu Met His Pro Gly Glu Arg Ile Met Phe Glu
225           230           235           240
Ser Asn Gly Gly Leu Ile Ala Pro Arg Tyr Gly Tyr Ile Ile Glu Lys
                245           250           255
Tyr Gly Thr Gly Thr Ile Phe Gln Ser Gly Val Arg Met Ala Lys Cys
                260           265           270
Asn Thr Lys Cys Gln Thr Ser Leu Gly Gly Ile Asn Thr Asn Lys Thr
                275           280           285
Phe Gln Asn Ile Glu Arg Asn Ala Leu Gly Asp Cys Pro Lys Tyr Ile
290           295           300
Lys Ser Gly Gln Leu Lys Leu Ala Thr Gly Leu Arg Asn Val Pro Ile
305           310           315           320
Pro Ile Gly Glu Arg
                325

```

```

<210> SEQ ID NO 44
<211> LENGTH: 324
<212> TYPE: PRT
<213> ORGANISM: Influenza A

```

-continued

&lt;400&gt; SEQUENCE: 44

```

Asp Arg Ile Cys Ile Gly Tyr Gln Ala Asn Gln Asn Asn Gln Thr Val
1      5      10      15
Asn Thr Leu Leu Glu Gln Asn Val Pro Val Thr Gly Ala Gln Glu Ile
20      25      30
Leu Glu Thr Asn His Asn Gly Lys Leu Cys Ser Leu Asn Gly Val Pro
35      40      45
Pro Leu Asp Leu Gln Ser Cys Thr Leu Ala Gly Trp Leu Leu Gly Asn
50      55      60
Pro Asn Cys Asp Asn Leu Leu Glu Ala Glu Glu Trp Ser Tyr Ile Lys
65      70      75      80
Ile Asn Glu Asn Ala Pro Asp Asp Leu Cys Phe Pro Gly Asn Phe Glu
85      90      95
Asn Leu Gln Asp Leu Leu Leu Glu Met Ser Gly Val Gln Asn Phe Thr
100     105     110
Lys Val Lys Leu Phe Asn Pro Gln Ser Met Thr Gly Val Thr Thr Asn
115     120     125
Asn Val Asp Gln Thr Cys Pro Phe Glu Gly Lys Pro Ser Phe Tyr Arg
130     135     140
Asn Leu Asn Trp Ile Gln Gly Asn Ser Gly Leu Pro Phe Asn Ile Glu
145     150     155     160
Ile Lys Asn Pro Thr Ser Asn Pro Leu Leu Leu Trp Gly Ile His
165     170     175
Asn Thr Lys Asp Ala Ala Gln Gln Arg Asn Leu Tyr Gly Asn Asp Tyr
180     185     190
Ser Tyr Thr Ile Phe Asn Phe Gly Glu Lys Ser Glu Glu Phe Arg Pro
195     200     205
Asp Ile Gly Gln Arg Asp Glu Ile Lys Ala His Gln Asp Arg Ile Asp
210     215     220
Tyr Tyr Trp Gly Ser Leu Pro Ala Gln Ser Thr Leu Arg Ile Glu Ser
225     230     235     240
Thr Gly Asn Leu Ile Ala Pro Glu Tyr Gly Phe Tyr Tyr Lys Arg Lys
245     250     255
Glu Gly Lys Gly Gly Leu Met Lys Ser Lys Leu Pro Ile Ser Asp Cys
260     265     270
Ser Thr Lys Cys Gln Thr Pro Leu Gly Ala Leu Asn Ser Thr Leu Pro
275     280     285
Phe Gln Asn Val His Gln Gln Thr Ile Gly Asn Cys Pro Lys Tyr Val
290     295     300
Lys Ala Thr Ser Leu Met Leu Ala Thr Gly Leu Arg Asn Asn Pro Gln
305     310     315     320
Met Glu Gly Arg

```

&lt;210&gt; SEQ ID NO 45

&lt;211&gt; LENGTH: 325

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Influenza A

&lt;400&gt; SEQUENCE: 45

```

Asp Gln Ile Cys Ile Gly Tyr His Ser Asn Asn Ser Thr Gln Thr Val
1      5      10      15
Asn Thr Leu Leu Glu Ser Asn Val Pro Val Thr Ser Ser His Ser Ile
20      25      30
Leu Glu Lys Glu His Asn Gly Leu Leu Cys Lys Leu Lys Gly Lys Ala

```

-continued

---

```

      35          40          45
Pro Leu Asp Leu Ile Asp Cys Ser Leu Pro Ala Trp Leu Met Gly Asn
 50          55          60
Pro Lys Cys Asp Glu Leu Leu Thr Ala Ser Glu Trp Ala Tyr Ile Lys
 65          70          75          80
Glu Asp Pro Glu Pro Glu Asn Gly Ile Cys Phe Pro Gly Asp Phe Asp
          85          90          95
Ser Leu Glu Asp Leu Ile Leu Leu Val Ser Asn Thr Asp His Phe Arg
          100          105          110
Lys Glu Lys Ile Ile Asp Met Thr Arg Phe Ser Asp Val Thr Thr Asn
          115          120          125
Asn Val Asp Ser Ala Cys Pro Tyr Asp Thr Asn Gly Ala Ser Phe Tyr
          130          135          140
Arg Asn Leu Asn Trp Val Gln Gln Asn Lys Gly Lys Gln Leu Ile Phe
          145          150          155          160
His Tyr Gln Asn Ser Glu Asn Asn Pro Leu Leu Ile Ile Trp Gly Val
          165          170          175
His Gln Thr Ser Asn Ala Ala Glu Gln Asn Thr Tyr Tyr Gly Ser Gln
          180          185          190
Thr Gly Ser Thr Thr Ile Thr Ile Gly Glu Glu Thr Asn Thr Tyr Pro
          195          200          205
Leu Val Ile Ser Glu Ser Ser Ile Leu Asn Gly His Ser Asp Arg Ile
          210          215          220
Asn Tyr Phe Trp Gly Val Val Asn Pro Asn Gln Asn Phe Ser Ile Val
          225          230          235          240
Ser Thr Gly Asn Phe Ile Trp Pro Glu Tyr Gly Tyr Phe Phe Gln Lys
          245          250          255
Thr Thr Asn Ile Ser Gly Ile Ile Lys Ser Ser Glu Lys Ile Ser Asp
          260          265          270
Cys Asp Thr Ile Cys Gln Thr Lys Ile Gly Ala Ile Asn Ser Thr Leu
          275          280          285
Pro Phe Gln Asn Ile His Gln Asn Ala Ile Gly Asp Cys Pro Lys Tyr
          290          295          300
Val Lys Ala Gln Glu Leu Val Leu Ala Thr Gly Leu Arg Asn Asn Pro
          305          310          315          320
Ile Lys Glu Thr Arg
          325

```

```

<210> SEQ ID NO 46
<211> LENGTH: 329
<212> TYPE: PRT
<213> ORGANISM: Influenza A

```

```

<400> SEQUENCE: 46

```

```

Gln Asp Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly
 1          5          10          15
His His Ala Val Pro Asn Gly Thr Leu Val Lys Thr Ile Thr Asp Asp
          20          25          30
Gln Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Ser Ser Ser Thr
          35          40          45
Gly Lys Ile Cys Asn Asn Pro His Arg Ile Leu Asp Gly Ile Asp Cys
          50          55          60
Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro His Cys Asp Val Phe Gln
          65          70          75          80

```

-continued

---

Asn Glu Thr Trp Asp Leu Phe Val Glu Arg Ser Lys Ala Phe Ser Asn  
 85 90 95

Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val  
 100 105 110

Ala Ser Ser Gly Thr Leu Glu Phe Ile Thr Glu Gly Phe Thr Trp Thr  
 115 120 125

Gly Val Thr Gln Asn Gly Gly Ser Asn Ala Cys Lys Arg Gly Pro Gly  
 130 135 140

Ser Gly Phe Phe Ser Arg Leu Asn Trp Leu Thr Lys Ser Gly Ser Thr  
 145 150 155 160

Tyr Pro Val Leu Asn Val Thr Met Pro Asn Asn Asp Asn Phe Asp Lys  
 165 170 175

Leu Tyr Ile Trp Gly Ile His His Pro Ser Thr Asn Gln Glu Gln Thr  
 180 185 190

Ser Leu Tyr Val Gln Ala Ser Gly Arg Val Thr Val Ser Thr Arg Arg  
 195 200 205

Ser Gln Gln Thr Ile Ile Pro Asn Ile Gly Ser Arg Pro Trp Val Arg  
 210 215 220

Gly Leu Ser Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly  
 225 230 235 240

Asp Val Leu Val Ile Asn Ser Asn Gly Asn Leu Ile Ala Pro Arg Gly  
 245 250 255

Tyr Phe Lys Met Arg Thr Gly Lys Ser Ser Ile Met Arg Ser Asp Ala  
 260 265 270

Pro Ile Asp Thr Cys Ile Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile  
 275 280 285

Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Lys Ile Thr Tyr Gly Ala  
 290 295 300

Cys Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met  
 305 310 315 320

Arg Asn Val Pro Glu Lys Gln Thr Arg  
 325

<210> SEQ ID NO 47  
 <211> LENGTH: 327  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 47

Gln Asn Tyr Thr Gly Asn Pro Val Ile Cys Leu Gly His His Ala Val  
 1 5 10 15

Ser Asn Gly Thr Met Val Lys Thr Leu Thr Asp Asp Gln Ile Glu Val  
 20 25 30

Val Thr Ala Gln Glu Leu Val Glu Ser Gln His Leu Pro Glu Leu Cys  
 35 40 45

Pro Ser Pro Leu Arg Leu Val Asp Gly Gln Thr Cys Asp Ile Val Asn  
 50 55 60

Gly Ala Leu Gly Ser Pro Gly Cys Asp His Leu Asn Gly Ala Glu Trp  
 65 70 75 80

Asp Val Phe Ile Glu Arg Pro Thr Ala Val Asp Thr Cys Tyr Pro Phe  
 85 90 95

Asp Val Pro Asp Tyr Gln Ser Leu Arg Ser Ile Leu Ala Asn Asn Gly  
 100 105 110

Lys Phe Glu Phe Ile Ala Glu Glu Phe Gln Trp Asn Thr Val Lys Gln  
 115 120 125

-continued

Asn Gly Lys Ser Gly Ala Cys Lys Arg Ala Asn Val Asn Asp Phe Phe  
 130 135 140  
 Asn Arg Leu Asn Trp Leu Thr Lys Ser Asp Gly Asn Ala Tyr Pro Leu  
 145 150 155 160  
 Gln Asn Leu Thr Lys Val Asn Asn Gly Asp Tyr Ala Arg Leu Tyr Ile  
 165 170 175  
 Trp Gly Val His His Pro Ser Thr Asp Thr Glu Gln Thr Asn Leu Tyr  
 180 185 190  
 Lys Asn Asn Pro Gly Arg Val Thr Val Ser Thr Gln Thr Ser Gln Thr  
 195 200 205  
 Ser Val Val Pro Asn Ile Gly Ser Arg Pro Trp Val Arg Gly Leu Ser  
 210 215 220  
 Ser Arg Ile Ser Phe Tyr Trp Thr Ile Val Glu Pro Gly Asp Leu Ile  
 225 230 235 240  
 Val Phe Asn Thr Ile Gly Asn Leu Ile Ala Pro Arg Gly His Tyr Lys  
 245 250 255  
 Leu Asn Ser Gln Lys Lys Ser Thr Ile Leu Asn Thr Ala Val Pro Ile  
 260 265 270  
 Gly Ser Cys Val Ser Lys Cys His Thr Asp Lys Gly Ser Ile Ser Thr  
 275 280 285  
 Thr Lys Pro Phe Gln Asn Ile Ser Arg Ile Ser Ile Gly Asp Cys Pro  
 290 295 300  
 Lys Tyr Val Lys Gln Gly Ser Leu Lys Leu Ala Thr Gly Met Arg Asn  
 305 310 315 320  
 Ile Pro Glu Lys Ala Thr Arg  
 325

<210> SEQ ID NO 48  
 <211> LENGTH: 321  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 48

Asp Lys Ile Cys Leu Gly His His Ala Val Ser Asn Gly Thr Lys Val  
 1 5 10 15  
 Asn Thr Leu Thr Glu Arg Gly Val Glu Val Val Asn Ala Thr Glu Thr  
 20 25 30  
 Val Glu Arg Thr Asn Val Pro Arg Ile Cys Ser Lys Gly Lys Arg Thr  
 35 40 45  
 Val Asp Leu Gly Gln Cys Gly Leu Leu Gly Thr Ile Thr Gly Pro Pro  
 50 55 60  
 Gln Cys Asp Gln Phe Leu Glu Phe Ser Ala Asp Leu Ile Ile Glu Arg  
 65 70 75 80  
 Arg Glu Gly Ser Asp Val Cys Tyr Pro Gly Lys Phe Val Asn Glu Glu  
 85 90 95  
 Ala Leu Arg Gln Ile Leu Arg Glu Ser Gly Gly Ile Asp Lys Glu Thr  
 100 105 110  
 Met Gly Phe Thr Tyr Ser Gly Ile Arg Thr Asn Gly Ala Thr Ser Ala  
 115 120 125  
 Cys Arg Arg Ser Gly Ser Ser Phe Tyr Ala Glu Met Lys Trp Leu Leu  
 130 135 140  
 Ser Asn Thr Asp Asn Ala Ala Phe Pro Gln Met Thr Lys Ser Tyr Lys  
 145 150 155 160  
 Asn Thr Arg Lys Asp Pro Ala Leu Ile Ile Trp Gly Ile His His Ser



-continued

---

210	215	220
Asp Phe His Trp Thr Leu Val Gln Pro Gly Asp Asn Ile Thr Phe Ser		
225	230	235 240
His Asn Gly Gly Leu Ile Ala Pro Ser Arg Val Ser Lys Leu Ile Gly		
	245	250 255
Arg Gly Leu Gly Ile Gln Ser Asp Ala Pro Ile Asp Asn Asn Cys Glu		
	260	265 270
Ser Lys Cys Phe Trp Arg Gly Gly Ser Ile Asn Thr Arg Leu Pro Phe		
	275	280 285
Gln Asn Leu Ser Pro Arg Thr Val Gly Gln Cys Pro Lys Tyr Val Asn		
	290	295 300
Lys Lys Ser Leu Met Leu Ala Thr Gly Met Arg Asn Val Pro Glu Ile		
305	310	315 320 325
Met Gln Gly Arg		

<210> SEQ ID NO 50  
 <211> LENGTH: 330  
 <212> TYPE: PRT  
 <213> ORGANISM: Influenza A

<400> SEQUENCE: 50

Gln Ile Thr Asn Gly Thr Thr Gly Asn Pro Ile Ile Cys Leu Gly His		
1	5	10 15
His Ala Val Glu Asn Gly Thr Ser Val Lys Thr Leu Thr Asp Asn His		
	20	25 30
Val Glu Val Val Ser Ala Lys Glu Leu Val Glu Thr Asn His Thr Asp		
	35	40 45
Glu Leu Cys Pro Ser Pro Leu Lys Leu Val Asp Gly Gln Asp Cys Asp		
	50	55 60
Leu Ile Asn Gly Ala Leu Gly Ser Pro Gly Cys Asp Arg Leu Gln Asp		
65	70	75 80
Thr Thr Trp Asp Val Phe Ile Glu Arg Pro Thr Ala Val Asp Thr Cys		
	85	90 95
Tyr Pro Phe Asp Val Pro Asp Tyr Gln Ser Leu Arg Ser Ile Leu Ala		
	100	105 110
Ser Ser Gly Ser Leu Glu Phe Ile Ala Glu Gln Phe Thr Trp Asn Gly		
	115	120 125
Val Lys Val Asp Gly Ser Ser Ser Ala Cys Leu Arg Gly Gly Arg Asn		
	130	135 140
Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr Lys Ala Thr Asn Gly Asn		
145	150	155 160
Tyr Gly Pro Ile Asn Val Thr Lys Glu Asn Thr Gly Ser Tyr Val Arg		
	165	170 175
Leu Tyr Leu Trp Gly Val His His Pro Ser Ser Asp Asn Glu Gln Thr		
	180	185 190
Asp Leu Tyr Lys Val Ala Thr Gly Arg Val Thr Val Ser Thr Arg Ser		
	195	200 205
Asp Gln Ile Ser Ile Val Pro Asn Ile Gly Ser Arg Pro Arg Val Arg		
	210	215 220
Asn Gln Ser Gly Arg Ile Ser Ile Tyr Trp Thr Leu Val Asn Pro Gly		
225	230	235 240
Asp Ser Ile Ile Phe Asn Ser Ile Gly Asn Leu Ile Ala Pro Arg Gly		
	245	250 255
His Tyr Lys Ile Ser Lys Ser Thr Lys Ser Thr Val Leu Lys Ser Asp		



-continued

Arg Cys Pro Arg Tyr Val Lys Gln Ser Ser Leu Pro Leu Ala Leu Gly  
305 310 315 320

Met Lys Asn Val Pro Glu Lys Ile His Thr Arg  
325 330

What is claimed is:

1. A method to prepare a plurality of influenza virus nucleic acid molecules encoding a H3 or H5 hemagglutinin (HA) having a reduced number of immune dominant epitopes, comprising: introducing random mutations at a plurality of codons in one or more immune dominant epitopes in an isolated parental influenza virus nucleic acid molecule encoding an influenza virus H3 or H5 hemagglutinin having at least two immune dominant epitopes, thereby providing a library of influenza virus nucleic acid molecules encoding a mutant H3 or H5 influenza virus hemagglutinin; introducing the library into cells so as to provide a library of cells that express the mutant hemagglutinins; and identifying a mutant hemagglutinin encoded by the library with a reduced number of the immune dominant epitopes relative to the parental hemagglutinin as a result of one or more substitutions and/or deletions at residues that form the one or more immune dominant epitopes, wherein if the mutant H3 hemagglutinin has substitutions, the mutant H3 hemagglutinin has more than five substitutions relative to the parental H3 hemagglutinin.

2. The method of claim 1 wherein at least 5, 10, 15 or 20 codons, or any integer between 5 and 20, are mutated.

3. The method of claim 1 wherein the immune dominant epitope that is mutated corresponds to residues 121 to 146 in H3 HA (site A), residues 156 to 196 in H3 HA (site B), residues 50 to 57 or 275 to 279 in H3 HA (site C), residue 164, residue 182 or residues 208 to 217 in H3 HA (site D) or residues 62 to 83 in H3 HA (site E).

4. The method of claim 1 wherein the cells are mammalian cells.

5. The method of claim 1 wherein the mutant HA has a substitution at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, or a deletion at one or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, in H3, or a combination thereof.

6. The method of claim 1 wherein the residue in H3 at position 121 is Q, R, I, L, V, T, S, F, Y or A, position 131 is R, K, <M, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, G, R, M, K, N, V, W, S, V, or P, position 138 is S, W, K, I, R, or L, position 140 is L, M, T, S, R, K, M, or P, position 142 is N, D, G, Y, Q, E, H, N, L, or P, position 144 is T, K, V, G, D, H, L or Q, position 145 is P, R, W or K, position 155 is C, I, F, H, R, A, V, S or N, position 156 is P, M, R, G, S, T, A, or C, position 157 is D, P, S, G, I, R or T, position 158 is R, V, S, A, K, C, Q, position 171 is T, F, L, E, H, C or R, position 189 is A, P, T, L, A, S, Y, or R, position 193 is Q, R, N, T, E, V, or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F.

7. The method of claim 1 wherein the residue in H5 at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A,

M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H.

8. A method to prepare an influenza virus encoding a mutant hemagglutinin that has fewer immune dominant epitopes relative to a parental influenza virus, comprising: introducing a mutation in a parental H3 HA nucleic acid molecule at two or more codons for residue 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, wherein the mutation encodes a residue that is not an immune dominant epitope residue in the parent H3 HA or introducing a mutation in a parental H5 HA nucleic acid molecule at two or more codons for residue 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, wherein the mutation encodes a residue that is not an immune dominant epitope residue in the parent H5 HA; and isolating or preparing one or more influenza viruses with the mutated H3 or H5 HA, wherein the mutated H3 nucleic acid has more than five of the codons mutated, and wherein numbering for H3 is H3 numbering.

9. The method of claim 8 wherein the residue in the mutated H3 HA at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T, position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or R, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F.

10. The method of claim 8 wherein the residue in H5 at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position 152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H.

11. A composition comprising a plurality of distinct isolated recombinant influenza viruses each encoding a H3 or H5 hemagglutinin comprising a plurality of antigenically distinct residues relative to residues that form an immune dominant epitope in a parent virus, wherein each of the plurality of influenza viruses comprises substitutions at two

## 121

or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, or one or more deletions of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, in H3, or any combination thereof, relative to the parent virus H3 hemagglutinin; or wherein each of the plurality of influenza viruses comprises a substitution at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, or a deletion in one or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, in H5, or any combination thereof, relative to the parent virus H5 hemagglutinin vims, wherein at least one of the plurality of distinct recombinant H3 viruses has a H3 hemagglutinin with more than five substitutions relative to the parental virus H3 hemagglutinin.

12. The composition of claim 11 which has at least three, four or five distinct viruses with the substitutions.

13. The composition of claim 11 which has five to ten distinct viruses with the substitutions.

14. The composition of claim 11 which has ten to twenty distinct viruses with the substitutions.

15. The composition of claim 11 wherein each distinct virus has at least one to five substitutions in antigenic site A or site B.

16. The composition of claim 11 wherein each distinct virus has at least one to ten substitutions in antigenic sites A and B.

17. The composition of claim 11 wherein each distinct virus has altered binding to antibodies that bind the corresponding parental hemagglutinin.

18. The composition of claim 11 wherein one of the influenza viruses comprises a) a H5 HA where the residue at position 119 is L, K, R, S, G, T, E, A, V, F or N; position 123 is L, Y, I, M, N, S, V, K, G, T or R; position 125 is L, D, N, G, W, M, I, R, K, F, A, or S; position 126 is S, R, I, G, N, Q, A, N or R; position 127 is V, A, S, M, L, K, F or Y; position 129 is D, S, G, K, W, R, E, V, Q, A, I, or F; position 138 is G, D, E, L, A, M, V, F, R or S; position 140 is T, G, S, R, D, K, Q, E, C, or V; position 141 is R, P, W, K, E, A, M, D, L, or Q; position 151 is T, S, L, Y, K, N, or Q; position

## 122

152 is A, P, T, Y, H, E, S, I, F, or D; position 153 is R, Q, T, N, S, F, P, V, or K; position 154 L, T, D, R, P, S, or H; position 155 is N, G, K, H, T, L, S, I, P, or Q; position 156 is T, F, R, S, D, P, H, G, A, or N; position 185 is L, D, N, G, E, F, S, L, Q, P, V, M, R, A, or S; or position 189 is Y, S, L, R, K, G, E, F, D, V, E, I, or H, or any combination of those residues at those positions; or b) a H3 HA wherein the residue at position 121 is Q, R, I, L, V, S, F, Y, or A, position 131 is R, V, S, Q, C, V, Y, D, E, or L, position 135 is Y, K, N, V, W, G, S, V, or P, position 138 is W, K, I, F, R, or L, position 140 is L, M, T, S, R, K, M, Y, or P, position 142 is N, G, Y, Q, E, H, N, or Q, position 144 is T, V, G, D, P, H, L, K, or Q, position 145 is P, D, R, W or N, position 155 is C, I, R, A, V, S, or Q, position 156 is P, G, S, T, A, or C, position 157 is D, P, S, G, I, Q, R or T, position 158 is R, V, S, A, K, C, Q, or G, position 171 is T, F, L, E, H, V, or R, position 189 is A, P, T, L, S, Y or R, position 193 is Q, R, N, T, E, V or P, position 212 is V, R, G, S, M, D or E, or position 225 is L, P, C, S, Q, G, Y, or F, or any combination of those residues at those positions.

19. A method to immunize an animal, comprising: administering an effective amount of a composition comprising a plurality of distinct isolated recombinant influenza viruses each encoding a H3 or H5 hemagglutinin comprising a plurality of antigenically distinct residues relative to residues that form an immune dominant epitope in a parent virus, wherein each of the plurality of influenza viruses comprises substitutions at two or more of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, or one or more deletions of positions 121, 131, 135, 138, 140, 142, 144, 145, 155, 156, 157, 158, 171, 189, 193, 212, or 225, in H3, or any combination thereof relative to the parent virus H3 hemagglutinin; or wherein each of the plurality of influenza viruses comprises a substitution at two or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, or a deletion in one or more of positions 119, 123, 125, 126, 127, 129, 138, 140, 141, 151, 152, 153, 154, 155, 156, 185, or 189, in H5, or any combination thereof, relative to the parent virus H5 hemagglutinin to an animal.

\* \* \* \* \*